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ABSTRACT
MECHANISMS THAT LIMIT OXIDATIVE PHOSPHORYLATION DURING HIGHINTENSITY MUSCLE CONTRACTIONS IN VIVO
SEPTEMBER 2019
MILES F. BARTLETT, B.S. UNIVERSITY OF MAINE ORONO
M.A., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
PH.D, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jane A. Kent

Skeletal muscle oxidative capacity plays a critical role in human health and
disease. Although current models of oxidative phosphorylation sufficiently describe
skeletal muscle energetics during moderate-intensity contractions, much is still unknown
about the mechanisms that control and limit oxidative phosphorylation during highintensity contractions. In particular, the oxygen cost of force generation is augmented
during exercise at workloads above the lactate threshold. Presently, it is unclear whether
this augmentation in muscle oxygen consumption is driven by increased rates of
oxidative ATP synthesis (ATPOX) or by decreases in the efficiency of ATPOX due to
mitochondrial uncoupling. To address this gap, 31P-MRS was used in two separate studies
to measure rates of ATPOX at the end of: 1) repeated bouts of supramaximal knee
extensions, and 2) each stage of an isotonic stepwise knee extension protocol. In both
studies, high-intensity contractions impaired the maximal capacity for ATPOX and
reduced the sensitivity of ATPOX to changes in ADP and cytosolic phosphorylation
potential. However, high-intensity contractions did not cause rates of ATPOX to increase
relative to workload, suggesting that the increased oxygen cost of exercise above the
lactate threshold is due to changes in mitochondrial coupling control (i.e., P/O ratio).
vi
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CHAPTER 1
INTRODUCTION
Apart from a few recently-discovered marine species (51), oxidative
phosphorylation is essential to multicellular life. Complete oxidation of foodstuffs not
only results in greater molar ATP yields than anaerobic metabolism, it also produces
gaseous waste products, which in contrast to the non-gaseous waste products of most
anaerobic energy producing pathways, can be excreted from multicellular organisms in
copious quantities via simple pulmonary ventilation. This is particularly important to our
understanding of skeletal muscle fatigue, where rates of ATP demand can increase more
than 100-fold over resting values in the transition from rest to maximal exercise (182).
Specifically, when the rate of skeletal muscle ATP demand exceeds the rate at which
ATP can be synthesized by oxidative phosphorylation, glycolytic ATP synthesis
increases dramatically, which leads to the accumulation of fatigue inducing metabolites,
such as protons (H+) and inorganic phosphate (Pi) (52, 53, 100, 157), that cannot be
excreted as quickly as they are being produced.
During moderate-intensity contractions ATP demand is met entirely by oxidative
ATP synthesis and steady-state muscle metabolism is linearly related to power output
(58, 219). However, during high-intensity contractions above the lactate threshold,
muscle oxygen consumption increases more than would be predicted by the linear
relationship observed for power outputs below the lactate threshold (58, 109) (Figure
1.1). This ‘excess’ oxygen consumption is also accompanied by augmentations in
phosphocreatine (PCr) breakdown, lactate accumulation, and acidosis (10, 44, 83, 85,
104, 170, 174, 191). The attainment of metabolic steady-state is also delayed, or in some
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cases, unachievable (58, 212, 213, 219). These metabolic changes indicate that highintensity contractions impair either the mechanical efficiency of skeletal muscle force
production or the efficiency of ATP synthesis via oxidative phosphorylation.

Figure 1.1: Augmentation of pulmonary VO2 during cycling exercise at power
outputs below the lactate threshold. Oxygen uptake increases linearly at a rate of about
10ml/Kg/Watt (11, 175). However, for power outputs above the lactate threshold (filled
circles), the increment in oxygen uptake per Watt of power output increases. This
‘excess’ increase in the oxygen cost of high-intensity exercise denotes a reduction in
either the mechanical efficiency of skeletal muscle force production or the efficiency of
ATP synthesis via oxidative phosphorylation. Figure from Roston et al. (175).

Collectively, these augmentations in skeletal muscle metabolism have become
known as the slow component of oxygen uptake kinetics (VO2SC). The VO2SC has
primarily been studied from changes in pulmonary oxygen uptake and blood lactate
accumulation during cycling exercise (58, 109). Although these variables reflect whole
body responses to exercise, multiple investigations have demonstrated that approximately
85% of the VO2SC originates within the contracting muscle mass (107, 167, 174),
particularly within fatiguing muscle fibers (29, 221). However, the biochemical and
molecular mechanisms underlying the VO2SC are not fully understood.
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At present, the leading hypothesis predicts that the VO2SC reflects an increased
ATP cost of force generation (35, 174), or a reduction in the mechanical efficiency of
force generation or summation (166). Rossiter et al. first proposed this explanation after
observing similar kinetic responses between pulmonary oxygen uptake and intramuscular
PCr breakdown during single leg knee extensions (Figure 1.2) (174). Given the
relationship between oxidative phosphorylation and creatine kinase shuttling (15, 149),
this led the authors to predict that the ATP cost of force generation increases during high
intensity contractions.

Figure 1.2: Changes in pulmonary VO2 and intramuscular PCr during moderate
and high-intensity dynamic contractions. Pulmonary oxygen uptake (upper left panel)
and intramuscular PCr breakdown (lower left panel) plateau within 3 minutes. However,
during high-intensity contractions, neither pulmonary VO2 (upper right panel) nor
intramuscular [PCr] (lower right panel) achieve a steady-state plateau. Given the
relationship between creatine kinase shuttling and oxidative phosphorylation (15, 149),
Rossiter et al. predicted the VO2SC is caused by an increased ATP cost of muscle force
generation (174). Figure from Rossiter et al. (174).

One mechanism that could increase the ATP cost of force generation during highintensity contractions is Type-II muscle fiber recruitment. Type-II muscle fibers exhibit a
significantly greater ATP cost of force generation than Type-I fibers (50, 69, 75) and are
3

selectively recruited at higher power outputs (60). Moreover, the magnitude of the VO2SC
(i.e., the volume of excess muscle oxygen consumption) correlates well with Type-II
myosin heavy chain (MHC) content (142, 143, 220). Inversely, greater expression of
Type-I MHC content is correlated higher mechanical efficiency during cycling (152), as
well as higher critical power thresholds, a marker of endurance capacity and skeletal
muscle fatigue resistance (200).
However, there are several biochemical aspects of the VO2SC that are difficult to
reconcile under the increased ATP cost of force generation hypothesis. For example, the
magnitude of the VO2SC is positively correlated with blood lactate accumulation (175),
the paradox being that the acidosis accompanying lactate accumulation should actually
impair muscle oxygen consumption due to its inhibitory effect on mitochondrial
respiration (70, 93). The augmentation of muscle oxygen consumption also occurs
despite a significant impairment to skeletal muscle oxidative capacity following highintensity contractions (28, 193). That is, it is difficult to explain how muscle oxygen
consumption can increase if the capacity for oxidative phosphorylation is decreased. That
the non-linear increase in muscle oxygen consumption is predicted to originate within
fast-twitch muscle fibers is also paradoxical given that they exhibit lower mitochondrial
density and tend to produce lower rates of ADP-limited respiration than slow-twitch
fibers (63, 86, 115), though this latter finding is not always consistent and can depend on
the substrates being oxidized (116, 153).
The alternative hypothesis for the VO2SC is that high-intensity contractions cause
mitochondrial uncoupling, a process that impairs the coupling between mitochondrial
oxygen consumption and oxidative ATP synthesis (i.e., P/O ratio; the ratio of ATP
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synthesized by ATP synthase per O2 molecule reduced by cytochrome c-oxidase) (35,
169, 214). Similar to reducing a car’s gas mileage, mitochondrial uncoupling increases
the volume of oxygen necessary to maintain a given rate of ATP synthesis. This directly
explains the non-linear increase in muscle oxygen consumption and may also explain
why the magnitude of the VO2SC (i.e., the volume of excess muscle oxygen consumption)
is so highly correlated with lactate accumulation (Figure 1.3) and augmentations in
phosphocreatine hydrolysis (174, 175), as progressive declines in P/O would increasingly
impair oxidative ATP synthesis, thereby necessitating greater recruitment of anaerobic
energy pathways to meet cellular ATP demand.

Figure 1.3: Correlation between the VO2SC magnitude and blood lactate
accumulation. During high-intensity cycling, the magnitude of the VO2SC, calculated as
the increase in oxygen uptake measured from minute 3 to the end of exercise, correlates
well (r=0.883) with the increase in blood lactate accumulation measured over the same
time period. Figure from Roston et al. (175).

Statement of the Problem
Myriad experimental limitations have hindered definitive demonstration of either
hypotheses for the VO2SC, with the primary limitation being that both hypotheses offer
5

logical and experimentally supported explanations for nearly every change in skeletal
muscle bioenergetics observed during high intensity contractions. Put another way, there
are very few changes in skeletal muscle bioenergetics during high-intensity contractions
that are exclusively predicted by one hypothesis but not the other, which has made
developing experiments that can separate the two hypotheses in vivo difficult. However,
one predictive difference between the two hypotheses is the impact high-intensity
contractions have on oxidative ATP synthesis. Whereas the increased ATP cost of force
generation hypothesis predicts the augmentation in skeletal muscle oxygen uptake is a
direct reflection of increased oxidative ATP synthesis, the mitochondrial uncoupling
hypothesis predicts oxidative ATP synthesis is reduced due to an impairment of the
mitochondrial P/O ratio. This predictive difference offers an opportunity to study and
compare the competing hypotheses for explaining the VO2SC.
Yet, where one opportunity presents itself, another challenge arises. Several
methods exist for using 31phosphorous magnetic resonance spectroscopy (31P-MRS) to
study changes in oxidative ATP synthesis within contracting skeletal muscles, but most
of these methods are inherently based on assumptions that either the ATP cost of
contraction does not change (99) or that mitochondrial uncoupling does not occur (29,
119, 206), and therefore cannot be used to study the VO2SC because of an inherent bias
against one hypothesis or the other. A third method for using 31P-MRS to study changes
in ATPOX is to measure the initial rate of post-exercise phosphocreatine resynthesis
(ViPCr) (19, 35). Although this method only yields one measure of ATPOX per bout of
contractions, it does not make any assumptions about the ATP cost of force generation or
mitochondrial uncoupling, and therefore offers an opportunity to study the VO2SC by
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having participants perform multiple durations of high-intensity contractions. Cannon et
al. recently used this approach and reported that although the ATP cost of force
generation did appear to increase during 8 minutes of high-intensity knee extensions, the
magnitude of the increase was insufficient to fully account for the VO2SC, suggesting
mitochondrial uncoupling may have played a role (35).
Another major experimental limitation is that there are only a few techniques
available for measuring mitochondrial uncoupling and P/O in vivo. Some groups have
tried to bridge this gap by combining pulmonary oxygen uptake with 31P-MRS (38, 128).
Although the VO2SC does primarily originate within the working muscle mass (167, 174),
the fact that pulmonary oxygen uptake is not just a measure of oxygen consumption by
the working muscle mass, but also includes oxygen uptake from other tissues, erodes
enthusiasm for using this technique to calculate skeletal muscle P/O ratio. Marcinek et al.
have combined optical and magnetic resonance spectroscopies to directly measure
mitochondrial uncoupling in vivo within resting muscle (1, 49, 146), but to the best of my
knowledge, this approach has not been applied following a period of contractions.

Study 1: Oxidative ATP Synthesis during High-Intensity Contractions
The primary aim of this study is to demonstrate that the rate of oxidative ATP
synthesis becomes impaired during high-intensity contractions. As discussed above, the
increased ATP cost of force generation hypothesis predicts that the augmentation in
skeletal muscle oxygen uptake during high-intensity contractions is directly caused by
increases in oxidative ATP synthesis. Consequently, this hypothesis can be eliminated if it
is demonstrated that rates of oxidative ATP synthesis decline during high-intensity
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contractions, leaving mitochondrial uncoupling as the primary hypothesis remaining for
the VO2SC. The secondary aim of Study 1 is to demonstrate that the accuracy of traditional
ATPOX calculations can be improved for bouts of high-intensity contractions by making
adjustments for changes in oxidative capacity (i.e., kPCr), thereby allowing ATPOX to be
calculated over time without needing to assume constant ATP cost of contraction or
maintained mitochondrial coupling (29, 99, 119, 206).
Nine healthy young men and women (ages 25-40) will complete multiple trials of
a high-intensity isokinetic (120°·s-1) knee extension protocol during a single visit to the
Human Magnetic Resonance Center (hMRC). One maximal voluntary dynamic
contraction (MVDC) will be performed every two seconds for 4 trials lasting 24, 60, 120,
and 240 seconds. Continuous measures of 31P-MRS will be collected before, during, and
after each of these trials, thereby allowing us to measure kPCr and ViPCr at 4 separate time
points. The primary outcome variables for this study will be kPCr (·s-1), Vmax (mM/s), Km
(i.e., the substrate concentration at ½Vmax), the Hill coefficient (nH), and ViPCr (mM/s)
following each of the 4 isokinetic MVDC protocols (all shown in Figure 1.4), as well as
the rates of ATPOX (mM/s), ATPtot (mM/s), and ATPcost (Watts/ATPtot) calculated using
the traditional and modified methods at 24, 60, 120, and 240 s of the 4th (240 s)
experimental trial. Secondary outcome measures will include muscle fatigue (% peak
power), total work (Joules), and changes in intramuscular metabolite concentrations such
as PCr, Pi, and H+. These variables will be compared across all 4 isokinetic MVDC trials
to ensure muscle performance and energetics are consistent across trials, thereby allowing
us to assume that the ViPCr measured after the 24, 60, and 120 trials is representative of
the true ATPOX rate observed during the 240 s trial.
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Vmax = 1.27 mM·s-1
Km = 0.93
nH = 0.7

kPCr = 0.036 s-1
ViPCr = 0.85 mM/s

Figure 1.4: Skeletal muscle oxidative capacity and multiparametric analysis of Vmax
and Km for ATPOX. Skeletal muscle oxidative capacity will be measured as the rate
constant (kPCr) of the PCr recovery response following each bout of contractions (left).
The fitted PCr recovery curve will then be used to calculate rates of ATPOX
(∆PCr/∆time), which will then be fitted against either the measured [ADP] or cytosolic
phosphorylation potential (CPP; shown in the right hand figure) to determine Vmax, Km,
and nH, according to the equation: PCr(t)=Vmax/(1+((Km/CPP)^nH))

Aim 1: Demonstrate that oxidative ATP synthesis is impaired during high-intensity
contractions.
Hypothesis 1a: Skeletal muscle oxidative capacity (kPCr) will steadily decline as the
duration of the fatigue trials get longer such that kPCr24 > kPCr60 > kPCr120 > kPCr240.
Hypothesis 1b: Oxidative ATP synthesis, measured as the ViPCr, will steadily decline
beyond the first minute of the fatigue trials such that ViPCr60 > ViPCr120 > ViPCr240.

Aim 2: Demonstrate that the accuracy of predicting ViPCr during high-intensity
contractions is improved by adjusting traditional ATPOX calculation methods (29, 119,
206) for measured changes in Vmax.
Although ViPCr does not make assumptions about the ATP cost of force generation
or mitochondrial coupling, it only yields one measure of ATPOX per bout of contractions
9

and therefore cannot be used to study changes in ATPOX over time unless participants
perform multiple bouts of performance-matched contractions. This appears feasible in
healthy young adults (35), but is not a long term solution to studying ATPOX in clinical
populations where muscle fatigue would make it difficult to repeat multiple bouts of
contractions. Consequently, a continuous method for calculating ATPOX that is not based
on assumptions about the ATP cost of force generation or mitochondrial coupling is
needed.
Hypothesis 2a: Calculations of ATPOX will be significantly greater than ViPCr
following the 120 and 240 second trials when using traditional ATPOX calculations, but
not when the traditional ATPOX calculations are adjusted to account for changes in Vmax.

Exploratory Aim 1: Compare methods of estimating Vmax for ATPOX calculations
Two methods exist for using oxidative capacity measurements to estimate Vmax
for ATPOX calculations. One method assumes creatine acts as a capacitor for distributing
oxidatively generated ATP and calculates Vmax as the product of kPCr-baseline · [PCr]rest,
with kPCr-baseline being the oxidative capacity of the muscle and [PCr]rest indicating
maximal capacitance capacity (149). The alternative approach is to calculate Vmax by
fitting the instantaneous rates of PCr recovery and ADP or cytosolic phosphorylation
potential (CPP) to a sigmoidal function using a multi-point analysis (90, 133). Recent
work from Layec et al. suggests accurate prediction of Vmax in vivo is only accomplished
using the multipoint analysis method, as kPCr-baseline · [PCr]rest appears to grossly
overestimate the State 3 in vitro measure of Vmax (131). Consequently, the purpose of this

10

exploratory aim is to compare methods for calculating Vmax and investigate their ability to
predict ViPCr throughout a 4-minute bout of high-intensity muscle contractions.
Hypothesis E1a: Vmax estimations will be significantly higher when estimated by
multiplying kPCr-baseline · [PCr]baseline compared to the ADP and CPP multi-point analyses.
Hypothesis E1b: ATPOX calculations during the 4-minute fatigue protocol will be
significantly greater when Vmax is estimated by multiplying kPCr · [PCr]baseline, but not
when using the ADP or CPP multi-point analysis methods.

Study 2: Mitochondrial Uncoupling and Oxidative ATP Synthesis during an
Incremental Knee Extension Protocol
My working hypothesis is that mitochondrial uncoupling (i.e., reduced P/O ratio)
impairs ATPOX during high-intensity contractions (12). This mitochondrial uncoupling
not only coincides with the lactate threshold but is directly responsible for it and causes
numerous other bioenergetic changes associated with high-intensity contractions and
muscle fatigue such as intramuscular acidosis and augmentations in PCr depletion, Pi/PCr
ratio, ADP accumulation, and changes in CPP.
To the best of my knowledge, methodological limitations have hindered the
measurement of skeletal muscle P/O in vivo following a period of high-intensity
contractions. To overcome this limitation, I adapted techniques used by Marcinek et al.
(1, 49, 146) and Ryan et al. (177) to replicate in vitro mitochondrial respirometry under
in vivo conditions using interleaved 1H- and 31P-MRS. Briefly, because PCr resynthesis is
an oxidative process (71, 168), the rate of PCr recovery following a period of
contractions can be used to estimate the rate of oxidative ATP synthesis. Similarly, the
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rate of muscle oxygen consumption can be estimated by using 1H-MRS to measure
deoxymyoglobin appearance, an intramuscular protein that binds molecular O2 and
becomes visible in the 1H-MRS spectrum as intramuscular pO2 declines. Thus, P/O ratio
within skeletal muscle can be estimated by measuring rates of PCr resynthesis and
deoxymyoglobin appearance during brief bouts of ischemia; the ischemia being necessary
to ensure that changes in deoxymyoglobin appearance are a direct reflection of the rate of
muscle oxygen consumption and not affected by oxygen delivery from the cardiovascular
system. Although muscle biopsy studies suggest PCr resynthesis does not occur in
ischemia (71, 168), pilot testing in our lab has shown small changes (1-2 mM) can be
observed early-on in the recovery period using 31P-MRS, which is likely due to the faster
temporal resolution of 31P-MRS compared to biopsy studies.
Consequently, mitochondrial P/O ratio will be measured in eight healthy young
men and women (21-40 years) after each stage of an incremental knee extension protocol.
A total of 6 stages will be complete, each lasting 3 minutes with one isotonic knee
extension being performed every 2 seconds. The starting workload will be equal to 10%
of maximal voluntary isometric (MVIC) torque and increase by a load equal to 8% MVIC
each stage thereafter. At the end of each stage, pressurized cuffs wrapped around the
upper thigh and calf muscles will be inflated to induce ischemia in the quadriceps. During
ischemia, the rates of PCr resynthesis and deoxymyoglobin appearance will be measured
using interleaved 31P- and 1H-MRS, which will allow us to investigate the impact
contraction intensity has on mitochondrial P/O ratio within skeletal muscle.

Aim 1: Directly demonstrate that P/O declines during high-intensity contractions.
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Hypothesis 1a: During incremental contractions of the knee extensors, skeletal
muscle P/O will remain constant for moderate-intensity contractions (i.e., power outputs
below the lactate threshold) but will decrease during high-intensity contractions (i.e.,
power outputs above the lactate threshold).

Successful completion of the proposed work will provide critical insight into the
mechanisms that limit oxidative phosphorylation in vivo. Study one will attempt to
demonstrate that, in contrast to the progressive increases observed for muscle oxygen
uptake, the rate of skeletal muscle oxidative ATP synthesis decreases throughout a bout
of high-intensity contractions. This would eliminate the possibility that increases in
muscle oxygen uptake are driven by increases in oxidative ATP synthesis (i.e., the
increased ATP cost of force generation hypothesis), leaving mitochondrial uncoupling as
the only remaining hypothesis to explain the VO2SC. Study two will attempt to
demonstrate that the onset of mitochondrial uncoupling within skeletal muscle coincides
with the onset of the lactate threshold, which occurs well before skeletal muscles reach
their capacity for maximal oxygen uptake. Together, these observations would all but
eliminate the possibility that oxidative phosphorylation can be limited by factors such as
oxygen availability or electron transport chain capacity and suggest instead that factors
related to mitochondrial phosphorylation capacity set the upper limit to oxidative ATP
synthesis. Subsequently, this would shift focus on the molecular limitations of oxidative
phosphorylation to transport proteins and enzymes such as ATP synthase or adenine
nucleotide translocase.
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CHAPTER 2
LITERATURE REVIEW
Current models of oxidative phosphorylation are sufficient to describe skeletal
muscle energetics during moderate-intensity contractions because ATP demand is met
mainly by oxidative ATP synthesis and steady-state muscle metabolism is linearly related
to power output. These metabolic conditions allow researchers to use 31-phosphorous
magnetic resonance spectroscopy (31P MRS) and basic principles of chemical
thermodynamics to calculate rates of oxidative ATP synthesis (ATPOX) from known
relationships with cytosolic free creatine, [ADP], or phosphorylation potential (CPP)
(119, 120, 129, 149, 215).
However, the mechanisms that limit and control oxidative phosphorylation in vivo
during high-intensity contractions (i.e., above the lactate threshold) are not fully
understood. Not only is steady-state metabolism delayed (58, 212, 213, 219), or
unachievable, but the linearity between skeletal muscle metabolism and power output is
distorted (58, 109). Specifically, the oxygen cost of high-intensity contractions is
significantly greater than would be predicted by the linear relationship observed during
moderate-intensity contractions, and is accompanied by non-linear augmentations in
phosphocreatine (PCr) hydrolysis, acidosis, [ADP], and the free energy of ATP
hydrolysis (10, 44, 83, 85, 104, 170, 174, 191). These non-linear changes in skeletal
muscle oxygen consumption only occur during high-intensity contractions at power
outputs above an individual’s lactate threshold, and cumulatively describe the
phenomenon known as the slow component of oxygen uptake kinetics (VO2SC).
At present, the biochemical and molecular mechanisms underlying the VO2SC
remain unclear (58, 109). The leading hypothesis for this response is that high-intensity
14

contractions increase the ATP cost of force generation, which was first proposed by
Rossiter et al. after observing similar kinetic responses between pulmonary oxygen
uptake and intramuscular PCr breakdown (174). However, there are several biochemical
aspects of the VO2SC that increased ATP cost cannot reconcile. For example, the
magnitude of the VO2SC is positively correlated with lactate accumulation (175), the
paradox being that the acidosis accompanying lactate accumulation should actually
impair muscle oxygen consumption due to its inhibitory effect on mitochondrial
respiration (70, 93). The augmentation of muscle oxygen consumption also occurs
despite the significant impairment to skeletal muscle oxidative capacity following highintensity contractions (28, 193). Thus, it is difficult to explain how muscle oxygen
consumption can increase if the capacity for oxidative phosphorylation is decreased. That
the non-linear increase in muscle oxygen consumption is predicted to originate within
Type-II muscle fibers is also paradoxical given that these fibers exhibit lower
mitochondrial density and tend to produce lower rates of ADP-limited respiration than
Type-I fibers (63, 86, 115), though this latter finding is not always consistent and can
depend on the substrates being oxidized (116, 153).
An alternative hypothesis for the VO2SC is that high-intensity contractions cause
mitochondrial uncoupling (169), a process that dissipates the thermodynamic constraints
of the proton motive force and allows the electron transport chain (ETC) to consume
oxygen without restriction from the ATP-synthesizing components of oxidative
phosphorylation. Not only does this hypothesis provide a direct explanation as to why
muscle oxygen consumption increases non-linearly, but it also explains why acidosis
does not inhibit mitochondrial respiration, as mitochondrial uncoupling permits passive
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movement of H+ across the inner mitochondrial membrane. Mitochondrial uncoupling
may also directly explain why the VO2SC coincides with both lactate accumulation and
increased PCr breakdown, as the mitochondrial malate-aspartate NADH shuttle and
adenine nucleotide translocator (ANT) are both electrophoretic (105, 118, 188), meaning
they rely on the electrical potential energy of the proton motive force to shuttle cytosolic
reducing equivalents (i.e., NADH) or ADP/ATP across the inner mitochondrial
membrane against their concentration gradients. Specifically, as the magnitude of
mitochondrial uncoupling increases, so too does dissipation of the electrical potential
energy across the inner mitochondrial membrane. Progressive impairment of the malateaspartate NADH shuttle would therefore be expected to cause progressively lower rates
of mitochondrial lactate oxidation, thereby explaining why the magnitude of the VO2SC is
so closely associated with lactate accumulation. Similarly, progressive impairment of
ANT would cause a net efflux of ADP from the mitochondrial matrix into the
intermembranous space and cytosol, which would cause a right-shift in the cytosolic
creatine kinase equilibrium, thereby explaining why the VO2SC also tends to coincide
with augmentations in PCr breakdown.
Despite several potential explanations for why mitochondrial uncoupling may be
responsible for altering muscle metabolism during high-intensity exercise, demonstration
of the concept has been hindered by a lack of testable predictions that can distinguish the
increased in ATPCOST and mitochondrial uncoupling hypotheses in vivo. That is, many of
mitochondrial uncoupling’s predicted biochemical consequences are synonymous with
those that would be predicted in response to an increased ATP cost of force generation.
One difference between the two hypotheses is their predicted effect on ATPOX. The
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ATPCOST hypothesis predicts that ATPOX increases during high-intensity contractions,
whereas the mitochondrial uncoupling hypothesis predicts that the relationship between
ATPOX and muscle power output is preserved, albeit at a higher rate of oxygen
consumption, or under severe circumstances, diminished.
Muscle ATPOX can be calculated during skeletal muscle contractions using 31P
MRS, but most of these calculation methods inherently assume that the ATP cost of force
generation remains constant (99) or that mitochondrial uncoupling does not occur (29, 55,
119, 206). Methods for measuring mitochondrial uncoupling in skeletal muscle in vivo
are also limited. Techniques have been developed for estimating mitochondrial P/O (i.e.,
the ratio of ATP synthesized to oxygen consumed) in resting skeletal muscle (1, 145,
146), but to the best of my knowledge, this has not been replicated in muscles following a
period of contraction.
Identifying experimentally-testable differences between these hypotheses requires
an approach that integrates a general understanding of how the VO2SC manifests at the
whole muscle and cellular levels with basic principles of chemical thermodynamics and
their application to oxidative phosphorylation. The remainder of this review will be
divided into sections that address each of these components.

Physiology Underlying the Slow Component of Oxygen Uptake Kinetics
The VO2SC primarily describes two important characteristics of skeletal muscle
metabolism during high-intensity exercise. First, in contrast to the pulmonary oxygen
uptake kinetics observed during moderate-intensity exercise, which increase
monoexponentially and achieve steady-state within 2-3 minutes (219), attainment of
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oxygen uptake steady state is significantly delayed, or unattainable, during high-intensity
exercise above the lactate threshold (219). Thus, the phrase ‘slow component’ developed
quite literally as a consequence of the slow and gradual increase in pulmonary oxygen
uptake observed beyond the 3rd minute of constant load work.
Figure 2.1: Augmentation of muscle
oxygen consumption during
incremental knee-extensions. Consistent
with the whole-body response shown in
Figure 1.1 (Chapter 1), the VO2SC can also
be observed in whole muscles using
single-joint contraction modes. During
high-intensity knee extensions at power
outputs above the lactate threshold, the
increment in oxygen uptake per Watt of
power output is greater than would be
predicted by the linear relationship
established during moderate-intensity
contractions (dashed line). Figure from
Andersen et al. (2).

Second, the VO2SC describes the augmentation in muscle oxygen uptake observed
for power outputs above the lactate threshold (Figure 2.1). Put another way, the oxygen
cost of high-intensity contractions is greater than would be predicted by the linear
relationship observed for power outputs below the lactate threshold (58). For example,
the oxygen cost of cycling equates to ~10 mL/W for power outputs below the lactate
threshold (11, 175) but increases by ~17 mL/W for power outputs approaching maximal
oxygen uptake (11). This increased oxygen cost of power production represents a
significant decline in the mechanical or metabolic efficiency of skeletal muscle and is
closely related to changes in muscle fatigue (29, 221).
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Observations of the VO2SC can be traced back to the early 1960s. In 1961, Astrand
and Saltin demonstrated that pulmonary oxygen uptake does not plateau during bouts of
exhaustive cycling lasting 2-8 minutes (4). Subsequent work by Whipp and Wasserman
in the 1970s-80s demonstrated the VO2SC only occurs above an individual’s lactate
threshold, regardless of fitness level (76, 208, 209, 212, 213). By the late 1980’s
researchers further understood that the magnitude of the VO2SC, measured as the change
in pulmonary oxygen uptake observed between the 3rd and 6th minute of exercise, is also
highly correlated with blood lactate accumulation (175). However, because pulmonary
oxygen uptake and blood lactate accumulation reflect whole body responses, it was
unclear whether the VO2SC originated within the contracting skeletal muscle or was
caused by increases in heart rate or ventilatory activity by the diaphragm. Poole et al.
resolved this question in 1991 by simultaneously measuring pulmonary and leg oxygen
uptake in healthy young males during light and high-intensity cycling. Results showed
that the exercising muscle mass accounts for approximately 85% of the pulmonary VO2SC
(167). Similar results have also been reported during knee-extension protocols (107, 111,
174). This was perhaps one of the most important findings in VO2SC research because it
established the contracting muscle mass as the primary origin of the VO2SC, which
stimulated new research investigations on the underlying whole muscle and cellular
mechanisms.
Several studies have used surface electromyography (EMG) to investigate the
relationship between the VO2SC and increases in motor unit recruitment, with some
reporting that increased EMG activity is associated with an increase in the VO2SC (81,
113, 161, 179, 183) and others reporting that the VO2SC can develop without changes in
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EMG activity (37, 61, 186). The discrepancies between these results are not readily
discernable but may be influenced by the methods used to calculate changes in VO2SC
magnitude or motor unit recruitment. Several studies have evaluated the VO2SC during
constant-load exercise by calculating changes in oxygen consumption or EMG activity
after the 3rd minute (179, 181, 183). However, this calculation method assumes
pulmonary or muscle oxygen consumption measured at 3-minutes reflects the response
that would be predicted from the linear VO2-power output relationship observed during
moderate intensity contractions. Given that VO2 on-kinetics can be influenced by factors
such as training or starting intensity (217), this method may lead to inaccurate calculation
of the VO2SC magnitude or changes in other physiological variables such as EMG, to be
calculated accurately.
The VO2SC has traditionally been characterized as an increase in oxygen uptake
during constant-load exercise (23, 173, 181). Recent investigations, however, have
demonstrated that the increase in oxygen uptake relative to muscle power output can also
be elicited by using ‘all-out’ exercise protocols in which oxygen uptake and muscle
metabolism reach maximal levels despite a fall in power output or force generation (29,
221). Zoladz et al. demonstrated this concept by maximally recruiting dog gastrocnemius
muscle for 4 minutes. Muscle oxygen consumption peaked within the first few minutes,
but torque generation steadily declined, thereby causing the VO2-torque time integral to
increase. Because motor unit recruitment remained maximal due to the use of stimulated
contractions, Zoladz et al. concluded that increased motor unit recruitment was not
necessary to cause a increase in VO2-power output or torque-time integral. Although this
approach was criticized by Borrani et al. on the basis that the VO2SC represents an
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increase in VO2 during constant load work (18), the data from all-out fatigue protocols
indicate the VO2SC manifests cellularly as a function of reduced metabolic or mechanical
efficiency within fatiguing muscle fibers. Put another way, increases in motor unit
recruitment or discharge rates are ultimately necessary to maintain muscle power output
as higher-order motor units fatigue, and this may cause an increase in whole muscle
oxygen consumption and the traditionally reported VO2SC response (18). However, the
VO2SC can still manifest as an increase in the VO2-power output relationship during allout exercise, where increases in motor unit recruitment are not possible, suggesting that
the mechanisms underlying the VO2SC are closely linked to those underlying muscle
fatigue.
Type-II muscle fibers have long been hypothesized to cause the VO2SC at the
cellular level due to the VO2SC’s strong relationship with lactate accumulation and muscle
fatigue (29, 175, 221). Consistent with this prediction, several studies have shown that
the magnitude of the VO2SC is positively correlated with MHC-II content (139, 141–143,
220), and Type-II fibers exhibit a greater ATP cost of force generation than Type-I fibers
(50, 69). Moreover, Krustrup et al. have shown that neuromuscular blockade of Type-I
fibers increases oxygen uptake during single-leg knee extension (112).
What remains unclear is how the VO2SC may manifest within Type-II fibers at the
biochemical and molecular levels. Once again, understanding that the onset of the VO2SC
coincides with the lactate threshold and progressively increases with increasing lactate
accumulation is important (58, 175). Studies using 31P-MRS to investigate other changes
in skeletal muscle bioenergetics during incremental contraction protocols further suggest
that the onset of the VO2SC also coincides with non-linear increases in PCr breakdown,
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acidosis, cytosolic ADP accumulation, and the cytosolic phosphorylation potential (10,
44, 83, 85, 104, 191). Although an increased ATP cost of force generation and
mitochondrial uncoupling have been hypothesized as biochemical mechanisms for the
VO2SC (169, 174), there are presently no experimentally testable predictions that are
unique to either hypothesis. Consequently, we must take a closer look at the
thermodynamic mechanisms that regulate and control oxidative phosphorylation, as well
as the integrative relationships between muscle fatigue and changes in energy demand by
ion pumping and cross-bridge cycling ATPases.

Chemical Thermodynamics and the Mechanism of Oxidative Phosphorylation
The favorability and direction of a chemical reaction is determined by its Gibbs
free energy (ΔG), which defines the energy required to do work. Negative ΔG values
indicate that a reaction is exergonic, or favorable, and has the capacity to be used for
work. In contrast, endergonic reactions exhibit a positive ΔG value, the magnitude of
which indicates the minimum amount of energy required to catalyze the reaction. In
biological systems, cellular work processes are accomplished by enzymes that physically
couple endergonic reactions to exergonic reactions of greater (i.e., more negative) ΔG
magnitude. That is, the free energy cost (+ΔG) of endergonic reactions are overcome, or
paid for, by enzymatic coupling with an exergonic reaction of greater free energy release
(–ΔG), such that the net ΔG of the combined reaction is negative and therefore overall
thermodynamically favorable (189). The clearest examples of this are enzymes that have
evolved to use the –ΔG of ATP hydrolysis to overcome the +ΔG cost of endergonic
cellular work processes, such as ion pumping by the Na+-K+- and Ca2+-ATPases or cross
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bridge cycling by the myosin-ATPases. This means cellular work cannot occur unless the
ΔG release of ATP hydrolysis exceeds the ΔG cost of the work being done, which has
significant implications for muscle fatigue because the ΔG of ATP hydrolysis decreases
as contraction intensity increases (85).
The reactions of oxidative phosphorylation, including the reduction of O2 to water
by cytochrome-c oxidase, also follow these simple principles of chemical
thermodynamics. At present, the currently accepted model of oxidative phosphorylation
is based upon the Chemiosmotic Theory detailed by Dr. Peter Mitchell in 1961 and
subsequent comprehensive works by others that elucidated the intracellular factors
responsible for regulating both the kinetics and stoichiometries of coupling mitochondrial
oxygen consumption to the phosphorylation of ADP within the mitochondrial matrix (15,
39, 88, 105, 151). Briefly, phosphorylation of matrical ADP by ATP synthase is driven
by the exploitation of an electrochemical potential energy (i.e., proton motive force),
generated by the unidirectional pumping of H+s across the inner mitochondrial membrane

Figure 2.2: Basic schematic of Peter Mitchell’s Chemiosmotic Theory of oxidative
phosphorylation (151, 159).

(Figure 2.2). This H+ pumping is accomplished by a series of enzymes forming an
electron transport chain that utilize the Gibbs free energy (ΔG) release of shuttling
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electron pairs to overcome the ΔG cost of pumping H+ against their concentration
gradient. Electron shuttling by the ETC concludes with the reduction of molecular O2 to
H2O by cytochrome-c oxidase, thereby releasing electron pairs from the ETC and
yielding H2O and CO2 as “waste” products, the latter of which is produced during the
oxidation of carbon-chain foodstuffs by enzymes of the citric acid cycle to generate the
NADH and FADH2 necessary to fuel the ETC with electron pairs.
The thermodynamics of ATP synthesis by ATP synthase are conceptually
straightforward. The ATP synthase complex contains two protein structures, F0 and F1,
that function cooperatively like a hydraulic turbine (136). Phosphorylation of ADP within
the mitochondrial matrix is catalyzed by the F0 subunits, which rotate mechanically when
H+s flow through the F1 stalk structure. Consequently, the endergonic phosphorylation of
ADP is thermodynamically favorable only when the electrochemical -ΔG of H+
translocation through F1 exceeds the +ΔG of ATP synthesis by F0, the latter of which is
controlled by the matrical phosphorylation potential (MPP).
The basic schematic in Figure 2.2 is expanded in Figure 2.3 (below) to
incorporate the mechanisms that control MPP. Pioneering works by Chance and
colleagues demonstrated that under state-3 conditions, in which thermodynamic
equilibrium is attained between rates of ATP synthesis and hydrolysis, mitochondrial
respiration in vitro is primarily controlled by changes in cytosolic [ADP] (39, 43), which
is transported across the inner mitochondrial membrane in exchange for ATP by the
adenine nucleotide translocator (ANT) (105, 188, 216). By the mid-1980s, advances in
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P MRS technology significantly improved the study of skeletal muscle bioenergetics in

vivo. Chance et al. leveraged these technological advances to show that changes in
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Figure 2.3: Expanded illustration of the control of oxidative phosphorylation.
Shuttling of ADP/ATP across the inner mitochondrial membrane (IMM) by adenine
nucleotide translocase (ANT) primarily controls the matrical phosphorylation potential
(MPP – ADP·Pi/ATP) and therefore the ΔG cost of ATP synthesis. Mitochondrial (mCK)
and cytosolic (cCK) creatine kinases act as chemical capacitors, which reduces ADP and
ATP diffusion distances and allows them to remain localized near sites of production
(ATP synthase) and consumption (cellular work processes). The outer mitochondrial
membrane has been omitted for visual clarity because it is permeable to most metabolites.

Pi/PCr, a proxy for cytosolic [ADP], are linearly related to increments in muscle workrate under steady-state conditions, suggesting the ADP-control of mitochondrial
metabolism observed in vitro is also observed in vivo when skeletal muscle metabolism
attains steady-state (40). Although others have shown that changes in [Pi] can also affect
the rate of oxygen consumption (84), recent work from Jeneson et al. has shown that
mitochondria are ultrasensitive to changes in cytosolic [ADP], which exhibits secondorder kinetic control over oxidative phosphorylation in vivo (90). Thus, while changes in
[Pi] can influence mitochondrial metabolism, the rate of oxidative phosphorylation is
overwhelmingly controlled by changes in cytosolic [ADP].
However, because cytosolic [ADP] is kept low, diffusion distances between sites
of production and phosphorylation may be limiting to oxidative phosphorylation. To
overcome this limitation, ANT is functionally coupled to the mitochondrial isoform of
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creatine kinase (mCK), which catalyzes the conversion of free creatine (fCr-) to PCr by
hydrolyzing ATP in the intermembranous space. This process occurs in the immediate
vicinity of ANT, allowing ADP to be quickly transported back into the mitochondrial
matrix where it can be phosphorylated once again. Thus, the creatine kinase shuttle acts
as a chemical capacitor that allows mitochondria to achieve rapid rates of oxidative
phosphorylation at low concentrations of ADP (15, 149).
Similar to the thermodynamic control of ATP synthesis by ATP synthase, the
thermodynamic control of oxygen consumption and ETC activity is relatively
straightforward. Like ATP synthesis, proton pumping by the ETC is endergonic and
therefore coupled to the exergonic electron shuttling reactions of complexes 1, 3, and 4.
Consequently, proton pumping by the electron transport chain only occurs when the ΔG
release of electron shuttling exceeds the ΔG cost of pumping H+s against their
concentration gradient. This relationship between proton pumping and electron shuttling
highlights oxygen’s importance to oxidative phosphorylation as an energetic system.
Without oxygen, electron pairs cannot be released from the ETC, which decreases the
thermodynamic favorability of electron shuttling and causes both electron shuttling and
proton pumping by the ETC to slow or cease. In turn, this hinders generation of the
proton motive force, thereby reducing the ΔG release of H+ flow through the F1 structure
of ATP synthase and impairing its ability to synthesize ATP. Hence, inadequate oxygen
supply, or hypoxia, hinders ATP synthesis by limiting the rate at which the proton motive
force and be generated and then subsequently utilized.
However, oxidative phosphorylation is designed such that oxygen consumption
and ETC activity are functionally controlled by the activity of ATP synthase. That is,

26

when cellular ATP demand is low there is no need to generate ATP and the ΔG cost of
ATP synthesis within the mitochondrial matrix exceeds the ΔG release of proton flow
through the F1 structure. Because this inhibits proton flow through ATP synthase, the ΔG
cost of proton pumping exceeds the ΔG release of electron shuttling, causing both ETC
activity and oxygen consumption to slow or cease. Under these conditions, oxidative
phosphorylation and mitochondrial respiration are under state-3 control. Though this is
commonly described as ‘ADP-limited respiration’ due to the manner in which state-3
oxygen consumption rates are stimulated in vitro by boluses of ADP (39, 43, 78), I
believe the more appropriate conceptual description is MPP-limited, as the ΔG cost of
ATP synthesis within the mitochondrial matrix is not determined solely by ADP, but
rather the ΔG cost of the entire ATP synthesis reaction (i.e., ADP + Pi → ATP).
What is absolutely critical to understand, however, is that in contrast to the
obligatory coupling observed between H+ flow and ATP synthesis by ATP synthase, or
H+ pumping and electron shuttling by the ETC, mitochondrial oxygen consumption and
ETC activity are only functionally coupled to ATP synthesis by ATP synthase (159). That
is, the only thermodynamic limitation to ETC chain activity and oxygen consumption is
the ΔG cost of pumping protons against the electrochemical potential energy of the
proton motive force. Under state-3 conditions, ATP synthase is the only major conduit
for H+ reentry into the mitochondrial matrix. However, if H+s can reenter the
mitochondrial matrix through channels other than ATP synthase, such as uncoupling
proteins or chemical protonophores (187, 196), then the magnitude of the proton motive
force is dissipated, which causes the ΔG release of electron shuttling to once again
exceed the ΔG cost of proton pumping. This process, known as mitochondrial
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uncoupling, is illustrated in Figure 2.4, which depicts the increased rate of oxygen
consumption and diminished capacity for ATP synthesis by ATP synthase due to passive
proton flow through an uncoupling protein (UCP). Thus, whereas oxygen consumption,
electron shuttling, and proton pumping are all obligatory for oxidative ATP synthesis
(Figures 2.2 and 2.3), oxidative ATP synthesis is not obligatory for proton pumping,
electron shuttling, and mitochondrial oxygen consumption.

Figure 2.4: Dissipation of the proton motive force by mitochondrial uncoupling. H+
flow through channels other than ATP synthase, such as an uncoupling protein (UCP),
diminishes the capacity for oxidative ATP synthesis while increasing ETC activity and
oxygen consumption. The bold lines indicate the relative activity level of each reaction.

This thermodynamic relationship between mitochondrial ATP synthesis and
oxygen consumption gives us an opportunity to investigate the biochemical mechanisms
underlying VO2SC by using 31P-MRS to examine the effect high-intensity contractions
have on oxidative ATP synthesis and PCr resynthesis. Before examining this relationship,
however, we need to review exactly how the increased ATP cost of force generation and
mitochondrial uncoupling hypotheses explain the VO2SC and other non-linear changes in
skeletal muscle bioenergetics during high-intensity contractions.
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Biochemical Mechanisms of the Slow Component of Oxygen Uptake Kinetics
The key predictions of the increased ATP cost (ATPCOST) of force generation
hypothesis are that augmentations in muscle oxygen consumption reflect increased rates
of oxidative ATP synthesis, and that the increase in PCr breakdown is a function of
greater creatine kinase shuttling activity, due to its role as a chemical capacitor to the
oxidative phosphorylation system (15, 149). Changes in lactate accumulation and
acidosis are also predicted to coincide with the augmentation of muscle oxygen
consumption as a result of oxidative ATP synthesis being unable to match cellular ATP
demand. Physiologically, the ATPCOST hypothesis is predicted to reflect Type IIb muscle
fiber recruitment, which is reasonable considering that these fibers exhibit lower
mitochondrial content than Type I fibers but a greater ATP cost of force generation (50,
63, 69). However, this hypothesis does not readily explain why the magnitude of the
VO2SC would be so closely correlated to lactate accumulation. The difference between
muscle ATP demand and oxidative ATP synthesis could progress linearly as power
output above the lactate threshold increases, but to the best of my knowledge, this has not
been investigated.
Alternatively, the mitochondrial uncoupling hypothesis predicts the increased rate
of muscle oxygen consumption is a function of proton leak across the inner mitochondrial
membrane (169), potentially due to the activation of mitochondrial uncoupling proteins
(152, 176). This would also alter the function of electrophoretic transport proteins that
rely on the proton motive force to shuttle metabolites across the inner mitochondrial
membrane, such as the malate-aspartate NADH shuttle and ANT. Consequently,
mitochondrial uncoupling could also explain why the VO2SC coincides and correlates
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with lactate accumulation and PCr breakdown, as increased uncoupling would
progressively impair the electrophoretic behavior of the malate-aspartate NADH shuttle
and ANT.
The only difference between the ATPCOST and mitochondrial uncoupling
hypotheses are their predicted effects on oxidative ATP synthesis. The ATPCOST
hypothesis predicts that increases in muscle oxygen consumption are a direct indication
of increased oxidative ATP synthesis, whereas the mitochondrial uncoupling hypothesis
predicts that oxidative ATP synthesis is impaired due to dissipation of the proton motive
force through non-ATP synthase conduits. Several methods exist for using 31P-MRS to
measure the rate of oxidative ATP synthesis in contracting muscle, but only a few
investigations have used 31P MRS to study the VO2SC. Broxterman et al. reported an
increase in the ATP cost of force generation during 5-minutes of ‘all-out’ isometric knee
extensions (29). However, a sigmoidal ADP model that excludes the possibility of
mitochondrial uncoupling was used to calculate oxidative ATP synthesis. As discussed
above, mitochondrial uncoupling impairs ANT function, which ultimately causes net
ADP export from the mitochondrial matrix (105, 188). Thus, sustained increases in ADP
may not necessarily reflect a concomitant increase in oxidative ATP synthesis, in which
case the increased ATP cost of force generation reported by Broxterman et al. was a
function of method bias (29).
Pilot work in our lab suggests that hyperbolic methods of calculating oxidative
ATP synthesis overestimate the initial rate of phosphocreatine resynthesis (ViPCr) during
high-intensity contractions. ViPCr is considered a gold standard for measuring oxidative
ATP synthesis because it requires no assumptions about metabolic steady-state, changes
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in the ATP cost of force generation, or mitochondrial coupling (Figure 2.5). However, a
major weakness of using ViPCr to calculate ATPOX is that it only yields 1 measurement of
oxidative ATP synthesis per bout of contractions, meaning multiple trials of varying
duration must be performed to investigate changes in oxidative ATP synthesis over time.
Cannon et al. recently used this method to study the VO2SC during moderate- and highintensity knee extensions and reported that, although the ATP cost of force generation
tended to increase during the high-intensity trial, this increase was insufficient to fully
account for the magnitude of the VO2SC (35), suggesting mitochondrial uncoupling may
have contributed to the augmentation of VO2.
Figure 2.5: Hyperbolic ATPOX
calculations vs. ViPCr. Traditional
methods for calculating oxidative
ATP synthesis (black circles)
overestimate the initial velocity of
PCr resynthesis (red bar) following
high intensity contractions. This
suggests that previous reports of
an increased ATP cost of force
generation (13) may be due to
calculation biases that fail to
include the potential for
mitochondrial uncoupling.

Notably, high inorganic phosphate concentration and acidosis have been shown to
impair creatine-stimulated respiration in vitro, despite not affecting maximal ADPstimulated respiration rates (205). This suggests ViPCr may not necessarily indicate the
true rate of oxidative ATP synthesis following high-intensity contractions, and may offer
an explanation as to how the rate of oxidative ATP synthesis could increase despite the
negative effects that high-intensity contractions have on oxidative capacity (28, 193),
which is commonly measured as the rate constant of PCr resynthesis (kPCr) (103, 130).
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Consistent with the ATPCOST hypothesis, the augmentation in cytosolic ADP
accumulation tends to coincide with the augmentation in PCr breakdown during
incremental contraction protocols (85, 170), which would be expected to occur if
mitochondrial sensitivity to creatine is progressively decreasing. The increase in cytosolic
ADP may also explain why these events, as well as the VO2SC, coincide and correlate
with changes in lactate accumulation, as ADP accumulation within the cytosol will also
stimulate greater activation of the glycolytic pathway and may cause a mismatch between
the rates of non-oxidative glycolysis and mitochondrial oxidation of cytosolic pyruvate
and NADH (94, 204). However, a closer examination of the thermodynamics associated
with muscle oxygen consumption during recovery suggest these considerations are
unlikely.
Recall that oxygen consumption only occurs when the ETC is active, which
requires the ΔG cost of H+ pumping to be lower than the ΔG release of electron shuttling.
In short, oxygen consumption indicates that protons are reentering the mitochondrial
matrix, but it does not necessarily indicate how the protons are reentering this matrix. If
the VO2SC is indeed caused by an increased ATP cost of force generation, then the
diminished rate of PCr resynthesis following high-intensity contractions should be
matched by a rapid decline in muscle oxygen consumption during the recovery period.
Consistent with this prediction, Krustrup et al. reported similar recovery kinetics for
muscle oxygen following low- and high-intensity contractions (111). However, measures
were collected on 7 participants, and only 4 of those demonstrated a VO2SC response,
suggesting three of the participants did not actually complete high-intensity contractions.
Moreover, only the kinetic parameters for the primary recovery component were
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reported, making it difficult to ascertain whether the overall rate of muscle oxygen
consumption in recovery following the high-intensity contractions was strictly
monoexponential or if a slow, secondary, component of elevated muscle oxygen
consumption was evident after the primary component.
In contrast, work by Bangsbo et al. has shown that following high-intensity
contractions, less than 50% of muscle oxygen consumption can be attributed to recovery
processes, such as ATP and PCr resynthesis (6–8). These data suggest that while the
primary time constants of muscle oxygen consumption may not differ following low- and
high-intensity contractions, a slow component of post-exercise oxygen consumption does
occur following high-intensity contractions, and therefore represents a large volume of
consumed oxygen that must be accounted for. That is, if PCr resynthesis is impaired, then
the only explanation that would still support the ATPCOST hypothesis is sustained activity
of ion-pumping ATPases. However, high-intensity contractions appear to impair the
activity of ion-pumping ATPases (56, 137, 138, 147) and maximal Na+-K+-ATPase
activity only appears to account for ~2 % of total ATP turnover (148). This is a crucial
detail, because if PCr resynthesis, ATP repletion, and ATP consumption by ion-pumping
ATPases cannot account for the excess muscle oxygen consumption observed following
high-intensity contractions, then the only thermodynamically possible explanation is
mitochondrial uncoupling. By extension, this suggests that ViPCr can still be used as a
gold standard of oxidative ATP synthesis during high-intensity contractions despite the
impairing effects of high H+ and Pi accumulation (205). More work investigating oxygen
consumption kinetics during recovery from high-intensity contractions is needed to
unravel these differences.
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Summary
The mechanisms of the VO2SC and altered control of oxidative phosphorylation
during high-intensity contractions are not fully understood. Increased ATP cost of force
generation and mitochondrial uncoupling are two leading hypotheses, but myriad
experimental limitations have hindered investigations that can distinguish between the
two in vivo. Both hypotheses offer logical explanations to why skeletal muscle
bioenergetics are non-linearly augmented during high-intensity contractions, but their
predictions about ATPOX are mechanistically different. The ATPCOST hypothesis predicts
that ATPOX increases during high-intensity contractions, whereas the mitochondrial
uncoupling hypothesis predicts diminished ATPOX.
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P-MRS can be used to measure muscle ATPOX during high-intensity muscle

contractions, but most methods are inappropriate for studying the VO2SC because they
inherently assume a constant ATP cost (99) or maintained P/O ratio (29, 55, 120, 206).
The initial velocity of PCr resynthesis can also be used to measure ATPOX, but this
method only yields 1 measurement per bout of contractions, and the metabolic conditions
associated with high-intensity contractions appear to impair PCr resynthesis (205). At this
time, the excess oxygen consumed by muscle following high-intensity contractions does
not appear to be related to a sustained rate of ATP turnover (47, 147, 148). Given the
thermodynamic constraints associated with mitochondrial oxygen consumption, these
results erode enthusiasm for the ATPCOST hypothesis and suggest that ViPCr is not only a
valid measure of ATPOX following high-intensity contractions, but that mitochondrial
uncoupling is at least partially responsible for the VO2SC (35). The goal of this
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dissertation is to provide experimental evidence indicating which of these two hypotheses
may be correct.
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CHAPTER 3
METHODS

Study 1 – Oxidative ATP Synthesis During High-Intensity Contractions
Participants
Nine healthy young adults, 25-40 years old, will be recruited from Amherst and
the surrounding communities using fliers and word-of-mouth. Individuals who
participated in previous studies and indicated they would be interested in participating
again in the future will be contacted by phone or email. All participating individuals will
be screened by telephone to determine their eligibility (see Telephone Eligibility
Screening Form (Study 1, Appendix B) before any visits were scheduled.

Inclusion and Exclusion Criteria
Inclusion criteria for Study 1 are:
•

Generally healthy, by self-report

•

Ambulatory without the use of walking aids

•

Living independently in the community

•

Non-smokers; for at least the preceding 2 years
Exclusion criteria for Study 1 were:

•

Metal implants or other contraindications for magnetic resonance studies

•

History of major neurological, neuromuscular, cardiovascular pulmonary or
metabolic disease

•

Uncontrolled hypertension (blood pressure > 140/90)
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•

Moderate to severe lower extremity arthritis or pain (i.e., pain on level walking or that
limits activities of daily living such as household ambulation and self-care)

•

The use of beta-blockers, sedatives, tranquilizers, or other medication that may impair
physical function, such as statins

•

Failure to pass the Physical Activity Readiness Questionnaire Plus (PAR-Q+,
Appendix D), to be cleared for participation in physical activity

•

Pregnancy, as determined by self-report

•

An inability to understand written and spoken English

•

An inability to follow instructions, as determined by the investigators during the
consenting process
Because exercise training improves skeletal muscle oxidative capacity (123, 124,

129), which may affect the muscle fatigue and bioenergetic responses during the
oxidative capacity and experimental trials (125), we will exclude participants who report
engaging in more than 1 hour of physical activity per day at least 5 days per week.

Paperwork and Experimental Setup
Study one will require one visit lasting 2-3 hours and take place in the Human
Magnetic Resonance Center (hMRC) at the Institute for Applied Life Sciences on the
University of Massachusetts Amherst campus. Upon arriving to the hMRC, participants
will read an informed consent document (Appendix A) and have any questions answered
by the investigator. After agreeing to participate and signing the consent form,
participants will fill out a Medical History Form (Appendix D), Physical Activity
Readiness Questionnaire Plus (Appendix E), and Magnetic Resonance (MR) Safety Form
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(Appendix F). Next, measures of blood pressure, height, and body mass will be obtained.
Before entering the magnet room, participants will meet with the MR Operator to review
their MR Safety Form, remove all jewelry, empty their pockets, and walked through a
metal detector.
Participants will then be escorted to the MR-scanner and positioned on their back
with their dominant leg on top of a custom-built knee extension ergometer. The ankle,
knee, and thigh will be strapped to the ergometer using Velcro straps. Inelastic straps will
also be secured over the participants’ hips to prevent unwanted extraneous movement
during the experimental protocols. To measure changes in intramuscular phosphate
concentrations, a dual-tuned probe (2 copper coil loops for proton and phosphorous, 10.5
x 8 cm) will be secured over the vastus lateralis muscle (VL) using elastic wrap and
Velcro straps. Headphones will be provided to limit the amount of noise from the MR
scanner and to enable clear communication between the participant and the investigators.
The participant’s VL will then be positioned in the center of the MR scanner.

Contraction Protocols
To investigate the effect that high-intensity contractions have on the rate of
oxidative ATP synthesis (ATPOX; mM·s-1) within skeletal muscle, participants will
complete multiple trials of a fatiguing knee-extension protocol. The duration of each trial
will progressively increase, allowing ATPOX to be measured directly from the initial
velocity of PCr resynthesis (ViPCr; mM·s-1) at multiple time points. To begin, participants
will perform 2-3 maximal voluntary isometric (i.e., ‘static’) contractions (MVIC), each
lasting 3-5 s, to determine their maximal torque. At least 1 minute of rest will be given
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between each of these contractions. Participants will then perform 2-3 sets of 3 maximal
voluntary isokinetic contractions (MVDC) at a speed of 120°·s-1 to determine maximal
power.
Next, participants will complete an oxidative capacity protocol starting with 90 s
of rest, followed by 24 s of isokinetic MVDCs (120°·s-1, 1 contraction every 2 s), and 7
minutes of passive recovery. Participants will then complete 3 more trials of isokinetic
MVDCs at a speed of 120°·s-1 (1 contraction every 2 s). Each trial will start with 90 s of
rest and be followed by 10 minutes of passive recovery. The duration of the contractile
period in these experimental will trials increased from 60 s in trial 1 to 120 and 240 s for
trials 2 and 3, respectively.
Measurements of force, velocity, and power produced for each contraction of the
oxidative capacity and experimental trials will be recorded by a custom-written
MATLAB program (The MathWorks Incorporated, Natick, Massachusetts) and
subsequently exported for further analysis in Excel. Contractions will be averaged in 4 s
intervals (i.e., 2 contractions) for the first 40 s and 10 s intervals thereafter (i.e., 5
contractions). Total work (Joules), torque-time integral (TTI; Nm·s), and muscle fatigue
(% max power) will be compared across all trials (i.e., at 24, 60, 120, and 240 s) to ensure
that muscle performance between trials is consistent, thereby allowing us to assume that
ViPCr measured at the end of the 24, 60, and 120 s trials is representative of ATPOX during
the 240-s trial. When total work or TTI during the 120 and 240 s trials are more than 15%
lower than the total work or TTI performed during both the 24 and 60 s trials, the
participant will be asked to reperform the 120 and 240 s trials.
Muscle fatigue will be quantified according to Callahan and Kent-Braun (33):
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Muscle Fatigue (% max power) = 100 · (avg PP) / (0.5 · (PPbaseline + PPprotocol)) Eq# 1
Where avg PP (peak power) is the average peak power measured over a given
time interval of the experimental trial (4 or 10 s), PPbaseline is the highest power measured
during the baseline isokinetic MVDCs, and PPprotocol is the highest power measured
during a single contraction at the beginning of the experimental trial.
Before leaving the hMRC, participants will be given a uniaxial accelerometer
(ActiGraph GT3X, Pensacola, Florida) to quantify habitual physical activity, which will
be analyzed to ensure that none of the participants are actively engaged in one or more
hours of physical activity per day, as per the exclusion criterion described above.
Participants will be instructed to wear the accelerometer on their right hip for 7 days and
to record their physical activity in a log book. At the end of the week-long wear period,
the accelerometer and physical activity log will be collected by the principal investigator
at a time and place that was most convenient for the participant. Accelerometer data will
be recorded in 60 s epochs and processed using ActiLife v6.13 software (ActiGraph,
Pensacola, FL), with a minimum of 10 hours of wear time being required for a given day
to be included in the analysis. Days meeting this criterion will be the analyzed for
average daily activity counts and minutes spent in moderate-vigorous physical activity
using established thresholds for uniaxial ActiGraph accelerometers (57).

Spectroscopy
Gradient-echo scout images of the thigh will be collected to ensure proper
placement of the coil relative to the participant’s thigh muscles, and of the muscles
relative to the magnetic isocenter of the MR scanner. The homogeneity of the magnetic

40

field will be optimized by shimming on the proton (1H) signal to minimize the full width
at half-maximum of the water peak. Measures of non-localized 31P-MRS will be collected
continuously throughout the oxidative capacity and MVDC trials using the following
acquisition parameters: 60° nominal hard pulse, 4,000 Hz bandwidth, 2,048 complex
points, and a 2s repetition time (TR). A total of 270, 375, 405, and 465 acquisitions will
be collected for the oxidative capacity protocol, and 60, 120, and 240 s experimental
trials, respectively.
All spectral analyses will be conducted in jMRUI v6.0beta (156). Because the
short TR used for the contraction protocols results in partial saturation of the spectra, the
first 30 s (15 free induction decays) of every protocol will be excluded from analysis in
order to avoid errors in metabolite quantitation due to changes in partial saturation effects
during this period. The remaining free induction decays will be averaged to yield
temporal resolutions of 60 s at rest, 4 s for all 24 s of the oxidative capacity protocol and
the first 40 s of the experimental trials, followed by 10-s temporal resolution thereafter.
During recovery, free induction decays will be averaged to yield temporal resolutions of
4 s for the first 20 s of recovery, 8 s for the ensuing 280 s of recovery, and 30 s for the
remainder of recovery. The resulting free induction decays will be zero-filled (2,048
points) and apodized using a 1Hz Lorentzian filter. Following Fourier transfrom, spectra
will be manually phased and the x-axis will be zeroed on PCr. An ER-Filter will be used
to truncate the bandwidth above and below 10 and -6 ppm, respectively. We will use the
AMARES algorithm and previously-developed prior knowledge files to linefit peaks
corresponding to phosphomonoesters (PME), the Pi doublet (when observeable),
phosphodiesters (PDE), PCr, and the γATP doublet (199).
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The concentration of γATP at rest will be assumed to equal 8.2 mM and used to
normalize γATP during and after all contraction protocols, so that potential changes in
[ATP] can be evaluated. The concentrations of Pi, PCr, and PME will be calculated by
correcting the measured signal intensities using experimentally-derived saturation
correction factors, and assuming the sum of Pi+PCr+PME is equal to 42.5 mM (72).
Although most previous studies have used the sum of only Pi and PCr (119, 124, 125),
recent work in our lab supports prior work by Bendahan et al. that signal loss due to Pi
trapping within the glycolytic pathway during high-intensity contractions may result in
poor estimations of metabolite concentrations when summing only the Pi and PCr signals
(14). Inclusion of the PME peak appears to rectify this inaccuracy (unpublished data).
Total creatine (TCr) will be assumed to be equal to 42.5 mM and the concentration of
free creatine (fCr) will be assumed to be equal to Pi (119, 122, 125). ADP concentration
will be calculated based on the creatine kinsae equilibrium (K’CK):
[ADP] (mM) = ([ATP][Pi]) / ([fCr] · K’CK)

Eq# 2

We will correct K’CK for changes in cytosolic pH according to an exponential
equation derived from experimental data reported by Golding et al. (65):
K’CK = 241147065 · e(-2.02·pH)

Eq# 3

Muscle pH will be calculated from the chemical shift between Pi and PCr (154),
and weighted for each peak when Pi splitting is observed, according to the equation:
pH = average (pH1· Pi1signal/Total Pisignal + pH2·Pi2signal/Total Pisignal)

Eq# 4

The cytosolic phosphorylation potential (CPP) will be calculated as:
CPP = ([ADP][Pi])/[ATP]

Eq# 5
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Data Analysis – Measurement of Skeletal Muscle kPCr
Baseline oxidative capacity will be determined following the 24-s MVDC
protocol by fitting the observed PCr recovery curve with a mono-exponential function:
PCr(t) = PCrEnd + Amp·(1-Exp(-kPCr · t))

Eq# 6

where PCr(t) is the measured [PCr] at time point t, PCrEnd is the [PCr] at the end
of the contraction, Amp is the amplitude of the recovery in mM, and kPCr is the monoexponential rate constant, which reflects the system’s oxidative capacity. Consistent with
the alteration of oxygen uptake kinetics during high intensity exercise and recovery (58),
PCr recovery following prolonged high-intensity contractions is impaired (28, 193), and
does not follow a mono-exponential recovery pattern (71, 193). Consequently, oxidative
capacity following the experimental protocols will be calculated by fitting the measured
PCr recovery curve with both mono- (Eq 6) and bi-exponential (Eq 7) functions:
PCr(t) = PCrEnd + ((Amp1·(1-Exp(-kPCr1 ·t ))) + (Amp2·(1-Exp(-kPCr2 · t)))

Eq# 7

where PCr(t), Amp, kPCr, and ‘t’ all have their original meanings, and 1 and 2
denote the primary and secondary recovery components, respectively. The function
yielding the lowest sum of least squared differences will be used to determine kPCr. An
example of improved fitting following a 240-s trial when using a biexponential function
compared to a mono-exponential function is demonstrated in Figure 3.1.

Data Analysis – Calculations of ATP Synthesis Rates
Rates of ATP synthesis by the creatine kinase reaction (CK), non-oxidative
glycolysis (Glyc), and oxidative phosphorylation will be calculated for each time point
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throughout all contraction protocols. ATP synthesis by CK will be calculated from the
rate of change in [PCr] over time as:
ATPCK (mM/s) = Δ[PCr]/Δt

Eq# 8
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Figure 3.1: Monovs. bi-exponential
fitting of PCr
recovery following
high-intensity
contractions. The
sum (Σ) of the
squared differences
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the bi-exponential
function, which
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delayed recovery of
[PCr] back to
baseline.

Glycolytic ATP synthesis will be calculated assuming 3 moles of ATP are
synthesized for every 2 moles of lactate (82), and that the ratio of lactate:H+
accumulation is 1:1 (144, 203). The rate of glycolytic ATP synthesis can then be
calculated by measuring changes in muscle pH and accounting for H+ buffering and
efflux according to the equation (119, 122):
ATPGlyc = 1.5 (θ(ΔPCr/Δt) + -βtot(ΔpH/Δt) + VEff)

Eq# 9

where ΔPCr/Δt and ΔpH/Δt are the changes in muscle [PCr] and pH between
successive time points, respectively, θ is a correction factor for the number of protons
consumed by the creatine kinase reaction, βtot is the total muscle buffering capacity in
mM H+/pH unit, and VEffExp is the pH dependent rate of H+ efflux (mM·s-1) measured
during the 240 s trial. θ will be calculated as (96):
θ = 1/(1+10pH-6.75)

Eq# 10
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βtot represents the total buffering capacity of the muscle in slykes (mM H+/pH
unit), which takes into account buffering by Pi (βPi; mM H+/pH unit), PME (βPME; mM
H+/pH unit), and the inherent buffering capacity (βi; mM H+/pH unit):
βtot = βPi + βPME + βi

Eq# 11

βPi and βPME will be calculated according to (96):
βPi = 2.3 · [Pi] / ((1+10(pH - 6.75)) · (1+10(6.75 - pH)))

Eq# 12

βPME = 2.3 · [PME] / ((1+10(pH - 6.2)) · (1+10(6.2 - pH)))

Eq# 13

Inherent buffering (βi; mM H+/pH unit) capacity will be determined by calculating
the apparent total buffering capacity (βApp; mM H+/pH unit) during the 24-s oxidative
capacity protocol and then subtracting the buffering due to Pi and PME (122):
βApp = θ · ((ΔPCr/Δt)/(ΔpH/Δt))

Eq# 14

βi = βApp – βPi – βPME

Eq# 15

where ΔPCr and ΔpH represent the changes in PCr and pH, respectively, and Δt
represents the change in time from rest to the peak of the intramuscular alkalosis, which
in our lab, occurs about 8-12 s into the contraction period.
The rate of H+ efflux (VEff; mM·s-1) during 240 s trial will be calculated from the
change in muscle pH from baseline (ΔpH). During the initial recovery period
intramuscular pH continues to decrease due to H+ release by Pi, after which time, pH
tends to recover linearly back to baseline (97, 206). During this linear phase, increases in
muscle pH are due to proton efflux from the muscle into interstitial fluid, which, after
accounting for H+ release by βi, βPi, βPME, and creatine, permits characterization of the
relationship between the rate of H+ efflux (VEff) and the change in muscle pH from
baseline (ΔpH). Although this relationship has traditionally been characterized as linear
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(122, 206), recent work in our lab suggests the relationship is better characterized by an
exponential function (Figure 3.2). Consequently, VEff during the experimental trials
(VEffExp) will be calculated using an exponential function, according to:
VEffExp (H+·s-1) = AmpVEffExp · Exp(k · ΔpH)

Eq# 16

where AmpVEffExp is the amplitude of the response, k is the rate constant, and ΔpH
is the change in pH from baseline at any given time point during the 3rd experimental
trial.
0.16
Measured Veff
0.12

Veff
0.08
(mM H+/s)

Exponential Fit Veff
Linear Fit Veff

0.04

0.00
0.00

0.15
0.30
0.45
0.60
ΔpH (from Baseline or Resting pH)

Figure 3.2: VEff
Calculation. The
rate of H+ efflux
(VEff) during
recovery, relative
to the change in pH
from baseline or
rest, is better
characterized by an
exponential
function rather
than the traditional
linear relationship
used by others (97,
122, 206).

This exponential equation in Equation 16 will be derived by fitting the calculated
rate of VEff (VEffRec) for each time point during the linear phase of pH recovery against
the ΔpHbaseline, according to the equation:
VEffRec (t) = C - AmpVEffExp·(1-Exp(-k · ΔpHbaseline))

Eq# 17

where C is the maximal measured rate of VEffRec, AmpVEffExp is the amplitude of
the change in pH from rest to the end of acidification during recovery, k is the rate
constant of the function, and ΔpHbaseline is the measured change in pH from rest for a
given time point. VEffRec at any time point (t) will be calculated as:
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VEffRec (H+·s-1) = (ΔβtotRec · (ΔpH/Δt)) + θ · (ΔPCr/Δt)

Eq# 18

where βtotRec · (ΔpH/Δt) and θ · (ΔPCr/Δt) account for H+ released by
intramuscular buffers and phosphorylation of free creatine, and βtotRec is calculated
according to the equation:
βtotRec (mM H+/pH unit) = (βi · ΔpHbaseline) + βPi + βPME

Eq# 19

To compare the accuracy of traditional oxidative ATP synthesis (ATPOX)
calculations to our new method, ATPOX will be calculated by three methods. The initial
rate of PCr resynthesis (ViPCr) will be calculated from the mono- or bi-exponential fitted
rate of change in [PCr] observed in the first 4 s of recovery (20, 35). Because PCr
resynthesis appears to be an entirely aerobic process (71, 168, 180), and because this
method makes no assumptions about changes in ATPCOST or mitochondrial uncoupling,
ViPCr will be considered the gold standard measurement of ATPOX during the isokinetic
MVDC protocols.
The other two ATPOX calculation methods will assume a hyperbolic relationship
between ATPOX and cytosolic [ADP] or CPP (29, 119, 122, 129), according to the
equation:
ATPOX (mM/s) = Vmax / (1 + (Km/X))

Eq# 20

where X is the calculated [ADP] or CPP, Km is the [ADP] or CPP at ½Vmax, kPCr is
skeletal muscle oxidative capacity, and Vmax (mM·s-1) is the maximal rate of ATPOX,
calculated as:
Vmax = kPCr · [PCr]baseline

Eq# 21

The traditional methods for calculating ATPOX from hyperbolic relationships with
[ADP] or CPP assume that: 1) ATPOX is in thermodynamic equilibrium with changes in
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cytosolic ADP or CPP (i.e., chemical steady state), 2) mitochondrial uncoupling does not
occur, and 3) delivery and availability of O2 and other substrates are not limiting to
mitochondrial metabolism. Under these conditions, any increase in [ADP] or CPP is a
direct indication that the rate of ATPOX has also increased. However, high-intensity
contractions do not always involve steady state conditions, and thus, kPCr (28, 193) and
Vmax may be impaired. Because traditional methods for calculating ATPOX do not adjust
for these changes in kPCr and Vmax (29), their estimations of ATPOX may be inflated.
Similarly, a fixed Km has generally been applied to all participants, instead of measuring
the Km for each individual both before and after high-intensity contractions (29, 119). To
overcome these limitations, we will adjust the traditional ATPOX equations to account for
changes in kPCr, Vmax, and Km measured from baseline to the end of the 240-s
experimental trial, according to the equation:
ATPOX (mM/s) = (Vmax - (t · Δ̇Vmax)) / (1 + (Km - (t · Δ̇Km)) /X))

Eq# 22

where t is the elapsed time during the 240-s trial and Δ̇Vmax and Δ̇Km are the
linearly scaled rates of change in Vmax and Km observed from baseline (i.e., 24-s
isokinetic oxidative capacity protocol) to the end of the 240-s experimental trial,
according to the equations:
Δ̇Vmax = (Vmax-baseline - Vmax-post240)/240 s

Eq# 23

Δ̇Km = (Km-baseline - Km-post240)/240 s

Eq# 24

A multiparametric analysis (MPA) will also be used to measure Vmax and Km after
each of the isokinetic MVDC protocols (90, 131). Briefly, MPA methods calculate Vmax,
Km, and the Hill coefficient (nH, which indicates the chemical order of control exerted by
a metabolite or group of metabolites) by fitting the instantaneous rates of PCr resynthesis,
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measured during the recovery period, to the observed [ADP] or CPP using a sigmoidal
function and least-squared differences (90, 131). Although the relationship between
ATPOX and metabolites such as ADP, creatine, and CPP does appear to be sigmoidal, the
time-course of PCr resynthesis, which is being used to estimate ATPOX, is exponential.
Thus, as depicted in Figure 3.3, calculations of Vmax, Km, and nH can be skewed if a large
number of slow PCr resynthesis rates are included in the fitting procedure because
[ADP], CPP, and [creatine] return to resting values much faster than [PCr].
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Figure 3.3: Comparison of multiparametric analyses outcomes when using just the
first 10 calculated rates of PCr resynthesis vs. rates above 0.002 mM/s. Fitting just
the first 10 points (green line) yielded an estimation of Vmax that was nearly 50% higher
than fitting all rates above 0.002mM/s (red line) and resulted in much more accurate
estimations of ViPCr when used to calculate ATPOX during the 240-s experimental trial
(data not shown).

Consequently, Vmax, Km, and nH will be calculated by fitting the first 10 fitted
rates of PCr resynthesis using the least-squared differences and the following hyperbolic
equation:
Δ̇PCr (mM/s) = Vmax / (1 + ((X / Km)^nH))
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Eq# 25

Where Vmax, Km, and nH all have their original meanings, X is the [ADP] or CPP
measured at a given time point, and ΔPCr is the corresponding instantaneous rate of PCr
resynthesis calculated from the mono- or bi-exponentially fitted PCr recovery curve.
To investigate the effect high intensity exercise has on the ATP cost of
contraction (ATPCOST; mM·s-1/W), the calculated rate of total ATP synthesis (ATPtot) by
the 3 main bioenergetic pathways will be divided by work rate (in Watts; W) over the
same time period:
ATPCOST = ATPtot / Watts

Eq# 26

Where ATPtot (mM·s-1) is the summed rate of ATP synthesis by creatine kinase,
glycolysis, and oxidative phosphorylation.
The primary outcome variables for this study will be kPCr, Vmax, Km, and ViPCr
following all 4 of the isokinetic MVDC protocols, as well as the rates of ATPOX, ATPtot,
and ATPcost calculated using the traditional and modified methods at 24, 60, 120, and 240
s of the 240-s experimental trial. Secondary outcome measures will include muscle
fatigue, total work, total torque-time integral, and changes in intramuscular metabolites.
These variables will be compared across all 4 isokinetic MVDC trials to ensure that
muscle performance and energetics were consistent across trials, thereby allowing us to
assume that the ViPCr measured after the 24, 60, and 120-s trials is representative of the
ATPOX rate at those time points during the 240-s trial.

Aims and Hypotheses
Aim 1: Demonstrate that oxidative ATP synthesis is impaired during high-intensity
contractions
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Hypothesis 1a: Muscle oxidative capacity (kPCr) will decline as the duration of the
fatigue trials increase, such that kPCr24 > kPCr60 > kPCr120 > kPCr240.
Hypothesis 1b: The rate of ATPOX, as measured by ViPCr, will steadily decline
beyond the first minute of the fatigue trials, such that ViPCr60 > ViPCr120 > ViPCr240.

Aim 2: Demonstrate that the accuracy of calculating ATPOX during high-intensity
contractions can be improved by adjusting traditional ATPOX calculation methods (29,
119, 206) for measured changes in oxidative capacity (i.e., kPCr)
Hypothesis 2a: Traditional methods for calculating ATPOX that do not adjust for
changes in kPCr and Vmax will overestimate ViPCr following the 60, 120, and 240-s trials.
Hypothesis 2b: ATPOX at 24, 60 and 120 s of the 240-s trial will not differ from ViPCr
following the 24, 60, 120, and 240-s trials when the ATPOX calculations are adjusted to
account for changes in kPCr and Vmax.
Exploratory Aim 1: Compare methods of estimating Vmax for ATPOX calculations
Hypothesis E1a: Vmax will be higher when estimated by multiplying kPCr-baseline ·
[PCr]baseline compared to the ADP and CPP multiparametric analysis methods.
Hypothesis E1b: ATPOX calculations during the 4-minute fatigue protocol will be
greater than ViPCr when Vmax is estimated by multiplying kPCr-baseline · [PCr]baseline, but not
when using the ADP or CPP multiparametric analysis methods.

Statistical Analyses
Sample size estimations were calculated in G-Power 3.1 (Franz Faul, Kiel
University, Germany) assuming α and β levels of 0.05 and 0.8, respectively, and an effect
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size of 1.588. Effect size was estimated from the Pillai’s Trace value obtained by running
a 3x4 repeated measures ANOVA (ATPOX method x time) in SPSS v25.0 (IBM
Statistics, Armonk, New York) on a sample of 3 participants that had completed the full
protocol. The results of this analysis suggested nine participants should be studied.
All statistical analyses will be conducted using SPSS v25.0 (IBM Statistics,
Armonk, New York). Significance will be accepted at the p≤0.05 level. We will report
group means and standard errors (SE), 95% confidence intervals, and p-values for
differences between means. Hypotheses 1a and 1b will be tested using 1x4 and 1x3
repeated measures ANOVAs, respectively. Hypotheses 2a and 2b will be tested using a
3x4 (ATPOX method x time) repeated measures ANOVA. Exploratory hypotheses E1a
and E1b will be tested using a 1x3 (Vmax method) and 2x4 (Vmax method x time) repeated
measures ANOVA, respectively. If the null hypothesis is rejected for one of the ANOVA
tests, a Tukey’s post-hoc analyses will be conducted to identify significant differences
between dependent variables where appropriate.

Study 2 – Mitochondrial Uncoupling and Oxidative ATP Synthesis During
Incremental Knee Extensions
Participants
Eight healthy young adults, 21-40 years old, will be recruited from Amherst and
the surrounding local communities. Individuals who participated in previous studies and
indicated they would be interested in participating again in the future will also be
contacted by phone or email. All individuals will be screened by telephone to determine
their eligibility (see Telephone Screening Form, Appendix H) before scheduling any

52

visits. Inclusion and exclusion criteria will be the same as for Study 1, except that we will
also exclude individuals who self-report vascular diseases, such as varicose veins, or deep
vein or pulmonary embolisms, to avoid complications from the ischemic procedures used
in this study. Unless otherwise noted, all spectroscopy acquisition and post-processing
will be the same as in Study 1.

Visit 1 – Paperwork and Familiarization
Visit 1 will take place in the Muscle Physiology Laboratory in the Totman
Building. Upon arrival, participants will read an informed consent document (Appendix
G) and have any questions answered by the investigator. Next, participants will fill out a
Medical History Form (Appendix C), Physical Activity Readiness Plus Questionnaire
(Appendix D), and Magnetic Resonance (MR) Safety Form (Appendix E). Measures of
blood pressure, height, and body weight will be obtained.
The participants will then be familiarized with the contraction procedures to be
completed during Visit 2, which will be described in detail below. Briefly, participants
will be strapped into a Biodex 3 dynamometer (Biodex Medical Systems, Shirley, New
York) with inelastic straps secured over their ankle, hips, and chest. They will then
perform the same series of isometric and dynamic contractions that will be used to
measure maximal knee extension torque and oxidative capacity during Visit 2.
Participants will also be familiarized with the isotonic incremental knee extension
protocol and intermittent ischemia procedures that will be used during Visit 2 to measure
the efficiency of oxidative phosphorylation. The intermittent ischemia procedures are
described in detail below.
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At the end of Visit 1, participants will be given a uniaxial accelerometer
(ActiGraph GT3X, Pensacola, FL) to quantify habitual physical activity, which will be
analyzed to ensure that none of the participants are actively engaged in more than one
hour of physical activity per day for 5 or more days per week, as per the exclusion
criterion described above. Accelerometer data will be recorded in 60 s epochs.
Participants will be instructed to wear the accelerometer on their right hip for 7 days, and
to record their physical activity in a log book. At the end of the week-long wear period,
the accelerometer and physical activity log will be collected by the principal investigator
at a time and place that is most convenient for the participant. Accelerometer data will be
processed using ActiLife v6.13 software (ActiGraph, Pensacola, FL), with a minimum of
10 hours of wear time being required in order for a given day to be included in the
analysis. Days meeting this criterion will be analyzed for average daily activity counts
and minutes spent in moderate-vigorous physical activity using established thresholds for
uniaxial ActiGraph accelerometers (57).

Visit 2 – Incremental Contraction Protocol and Mitochondrial P/O
To investigate the impact that high-intensity contractions may have on
mitochondrial uncoupling, we will measure the P/O ratio in the VL after each stage of an
incremental knee extension protocol using a new experimental technique adapted from
Marcinek et al. (145) and Ryan et al. (177). Briefly, P/O ratio will be calculated by
comparing the rates of PCr resynthesis and deoxymyoglobin appearance during brief
periods of ischemia. Although previous 31P MRS and muscle biopsy studies suggest that
post-contraction PCr resynthesis does not occur during ischemia (71, 168, 194), our
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recent pilot testing has shown that small changes (1-2 mM) can be observed early in the
recovery period (Figure 3.4). This new experimental technique will be used during Visit
2, which will take place at the hMRC in the Institute for Applied Life Sciences on the
University of Massachusetts Amherst campus. Upon arriving to the hMRC, participants
will meet with the MR Operator to review their MR Safety Form. Before entering the
magnet room, participants will remove jewelry, empty their pockets, and walk through a
metal detector. Participants will then be escorted to the MR scanner and positioned on
their back with their dominant leg on top of a custom-built knee extension ergometer.
The ankle, knee, and thigh will be strapped to the ergometer using Velcro straps. Inelastic
straps will also be secured over the participants’ hips to prevent unwanted extraneous
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Figure 3.4: Phosphocreatine resynthesis (A) and deoxymyoglobin appearance (B)
during 32s of ischemia that followed a 24s MVC. The calculated P/O ratio was 2.33.

phosphate and deoxymyoglobin concentrations, a dual-tuned probe (2 copper coil loops
for proton and phosphorous, 10.5 x 8 cm) will be secured over the vastus lateralis using
athletic wrap and Velcro straps. Headphones will be provided to limit noise from the MR
scanner and enable clear communication with the investigator.
Lastly, two large inflatable blood pressure cuffs, attached to a Hokanson EG20
rapid cuff inflator (D.E. Hokanson Incorporated, Bellevue, Washington) will be wrapped
around the participant’s leg, one each around the upper thigh and calf. To ensure that the
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inflatable cuffs are comfortable for the participants and positioned correctly, we will
perform a familiarization procedure. First, we will inflate the cuffs to a low pressure
(~150 mmHg) and then slowly increase the pressure to 240 mmHg, which will be the
target pressure during the experimental protocol. Once the participant is comfortable with
the cuff placements, we will perform 1-2 rapid inflations (~ 1 s), which will be used to
induce ischemia after each stage of the incremental protocol. If necessary, the cuffs will
be repositioned after these rapid inflations, to make the participant more comfortable
before positioning them in the isocenter of the MR scanner.
Before starting the incremental protocol, participants will complete 2-3 MVICs,
each lasting 3-5 s, to determine their maximal torque. One minute of rest will be given
between each of these contractions. Two of these contractions must be within 10% of
each other in order to confirm a maximal value. Participants will then be refamiliarized
with the isokinetic MVDCs by performing 2-3 sets of 3 MVDCs at a speed of 120°·s-1.
Once participants are comfortable with these contractions, they will perform a rest,
exercise, recovery protocol to measure baseline oxidative capacity (123, 124). The
protocol will begin with 90 s of rest, followed by 24 s of isokinetic MVDCs (0.5 Hz) and
7 minutes of passive recovery.
Participants will then practice a brief series of isotonic contractions before
completing an isotonic incremental knee extension protocol. The incremental protocol
will consist of 6 stages. Each stage will consist of 1 contraction every 2 s for 3 minutes.
Workload will increase with each stage, starting at 10% of the participant’s MVIC force,
and increasing by 8% for each stage thereafter. Immediately after each stage, we will
measure the efficiency of oxidative phosphorylation (i.e., P/O ratio) using an intermittent-
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ischemia protocol adapted from Ryan et al. (177), which will be performed in the
following sequence:
1- Up to 12 s of rest will be given to allow the muscle to reoxygenate
2- The inflatable cuffs will be rapidly inflated to 240 mmHg
3- The cuffs will remain inflated for up to 40 s while we measure rates of muscle
energy production and oxygen consumption
4- The cuff will be rapidly deflated to allow muscles to recover and reoxygenate
Following Step 4 of the intermittent-ischemia protocol, the next 3-minute stage of
contractions will begin. To ensure that our MR-acquisition of 1H and 31P signals remain
time-aligned with the contraction protocol, we will restart MR-acquisition after every
stage, with 30 s of rest added to the beginning of the stage to eliminate the effects of MRsaturation. After the intermittent ischemia procedures have been completed for Stage 6
(the final stage), participants will complete one more minute of stage 6 isotonic
contractions, followed by a 10 min recovery period, which will allow us to re-measure
the participant’s kPCr and accurately calculate rates of ATPOX during the incremental
protocol. This will also provide critical insight into how changes in kPCr relate to changes
in the efficiency of oxidative phosphorylation. After the recovery measures have been
collected at the end of the incremental protocol, the participants will rest quietly during a
10-minute ischemic calibration protocol. This is a standard procedure our lab uses to
determine complete desaturation of myoglobin for use in normalizing (% maximum) the
deoxymyoglobin (dMb) signal during all protocols (121, 194).

Muscle Torque, Power, and Total Work
Torque and power data for each contraction of the isotonic incremental kneeextension protocol will be collected by a custom MATLAB program (The MathWorks
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Incorporated, Natick, Massachusetts) and exported for further processing in Excel. Total
work (in Joules) will be summed in 20-s increments and then converted to power (in
Watts, Joules/s).

Spectroscopy
Before starting the contraction protocol, gradient-echo scout images of the thigh
will be collected to ensure proper placement of the coil relative to the participant’s thigh
muscles, and the thigh relative to the magnetic isocenter of the MR scanner. The
homogeneity of the magnetic field will be optimized by minimizing the full width at half
maximum (FWHM) of the water peak using non-localized shimming of the proton (1H-)
signal. Absolute quantitation of intramuscular phosphates at rest will be calculated using
the non-localized water signal as an internal reference (21, 32, 202). The non-localized
water signal will be collected from the 1H-channel using the following acquisition
parameters: 60° hard pulse, 2,000 Hz bandwidth, 1,024 complex points, 2 s TR, 0.35 ms
echo time (TE), and a total of 70 acquisitions. Non-localized phosphate signals will then
be collected from the phosphorous (31P) channel using the following parameters: 60° hard
pulse, 4,000 Hz bandwidth, 2,048 complex points, 2 s TR, and a total of 70 acquisitions.
Absolute quantitation of muscle creatine will be determined using localized spectroscopy
and the water signal as an internal reference (22, 27, 59).
The homogeneity of the magnetic field will then be optimized for a 2x2x2cm
voxel centered within the vastus lateralis, and if necessary, parts of the rectus femoris, by
minimizing the FWHM of the tissue water signal. The localized water signal will be
collected from the 1H-channel using the following parameters: water unsuppressed 90°
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hard pulse, 2,000 Hz bandwidth, 2,048 complex points, 2 s TR, 30 ms TE, and a total of
70 acquisitions. The localized creatine signal will be collected from the 1H-channel using
the following parameters: water suppressed 90° hard pulse, 2,000 Hz bandwidth, 2,048
complex points, 2 s TR, 30 ms TE, and a total of 70 measurements.
Lastly, muscle dMb (mM) will be calculated using the non-localized water signal
as an internal reference (110). During the intermittent ischemia and ischemic calibration
procedures, the non-localized dMb signal will be collected from the 1H-channel using the
following parameters: 90° gaussian pulse, 30,120 Hz bandwidth, 256 complex points, 2 s
TR, and 0.35 ms TE. Consequently, to ensure the signal magnitudes are comparable, we
will measure the non-localized water signal (a second time) using the following
parameters: 90° gaussian pulse, 30,120 Hz bandwidth, 256 complex points, 10 s (fully
relaxed) TR, 0.35 ms TE, and 6 acquisitions. This water signal will be acquired following
acquisition of the water signal for absolute quantitation of the phosphorous metabolites.
The peak dMb signal, which will be used for quantification, will be acquired at the end of
the 10-minute ischemic calibration period.
Measures of non-localized 31P-MRS will be collected continuously throughout the
oxidative capacity protocol using the following parameters: 60° hard pulse, 4,000 Hz
bandwidth, 2,048 complex points, a 2 s TR, and a total of 270 measurements. During the
isotonic incremental protocol, measures of non-localized 1H- and 31P-MRS will be
collected continuously using an interleaved sequence. For 31P-acquisition, we will use the
following parameters: 60° hard pulse, 4,000 Hz bandwidth, 2,048 complex points, a 2 s
TR, and a total of 180 measurements. For 1H-acquisition, we will use the following
parameters: 90° gaussian pulse, 30,120 Hz bandwidth, 256 complex points, 40 ms TR,
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and 0.35 ms TE. Fifty 1H-FIDs will be acquired during each pass of the 1H signal to yield
a temporal resolution of 2 s per acquisition for a total of 180 measurements. However,
because of the interleaved sequencing, the true temporal resolution for both the 1H and
31

P acquisitions will be 4 seconds.

Spectral Analyses
All spectral analyses will be conducted in jMRUI v6.0beta (156). Because of the
short TR (2 s) being used for the contraction protocols, the first 30 s of every acquisition
will be excluded from the oxidative capacity protocol and each stage of the incremental
protocol, to avoid errors in metabolite quantitation due to partial saturation effects. The
remaining free induction decays (FIDs) from the oxidative capacity protocol will be
analyzed as described for Study 1. For the incremental protocol, FIDs will be averaged to
yield temporal resolutions of 20 s during contractions. No averaging will be done for the
FIDs acquired during the 10 s of recovery or intermittent ischemia periods. During the
extra 1 minute of stage 6 contractions, FIDs will be averaged to yield temporal
resolutions of 20 s at rest, 10 s during contractions, 4 s for the first 20 s of recovery, 8 s
for the ensuing 280 s of recovery, and 30 s for the remainder of recovery.
Phosphorous FIDs will be zero-filled (2,048 points) and apodized using a 1 Hz
Lorentzian filter. Following Fourier transfrom, spectra will be manually phased and the
x-axis (frequency in ppm) will be zeroed on PCr. We will use the AMARES algorithm
and prior knowledge files to linefit peaks corresponding to phosphomonoesters (PME),
the Pi doublet (when observeable), phosphodiesters (PDE), PCr, and the γATP doublet
(199). To ensure that the γATP signal is not contaminated by PCr, the ER Filter will also

60

be used to truncate the bandwidth above and below -1.5 and -6 ppm, respectively, to
allow individual linefitting of the γATP peaks.
Proton FIDs will be zero-filled (512 points) and apodized using a 10-Hz Gaussian
filter. Following Fourier transform, the x-axis will be referenced on the water peak (4.65
ppm). The water signal will then be filtered out using the Hankel Lanczos Squares
Singular Decomposition (17). The resulting spectrum will then be phased manually on
the deoxymyoglobin peak at ~78 ppm, and truncated above and below 100 and 60 ppm
using the ER Filter. The AMARES algorithm (199) will then be used to linefit the peak
corresponding to deoxymyoglobin using a prior knowledge file.

Data Analysis – Metabolite Quantification, kPCr, and ATP Flux
Phosphorous metabolites, total creatine, and dMb will be quantified using the
water signal as internal reference and assuming a muscle water concentration of 85.5 M
(32, 59, 110). The methods for calculating skeletal muscle kPCr, Vmax, Km, nH and ATP
flux through the 3 main bioenergetic pathways will be identical to those described for
Study 1.

Data Analysis – Calculating P/O Ratios
The primary outcome variable for this study will be P/O at the end of each stage.
The efficiency of oxidative phosphorylation will be calculated from the changes in PCr
and dMb measured during the ischemic period following each stage of the incremental
protocol. Although previous work has shown that PCr resynthesis appears to be an
entirely oxidative process (71, 168), pilot work in our lab suggests PCr resynthesis can
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occur early in ischemia provided there is still oxygen bound to myoglobin. Consequently,
we will measure the rate of oxidative ATP synthesis (mM·s-1) by fitting the PCr recovery
signal, measured during ischemia, with a linear regression. Similarly, the dMb signal
increases as the partial pressure of intracellular oxygen pO2 declines Thus, if total dMb
content can be estimated then the rate of muscle oxygen consumption can be estimated
from the rate of change in the dMb signal (mM·s-1). The rates of PCr resynthesis and
dMb appearance can then be used to calculate P/O according to the equation:
P/O = Δ̇PCr (mM/s) / Δ̇dMb (mM/s)

Eq# 27

Lastly, I am hypothesizing that mitochondrial uncoupling (i.e., reduced P/O ratio)
will only occur during power outputs above an individual’s acidic threshold, which will
be used as a proxy for the lactate threshold because we will not be able to measure
intramuscular lactate directly. Acidic threshold will be calculated for each individual
according to Systrom et al. (191) as the first workload in which end-stage pH falls below
the 95% confidence interval range for resting pH, as determined from the average of
resting pH measured at the start of the first 3 stages.

Aims and Hypotheses
Aim: To demonstrate that P/O declines during high-intensity contractions above the
acidic threshold.
Hypothesis: During incremental contractions of the knee extensor muscles, skeletal
muscle P/O will remain constant for all workloads below the acidic threshold, and
progressively decrease as workload increases during stages above the acidic threshold.
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Statistical Analyses
Sample sizes were calculated in G-Power 3.1 (program designed by Franz Faul,
Kiel University, Germany) assuming α and β levels of 0.05 and 0.8, respectively, and an
effect size of 0.5. To the best of my knowledge, there are no data directly measuring
mitochondrial P/O ratio following high-intensity contractions in vivo. Amara et al.
reported that mitochondrial P/O ratio in resting skeletal muscle was 40% lower in the
flexor digitorum longus of older vs. younger adults (1) but no age-related differences
were found for the tibialis anterior muscle. For these reasons, I conservatively estimated a
partial eta- (η) squared of 0.2, which resulted in an effect size calculation of 0.5. I also
assumed a conservative correlation among repeated measures of 0.5 and a non-sphericity
correction of 0.6 (possibility range of 1.0 to 0.2). The resulting sample size calculations
indicated eight participants would be needed.
All statistical analyses will be conducted using SPSS v25.0 (IBM Statistics,
Armonk, New York). Significance will be accepted at the p≤0.05 level. We will report
group means and standard errors (SE), 95% confidence intervals, and p-values for
differences between compared means. Hypothesis 1a will be tested using a repeated
measures ANOVA to analyze differences in P/O between stages. If the null hypothesis is
rejected, a Tukey’s post-hoc analysis will be conducted to identify significant differences.
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Postori Methodological Amendments
Although I proposed that workload would increase by 8% of MVIC torque
between each stage of the step-wise test in study 2, pilot testing indicated that only 2%
increments were necessary. Similarly, it was necessary to reduce the starting workload to
8% MVIC torque in some participants to allow them to complete a total of six stages.
Finally, due to circumstances outside of our control, we were unable to develop
the interleaved 1H/31P-MR sequence needed to perform the intermittent ischemia
technique I developed for measuring skeletal muscle P/O ratio after a period of
contractions. Consequently, the primary aim of Study 2 was unachievable, and the
protocol was adapted to better examine changes in the rate and control of oxidative ATP
synthesis above and below the acidic threshold. Specifically, each stage of the stepwise
isotonic knee extension test was separated by 3 minutes of passive recovery, which
allowed us to perform two critical analyses: 1) calculate rates of oxidative ATP synthesis
at the end of each stage from the initial velocity of PCr resynthesis, which Study 1
showed was unaffected by severe decreases in muscle pH, and 2) conduct
multiparametric analyses describing the control of oxidative ATP synthesis by cytosolic
ADP and phosphorylation potential. Subsequently, our Aims and hypotheses changed as
follows:

Study 2 – New Aims and Hypotheses
Aim 1: Examine the relationship between skeletal muscle workload and end-stage
changes in cytosolic ADP, phosphorylation potential, and PCr breakdown for workloads
above and below the acidic threshold.
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Hypothesis 1: The slope of cytosolic ADP, phosphorylation potential, and PCr
breakdown, relative to changes in workload, will be greater above the lactate threshold
than below.
Aim 2: Examine the relationship between skeletal muscle workload and steady state rates
of oxidative ATP synthesis for workloads above and below the acidic threshold.
Hypothesis 2: The slope of oxidative ATP synthesis, relative to changes in workload,
will be greater below the lactate threshold than above.
Aim 3: Examine the impact workloads above and below the acidic threshold have on
kinetic parameters that describe the control of oxidative ATP synthesis by cytosolic ADP
and phosphorylation potential, including Vmax, Km, and the Hill coefficient (nH).
Hypothesis 3: Vmax, Km, and nH will be similar for workloads below the acidic
threshold but then become progressively impaired as workload increases above the acidic
threshold.

Statistical Analyses
All statistical analyses will be conducted using SPSS v25.0 (IBM Statistics,
Armonk, New York). Significance will be accepted at the p≤0.05 level. We will report
group means and standard errors (SE). Hypotheses 1 and 2 will be tested using paired ttests or the non-parametric equivalent Friendman Test. Hypothesis 3 will be tested using
repeated measures ANOVAs. If the null hypothesis is rejected, the estimated marginal
means will be used to identify significant differences.
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CHAPTER 4
ACCURACY AND VALIDITY OF CALCULATING OXIDATIVE ATP
SYNTHESIS DURING HIGH-INTENSITY CONTRACTIONS

Abstract
A full understanding of intracellular bioenergetics during muscular work requires
accurate quantitation of the energy (ATP) produced by each metabolic pathway: the
creatine kinase reaction, nonoxidative glycolysis, and oxidative phosphorylation. Several
methods exist for using 31P-MRS to continuously measure rates of oxidative ATP
synthesis (ATPOX) during moderate-intensity muscle contractions, but their efficacies
have not been validated for high-intensity contractions where relationships between
muscle work and oxygen consumption, ADP accumulation, and cytosolic
phosphorylation potential are augmented. Specifically, it is unclear whether these
augmentations in muscle metabolism are is driven by greater rates of ATPOX due to
increases in the ATP cost of force generation (ATPCOST), or mitochondrial uncoupling, a
process that reduces the efficiency of ATPOX. To overcome these limitations, we
measured phosphate concentrations and muscle pH in the vastus lateralis of 9 young
adults during 4 rest-exercise-recovery trials lasting 24, 60, 120, and 240 s. Maximal
isokinetic knee extensions (120°·s-1, 1 every 2 s) were performed in a 3 Tesla magnetic
resonance system. The initial velocity of phosphocreatine resynthesis (ViPCr) following
each trial served as the criterion ATPOX measure, and estimated rates of ATPOX
calculated from several continuous ATPOX calculation methods were evaluated. Changes
in power, metabolites (PCr, Pi, ATP, ADP) and pH were highly reproducible across
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trials. ViPCr plateaued from 60-120 s but was reduced following the 240-s trial (p<0.05).
Methods assuming a constant relationship between muscle work and ATPCOST were able
to model this behavior but showed poor ability to accurately predict ViPCr across a wide
range of ATPOX values. In contrast, methods that assumed no mitochondrial uncoupling
were considered invalid because they did not model the decline in ViPCr. However,
adjusting these ATPOX calculations for fatigue-induced changes in maximal ATPOX
capacity (i.e., Vmax) eliminated this error. Subsequently, we identified additional
weaknesses of each ATPOX method and propose solutions for further improving their
accuracies. This study demonstrated that high-intensity contractions impair the capacity
for ATPOX and validates a new, improved methodology for using 31P-MRS to
continuously calculate ATPOX.
Index Terms: muscle, VO2 slow component, ATP cost, mitochondrial uncoupling,
oxidative phosphorylation

Introduction
During moderate-intensity contractions (i.e., below the lactate threshold), skeletal
muscle oxygen consumption is linearly related to power output and ATP demand is met
largely by oxidative metabolism (2, 58). However, during high-intensity contractions at
power outputs above the lactate threshold, the linear relationship between skeletal muscle
oxygen consumption and power output is augmented (4, 174, 212) and steady-state ATP
turnover is increasingly supplemented by anaerobic metabolism (102, 175). Together,
these observations have become known as the slow component of oxygen uptake kinetics
(VO2SC).
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The biochemical mechanisms underlying the VO2SC are not fully understood, but
increased ATP cost of force generation (ATPCOST) and mitochondrial uncoupling are two
leading hypotheses (169, 174). Definitive support for either hypothesis has been hindered
by an inability to identify testable predictions that distinguish the two hypotheses from
one another in vivo. However, one major difference between the two hypotheses is their
prediction about the impact high-intensity contractions have on oxidative ATP synthesis
(ATPOX). Whereas the increased ATPCOST hypothesis predicts that augmentations in
muscle oxygen consumption are a direct reflection of increased rates of ATPOX, the
mitochondrial uncoupling hypothesis predicts that high-intensity contractions impair the
efficiency of oxidative phosphorylation (i.e., decreases the number of ATP produced per
dioxygen molecule consumed, or P/O ratio). Thus, it may be possible to distinguish the
increased ATPCOST and mitochondrial uncoupling hypotheses from one another in vivo by
directly measuring changes in ATPOX during moderate- and high-intensity contractions.
Yet, where one solution is offered, another limitation presents itself. Under the
steady-state conditions of moderate-intensity contractions, 31-phosphorous magnetic
resonance spectroscopy (31P-MRS) can be used to continuously calculate rates of ATPOX
from changes in muscle force production (99), PCr breakdown (149), cytosolic ADP
accumulation (29, 197), or increases in cytosolic phosphorylation potential (CPP) (119,
206). Although prior work has demonstrated most of these methods show good
agreement for estimating ATPOX during moderate-intensity contractions (129), their
accuracies have not been validated during high-intensity fatigue protocols. Moreover, all
these methods are inherently based on an assumption of either constant ATPCOST or
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mitochondrial coupling, and are therefore all inherently, mathematically biased against
one of the two competing hypotheses.
A third method for using 31P-MRS to calculate ATPOX is to measure the initial
velocity of PCr resynthesis (ViPCr) (19, 35, 158). This method assumes that, glycolysis
does not substantially contribute to PCr resynthesis during recovery, and that ATP
consumption by ion pumping ATPases is negligible (35, 95). The primary strength of
using ViPCr to measure ATPOX during high-intensity contractions is that it makes no
assumptions about constant ATPCOST or mitochondrial coupling. However, it only yields
one measurement of ATPOX per bout of contractions, and therefore cannot be used to
study changes in ATPOX over time unless participants perform multiple bouts of exercise
that vary in duration. Cannon et al. recently used this approach to investigate the VO2SC
by having participants perform multiple bouts of moderate- and high-intensity knee
extensions lasting 3 and 8 minutes (35). Although ViPCr and ATPCOST both appeared to
increase from minutes 3-8 during high-intensity contractions, the increases were
insufficient to account for the full magnitude of the VO2SC, suggesting mitochondrial
uncoupling may have also played a role.
There is a clear need to delineate whether high-intensity contractions augment or
impair ATPOX, as well as to validate methods for using 31P-MRS to continuously measure
ATPOX during high-intensity contractions in vivo. To address these gaps, we combined
experimental approaches from Layec et al. (129) and Cannon et al. (35). Briefly,
participants performed 4 bouts of maximal isokinetic knee extensions, lasting 24, 60, 120,
and 240 s. ViPCr was calculated after each trial, yielding 4 gold-standard measurements of
ATPOX across time. Subsequently, this allowed us to: 1) examine the impact high-
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intensity contractions have on ATPOX via changes in ViPCr, and 2) assess the validity and
accuracy of traditional methods for calculating ATPOX during high-intensity contractions
by comparing ATPOX estimations obtained during the 240-s trial to ViPCr measurements
made at the corresponding timepoints. Here, validity will refer to the ability of an ATPOX
method to model changes in ViPCr (i.e., increasing, decreasing, or plateauing), whereas
accuracy will refer to the magnitude of separation between pairs of ATPOX estimations
and ViPCr measurements.
Our primary hypotheses were that: 1) peak ViPCr would be achieved following
either the 60- or 120-s trials, 2) ViPCr would decline from its peak by the end of the 240-s
trial, 3) the maximal capacity for ATPOX (i.e., kPCr or Vmax) would decline from its peak
by the end of the 240-s trial, and 4) ATPCOST would not change across time. Our
secondary hypotheses were: 1) adjusting traditional, continuous ATPOX calculation
methods for changes in muscle oxidative capacity (kPCr) or maximal rates of oxidative
ATP synthesis (Vmax, mM·s-1) would improve the accuracy of predicting ViPCr at 24, 60,
and 120 s during the 240-s experimental trial, and 2) given that prior work has shown that
the different methods for estimating Vmax in vivo yield significantly different values
(131), the method used to estimate Vmax would affect the accuracy of ATPOX calculations.

Methods
Participants
Participants were recruited from Amherst and the surrounding communities using
fliers and word-of-mouth. Prior to enrollment, prospective participants were screened by
telephone to determine their eligibility and excluded if they reported cardiovascular,
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respiratory, or musculoskeletal diseases that would impair their ability to complete the
contraction protocol. Subsequently, nine healthy young adults (3 females) were enrolled
in the study after providing written informed consent, as approved by the Institutional
Review Board at the University of Massachusetts Amherst and in accordance with the
Declaration of Helsinki. Because exercise training improves skeletal muscle oxidative
capacity (123, 124, 129), which may affect the muscle fatigue and bioenergetic responses
during the oxidative capacity and experimental trials (125), we exclude participants who
reported engaging in more than 1 hour of physical activity per day at least 5 days per
week. Additionally, we quantified habitual physical activity using uniaxial accelerometry
(ActiGraph GT3X, Pensacola, Florida). Participants were instructed to wear the
accelerometer during all waking hours for a full week and to record their physical activity
in a daily logbook. Daily activity (counts·day-1/1000) and minutes spent in moderatevigorous physical activity (MVPA) were quantified using established thresholds for
uniaxial ActiGraph accelerometers (57).

Experimental Approach
To examine the validity and accuracy of traditional methods for continuously
calculating ATPOX during high-intensity contractions, participants completed 4 trials of a
fatiguing knee-extension protocol inside the bore of a 70 cm 3-Tesla MR system
(Siemens, Erlangen, Germany). Phosphate concentrations were measured continuously in
the vastus lateralis before, during, and for up to 10 minutes after each trial. The duration
of each trial progressively increased (24, 60, 120, and 240 s), thereby allowing ATPOX to
be measured from the initial velocity of PCr resynthesis (ViPCr; mM·s-1) following

71

multiple contraction protocol durations. The ViPCr method is considered here as the ‘gold
standard’ measurement of ATPOX that all continuous ATPOX calculation methods were
compared to. Total work (Joules), muscle fatigue, and changes in metabolite
concentrations such as phosphocreatine (PCr), inorganic phosphate (Pi), and H+ were
compared across all 4 trials to ensure muscle performance and energetics were consistent,
thereby allowing us to assume that ViPCr measured after the 24, 60, and 120-s trials were
representative of the ATPOX rates occuring at those same timepoints during the 240-s
trial. Subsequently, we calculated ATPOX continuously throughout the 240-s trial using
several traditional ATPOX calculations (29, 99, 119, 158, 197, 206), and assessed validity
and accuracy by comparing ATPOX calculations from each method to the corresponding
ViPCr measurements.

Experimental Setup
Participants were positioned supine inside a 3-Tesla MR system (Siemens,
Erlangen, Germany) with their dominant leg strapped securely to a custom-built kneeextension ergometer (Jabr et al., submitted) at the ankle, thigh, and hips, and a dual-tuned
31

P/1H surface coil (8 x 10.5 cm) positioned over the vastus lateralis. The knee-extension

ergometer’s contraction mode, duration, and frequency were all controlled using a
custom-written MATLAB program (Mathworks, Natick, Massachusetts). Torque, power,
position, and work were recorded for each contraction and exported for post-processing
in Excel (Microsoft, Redmond, Washington). The program also provided participants
with real-time visual feedback about torque production and muscle fatigue through
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display on a non-magnetic digital screen (LCD BOLDscreen, Cambridge Research
Systems Ltd., United Kingdom).

Contraction Protocol
Prior to the contraction protocol, participants performed 2-3 maximal voluntary
isometric contractions (MVIC), each lasting 3-5 s and followed by at least 1 minute of
rest. Participants then performed 2-3 sets of maximal voluntary dynamic contractions
(MVDCs) to measure maximal knee-extension power. All MVDCs were isokinetic
(120°·s-1) and performed at a frequency of 1 contraction every 2 s.
The experimental protocol consisted of 4 trials of isokinetic MVDCs (120°·s-1, 1
contraction every 2 s), starting with 90 s of rest, followed by 24, 60, 120, or 240 s of
contractions, and 7-10 minutes of quiet recovery. Muscle fatigue, power, and concentric
work were calculated for each contraction of all 4 experimental trials and averaged in 4-s
intervals (i.e., 2 contractions) for the first 40 s of contractions and 10-s intervals
thereafter (i.e., 5 contractions). Muscle fatigue was quantified according to Callahan and
Kent-Braun (33):
Fatigue (% max power) = (average PP) / (average (PPbaseline + PPprotocol)) · 100

Eq 1

where PP (peak power) is the peak power achieved during a single MVDC,
average PP is the average PP measured across MVDCs over a given time interval (i.e., 4
or 10 s), PPbaseline is the greatest PP measured during any of the baseline isokinetic
MVDCs, and PPprotocol is the greatest PP measured during a single contraction of the
experimental trial.
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Spectroscopy
Gradient-echo scout images of the thigh were acquired to ensure proper
placement of the coil relative to the participant’s vastus lateralis and magnetic isocenter
of the MR-scanner. The homogeneity of the magnetic field was optimized by shimming
on the proton (1H) signal to minimize the full width at half-maximum of the PCr peak
(12.1 ±0.3 Hz), with the carrier frequency placed midway between the PCr and
phosphodiester peaks. During the 4 experimental trials, non-localized 31P-MRS freeinduction decays (FIDs) were collected continuously (60° nominal hard pulse, 4,000 Hz
bandwidth, 2,048 complex points, 2 s repetition time) for 90 s of rest, throughout the
contractile period (i.e., 24-240 s), and during quiet recovery (7 min for the 24-s trial, 10
min for the 60-, 120-, and 240-s trials).
All spectral analyses were completed in jMRUI v6.0beta (156). The first 30 s (15
FIDs) of each trial were excluded from analysis to avoid partial saturation effects. The
remaining FIDs were averaged to yield temporal resolutions of 60 s at rest, 4 s for the
first 40 s of the experimental trials, and 10 s for the remainder of the contraction period.
During recovery, FIDs were averaged to yield temporal resolutions of 4 s for the first 20 s
of recovery, 8 s for the ensuing 280 s of recovery, and 30 s for the remainder of recovery.
FIDs were then zero-filled (2,048 points) and apodized using a 1-Hz Lorentzian filter.
Following Fourier transfromation, spectra were manually phased and the frequency set to
zero at PCr. The AMARES algorithm was used to linefit peaks corresponding to
phosphomonoesters (PME), the inorganic phosphate (Pi) doublet, phosphodiesters (PDE),
phosphocreatine (PCr), the γ- and α-ATP doublets, and the β-ATP triplet (199).
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Millimolar concentrations of phosphorous metabolites were calculated by
correcting metabolite signal intensities using experimentally-derived saturation correction
factors, and assuming that resting [Pi]+[PCr]+[PME] = 42.5 mM and [ATP] = 8.2 mM
(119, 122, 125). Total muscle creatine was assumed to equal 42.5 mM and the
concentration of free creatine (fCr) was assumed to be equal to [Pi] (119). Changes in
[ATP] during the experimental trials were calculated by comparing the sum of the γ- and
α-ATP signal intensities at each timepoint to the sum of the γ- and α-ATP signal
intensities at rest, along with a 5-point rolling average to minimize fluctuations due to
noise.
[ADP] (mM) was calculated based on the creatine kinase equilibrium (K’CK):
[ADP] = ([ATP] [fCr]) / ([PCr]· K’CK)

Eq 2

K’CK was corrected for changes in cytosolic pH according to an exponential
equation derived from experimental data reported by Golding et al. (65). Muscle pH was
calculated from the chemical shift between Pi and PCr (154). The cytosolic
phosphorylation potential (CPP) was calculated as:
CPP = ([ADP][Pi])/[ATP]

Eq 3

Adenosine monophosphate (AMP) concentration (mM) was calculated based on
the adenylate kinase equilibrium (K’AK):
[AMP] = ( K’AK · [ADP]2)/[ATP]

Eq 4

K’AK was corrected for changes in cytosolic pH according to an exponential
equation derived from experimental data reported by Golding et al. (65).
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Skeletal Muscle Oxidative Capacity
Baseline skeletal muscle oxidative capacity (kPCr) was determined following the
24 s trial by fitting PCr recovery to a monoexponential function:
PCr (t) = PCrEnd + Amp·(1-Exp(-kPCr · t))

Eq 5

where PCr (t) is the calculated [PCr] at time point (t), PCrEnd is the measured
[PCr] at the end of the 24 s trial, Amp is the amplitude of the recovery in mM, and kPCr is
the mono-exponential rate constant, which reflects the system’s oxidative capacity (149,
150). In most cases, PCr recovery following the 60, 120, and 240 s trials did not follow a
mono-exponential recovery pattern (28, 71, 193), and were better fit (i.e., lower sum of
squares) using a bi-exponential function (206):
PCrFit (t) = PCrEnd + ((Amp1·(1-Exp(-kPCr1 ·t ))) + (Amp2·(1-Exp(-kPCr2 · t)))

Eq 6

where PCrFit, (t), Amp, and kPCr, all have their original meanings, and 1 and 2
denote the primary and secondary PCr recovery components, respectively. To avoid
physiologically unrealistic amplitude and kPCr estimations, the sum of Amp1 + Amp2 was
constrained to be no greater than the difference between [PCr]Baseline and [PCr]EndTrial.
Subsequently, the overall kPCr of the biexponential function was calculated by weighting
the kPCr1 and kPCr2 rate constants to their respective amplitudes:
Biexponential kPCr = (kPCr1 · (Amp1/Total Amp)) + (kPCr2 · (Amp2/Total Amp))

Eq 7

Skeletal Muscle ATP Flux
Rates of ATP synthesis by the creatine kinase reaction (ATPCK), adenylate kinase
reaction (ATPAK), non-oxidative glycolysis (ATPGLYC), and oxidative phosphorylation

76

(ATPOX) were calculated at each time point throughout the 240 s experimental trial.
ATPCK (mM·s-1) was calculated from the change in [PCr] between successive timepoints:
ATPCK = Δ[PCr]/Δt

Eq 8

ATPAK (mM·s-1) was calculated from the change in AMP accumulation between
successive timepoints:
ATPAK = Δ[AMP]/Δt

Eq 9

ATPGLYC (mM·s-1) was calculated assuming 3 moles of ATP are synthesized for
every 2 moles of lactate (82) and that the ratio of lactate:H+ accumulation is 1:1 (144,
203). The rate of glycolytic ATP synthesis was then calculated by measuring changes in
cytosolic pH and accounting for H+ buffering and efflux according to the equation (119,
122):
ATPGLYC = 1.5 · ( (θ(ΔPCr/Δt)) + (-βtot · (ΔpH/Δt)) + VEff )

Eq 10

where ΔPCr/Δt and ΔpH/Δt are the changes in muscle [PCr] and pH between
successive timepoints, θ is a correction factor for the number of protons consumed by the
creatine kinase reaction, βtot is the total muscle buffering capacity in mM H+/pH unit, and
VEff is the pH dependent rate of H+ efflux (mM·s-1) measured following the 240 s trial.
θ was calculated as (96):
θ = 1/(1+10pH-6.75)

Eq 11

βtot represents the total buffering capacity of the muscle in slykes (mM H+/pH
unit), which takes into account buffering by Pi (βPi), PME (βPME), and other inherent
buffers (βi):
βtot = βPi + βPME + βi

Eq 12

βPi and βPME were calculated according to Kemp and Radda (96):

77

βPi = 2.3 · [Pi] / ((1+10(pH - 6.75)) · (1+10(6.75 - pH)))

Eq 13

βPME = 2.3 · [PME] / ((1+10(pH - 6.2)) · (1+10(6.2 - pH)))

Eq 14

Inherent buffering capacity (βi) was determined by calculating the apparent total
buffering capacity (βApp; mM H+/pH unit) during the 24-s trial and then subtracting the
buffering due to Pi and PME (122):
βApp = θ · ((ΔPCr/Δt)/(ΔpH/Δt))

Eq 15

βi = βApp – βPi – βPME

Eq 16

where ΔPCr and ΔpH represent the changes in PCr and pH, respectively, and Δt
represents the change in time from rest to the peak of intramuscular alkalosis, which
occurred 8-12 s into the contraction period.
During the initial phase of PCr recovery, intramuscular pH decreases due to H+
release by Pi and free creatine, after which time, pH recovers linearly back to baseline
(97, 206). During this linear phase of pH recovery, increases in muscle pH are due to H+
efflux from the muscle into the interstitial fluid, which, after accounting for H+ release by
βi, βPi, βPME, and creatine, permits quantification of H+ efflux (VEffRec) as:
VEffRec (H+·s-1) = (βtotRec · (ΔpH/Δt)) + θ · (ΔPCr/Δt)

Eq 17

where βtotRec · (ΔpH/Δt) and θ · (ΔPCr/Δt) account for H+ released by
intramuscular buffers and the phosphorylation of free creatine. βtotRec (mM H+/pH unit)
was calculated as:
βtotRec = (βi · ΔpHbaseline) + βPi + βPME

Eq 18

VEffRec was fit then with a biexponential function across time as:
VEffRec (t) = C – (AmpVEffRec1·(1-Exp(-k1 · t))) + (AmpVEffRec2·(1-Exp(-k2 · t)))
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Eq 19

where C is the maximally measured rate of VEffRec, (t) is recovery time in seconds,
AmpVEffExp is the amplitude of the VEffRec response, k is the rate constant, and 1 and 2
denote the primary and secondary components. Subsequently, we then calculated the
exponential relationship (VEffExp) between VEffRec and the change in muscle pH (∆pH,
from resting baseline) as:
VEffExp (H+·s-1) = (AmpVEffRec1 · Exp(k1 · ΔpH)) + (AmpVEffRec2 · Exp(k2 · ΔpH))

Eq 20

where AmpVEffRec and k have their previous meanings, the numbers 1 and 2
denote the primary and secondary components, and ΔpH is the change in pH from rest at
any given time point during recovery after the 240 s trial.

Calculating Oxidative ATP Synthesis
The initial velocity of PCr resynthesis (ViPCr) reresents the suprabasal rate of
ATPOX achieved at the end of a bout of contractions (35, 95, 158). In this study, ViPCr was
calculated as the change in [PCr] measured over the first 4 s of fitted PCr recovery
(mono-exponential fit for the 24 s trial and biexponential fit for the 60, 120, and 240 s
trials), yielding 4 measurements of ATPOX across time from 24 to 240 s. We then
calculated rates of ATPOX throughout the 240 s trial using existing, continuous, ATPOX
calculation methods (119, 197, 206), and compared the calculated rates of ATPOX from
each method to the corresponding ViPCr measurements at each timepoint.
ATPOX Method 1 – Indirect Method of Calculating ATPOX
The Indirect method (Method 1) for calculating ATPOX (ATPOX-M1)inherently
assumes that the ATPCOST of force generation remains constant (99). Consequently, if
muscle force and power production are measured for each contraction, then ATPOX can
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be calculated as the difference between the estimated ATPCOST (ATPCOST-EST) of the work
performed and the rate of anaerobic ATP synthesis by creatine kinase and glycolysis
(ATPANAEROBIC):
ATPOX-M1 = ATPCOST-EST – ATPANAEROBIC

Eq 21

In the present study, estimated ATPCOST (mM·s/Watts) was calculated over the
first 12 seconds of the 240-s trial, where rates of ATPOX were lowest, as the average rate
of ATPANAEROBIC divided by the average power output (Watts).
ATPOX Methods 2-6 – Direct Methods of Calculating ATPOX
Direct methods of calculating ATPOX assume a constant hyperbolic or sigmoidal
relationship between ATPOX and [ADP] or CPP according to the general equation:
ATPOX = Vmax / (1 + ( Km / X )nH)

Eq 22

where X represents [ADP] or CPP, Vmax is the maximal capacity for ATPOX (mM
· s-1), Km is the concentration of X at which ATPOX is equal to ½Vmax, and nH is the Hill
coefficient, which describes the order of control ADP exerts over ATPOX. However, on
the basis that different methods for calculating Vmax can produce variable estimations
(131), we examined the impact that 5 different methods for calculating Vmax had on
Direct calculations of ATPOX (Methods 2-6), which are summarized in Table 4.1 and then
described methodologically below.
ATPOX Method 2 – Linear Model
ATPOX Method 2 estimates Vmax using the linear analog model described by
Meyer (149). Given that the rate constant of PCr recovery (kPCr, s-1) is linearly related to
skeletal muscle oxidative capacity (150), Vmax can be estimated as the product of kPCr and
resting [PCr] (119, 207):
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VmaxM2 = PCrRest · kPCr

Eq 23

Consistent with its use in previous studies, this method for estimating Vmax was
paired with a CPP model for calculating ATPOX (119, 206):
ATPOXM2 = VmaxM2 / (1 + ( 0.11 / CPP ))

Eq 24

where VmaxM2 (M2 – Method 2) and CPP have their original meanings and 0.11 is
the Km for the CPP (206).
ATPOX Method 3 – First-Order ADP Model
ATPOX Method 3 is based on pioneering in vitro and in vivo works by Chance and
colleagues (39–41, 43), and assumes that ADP exerts first-order (i.e., classical MichaelisMenten hyperbola) control over changes in ATPOX. Subsequently, Vmax can be estimated
as:
VmaxM3 = ViPCr · ( 1 + (Km / [ADP]End) )

Eq 25

where ViPCr is the initial velocity of PCr resynthesis, Km = 30μM, and [ADP]End is
the concentration of [ADP] at the end of the contractile bout. ATPOX was then calculated
as:
ATPOXM3 = VmaxM3 / ( 1 + (Km / [ADP]) )

Eq 26

where VmaxM3 (M3 – Method 3), Km, and ADP all have their original meanings,
and nH was omitted because nH = 1 (i.e., first-order control).
ATPOX Method 4 – Multiparametric ADP Model-A
Method 4 for estimating Vmax assumes that the kinetic parameters of Equation 22
can be estimated directly using multiparametric analyses to fit rates of muscle oxygen
consumption or ViPCr against changes in [ADP] (90, 218). To maintain consistentcy with
other investigations that have compared multiparametric analysis methods for estimating
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Vmax in vivo (131), we modeled the control of ATPOX by [ADP] using a least-square
technique to fit the function described by Wüst et al. (218):
VPCr (t) = (VmaxM4 · [ADP]nHM4) / (KmM4 + [ADP]nHM4)

Eq 27

where VPCr is the fitted rate of PCr resynthesis (mM · s-1) observed at timepoint (t)
during recovery, [ADP] is the corresponding concentration of cytosolic ADP, VmaxM4
(M4 – Method 4) and KmM4 have their original meanings, and nHM4 is the Hill coefficient
describing the sigmoidal relationship between ATPOX and changes in [ADP]. VmaxM4,
KmM4, and nHM4 were all left as unconstrained parameters, and the fitting procedure was
conducted on all VPCr rates > 0.02 mM · s-1 (90, 131). ATPOX was then calculated as:
ATPOXM4 = VmaxM4 / ( 1 + (KmM4 / [ADP])nHM4 )

Eq 28

where VmaxM4 (M4 – Method 4), KmM4, nHM4, and ADP all have their original
meanings.
ATPOX Method 5 – Second-Order ADP Model-B
Studies that have implemented Method 4 for estimating Vmax have provided
compelling evidence that ADP exerts at least 2nd-order control over ATPOX (90, 131).
Based on these results, Method 5 for estimating Vmax assumes ATPOX is sigmoidally
controlled by changes in cytosolic [ADP], but does not use a multiparametric analysis to
estimate Vmax. Instead, VmaxM5 (M5 – Method 5) is estimated as (29, 197):
VmaxM5 = ViPCr · ( 1 + ((Km / [ADP]End)2.2) )

Eq 29

where ViPCr is the initial velocity of PCr resynthesis , Km = 30μM, and 2.2 is the
set value for the nH based upon data from Jeneson et al. and others (90, 131). Consistent
with prior studies that have used this method to calculate Vmax (29, 197), ATPOX was
calculated as:
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ATPOXM5 = VmaxM5 / ( 1 + (Km / [ADP])2.2 )

Eq 30

where VmaxM5 (M5 – Method 5), Km = 30μM, and [ADP] all have their original
meanings and 2.2 is the set value for the nH.
ATPOX Method 6 – Multiparametic ADP-Model
Our preliminary results showed that ATPOX Method 2 drastically overestimated
ViPCr, whereas ATPOX Methods 3-5 tended to underestimate ViPCr. The prior observation
was not surprising given that recent work by Layec et al. has shown that VmaxM2
significantly overestimates maximal rates of ADP-stimulated respiration in vitro (131).
However, the latter observation, that Methods 3-5 underestimated ViPCr, was less
expected. For Method 4, this error appeared to be influenced by the number of VPCr data
points being included in the multiparametric fitting procedure. Specifically, Vmax
estimations were low when all VPCr rates > 0.02 mM · s-1 were included in the fitting
procedure. Consequently, we adapted the multiparametric analyses described in Method 4
to enhance the accuracy of estimating ATPOX (Method 6).
Like Methods 2-5, Method 6 assumes that the control of ATPOX by [ADP] can be
estimated using multiparametric analysis. Thus, we followed the approach of Jeneson et
al. (90) and elected to estimate Vmax using CPP:
VPCr (t) = Vmax-M6 / ( 1 + (Km / CPP )nH )

Eq 31

where VPCr is one of the first 10 rates of PCr resynthesis (mM · s-1) observed at
timepoint (t) during the mono- or biexponential fit of PCr recovery following an
experimental trial, CPP is the cytosolic phosphorylation potential at the same
corresponding timepoint, and Vmax-M6 (M6 – Method 6), Km, and nH all have their original
meanings. Vmax-M6 and Km were left unconstrained and nH was constrained to all values ≥
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0.7. We then reperformed the multiparametric analysis against changes in [ADP] by
constraining Vmax-M6 to the value obtained in the CPP-fit and leaving KmM6 and nHM6
unconstrained according to:
VPCr (t) = Vmax-M6 / ( 1 + (KmM6 / [ADP] )nHM6 )

Eq 32

where VPCr is one of the first 10 rates of PCr resynthesis (mM · s-1) observed at
timepoint (t) during the mono- or biexponential fit of PCr recovery following an
experimental trial, [ADP] is the cytosolic ADP concentration at the same corresponding
timepoint, and VmaxM6, KmM6, and nHM6 all have their original meanings.
Subsequently, ATPOX for Method 6 was calculated as:
ATPOX = Vmax-M6 / ( 1 + (KmM6 / ADP)nHM6 )

Eq 33

Does the Timing of Vmax Estimations Matter?
Method 2 for estimating Vmax is well known to be effected by decreases in muscle
pH (206), whereas Method 3 appears to be more influenced by the magnitude of
metabolic strain (48). The contractile duration of an oxidative capacity protocol can
therefore have a significant impact on both the estimation of Vmax and subsequent
calculations of ATPOX. Furthermore, as depicted in Equation 22, Direct ATPOX Methods
inherently assume that mitochondrial uncoupling does not occur because Vmax is held
constant throughout a bout of contractions, regardless of contractile intensity. However, if
mitochondrial uncoupling does occur, and Vmax is impaired, then Direct ATPOX
calculations could also be affected by when Vmax is calculated (i.e., at baseline or
following high-intensity fatiguing exercise) and how the final ATPOX calculations
account for these changes. Both of these limitations may be surmountable by adjusting
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ATPOX calculations for changes in Vmax observed from baseline to post-fatigue.
Consequently, for each of the 5 Vmax and Direct ATPOX methods described above
(Methods 2-6), we calculated ATPOX in 3 ways: 1) Vmax was measured at baseline (i.e.,
end of the 24-s trial) and held constant in the calculation of ATPOX throughout the 240-s
trial, 2) Vmax was measured at the end of the 240-s trial and held constant in the
calculation of ATPOX throughout the 240-s trial, or 3) Vmax was measured both at baseline
and at the end of the 240-s trial and the value for Vmax in the calculation of ATPOX was
linearly scaled for the observed change in Vmax according to the equation:
ATPOX-Adj = (Vmax24 + (Δ̇Vmax · ∆t)) / ( 1 + ((Km/X)nH)

Eq 34

where Vmax24 is the Vmax measured at baseline following the 24 s trial, ∆t is the
change in time from 24 s to the respective timepoint of the ATPOX calculation, and
Δ̇Vmax is the linearly scaled rate of change in Vmax, which was calculated as:
Δ̇Vmax = (Vmax240s – Vmax24s) / 216 s

Eq 35

where Vmax240s and Vmax24s are the calculated Vmax values following the 240- and
24-s trials, respectively, and 216 s represents the contractile duration separating the two
measurements (i.e., 240 s – 24 s = 216 s). Additionally, because the multiparametric
analysis methods (i.e., Methods 4 and 6) also directly estimated Km and nH at baseline and
at the end of the 240-s trial, these parameters were also adjusted using the same formulas
as described for Vmax (equations 34 and 35), leaving the final ATPOX calculations for
Methods 4 and 6 as:
ATPOX-Adj = (Vmax24 + (Δ̇Vmax · ∆t)) / ( 1 + ( ((Km+ (Δ̇Km · ∆t)) / X)(nH+(Δ̇nH · ∆t)) ) Eq 36
The ATP cost of force generation (ATPCOST) was quantified at each timepoint by
dividing power output (Watts) by the sum of ATP synthesis rates (mM·s-1) from creatine
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kinase, adenylatae kinase, non-oxidative glycolysis, and oxidative phosphorylation.
Because [ATP] decreased throughout the 240-s trial, we also incorporated changes in
[ATP] between successive timepoints as rates of ATP consumption, leaving our final
calculation of ATPCOST (W/mM·s-1) as:
ATPCOST = Watts / (ATPCK + ATPAK + ATPGLYC + ATPOX + Δ̇[ATP])

Eq 37

Finally, to investigate whether high-intensity contractions effect the sensitivity of
ATPOX to changes in ADP, the Vmax, Km, and nH that were calculated for each participant,
after each trial, using ATPOX Method 6, were subsequently used to estimate rates of
ADP-specific ATPOX at set ADP concentrations ranging from 0.01 to 0.5 mM.

Statistical Analyses
All statistical analyses were conducted using SPSS v25.0 (IBM Statistics,
Armonk, New York). Data are presented as mean ± SE, with p-values < 0.05 considered
statistically significant. Prior to conducting any statistical comparisons, data were tested
for normal distrubution using the Shapiro-Wilk test. Normally distributed data were
analyzed by t-tests, repeated measures ANOVAs, or Mixed Model ANOVAs. If a
significant Trial effect was observed, differences between trials were analyzed from the
estimated marginal means. Non-normally distributed data were analyzed using the nonparametric Friedman’s test. If a significant Trial effect was observed, differences between
Trials were analyzed using individual Wilcoxon signed rank tests, with no corrections
made for multiple comparisons. Due to our low sample size, no corrections were made
for multiple comparisons.
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To evaluate the consistency of muscle performances across trials, changes in
metabolite concentrations and power output were compared using repeated measures
ANOVAs at 24, 60, and 120 s, as well as at rest. Specifically, data from all 4 trials were
compared at rest and 24 s; the 60, 120, and 240-s trials were compared at 60 s; and the
120 and 240-s trials were compared at 120 s. Changes in muscle metabolites and power
throughout the 240 s trial were also analyzed using either repeated measures ANOVAs or
Friedman’s tests.
To test hypotheses 1 and 2, ViPCr measurements were normalized to each
participant’s Vmax and then compared across trials using a 1x4 Mixed Model ANOVA.
Similarly, to test test hypothesis 3, Vmax calculations were normalized to Vmax at baseline
and then compared across trials using a 1x4 Mixed Model ANOVA. The same approach
was used for change in Km, nH, and ADP-specfici ATPOX across trials. To test hypothesis
4, changes in ATPCOST across trials were analyzed using a 1x4 Mixed Model ANOVA.
As described above, calculations of ATPOX can be affected by 3 major factors: 1)
model selection (i.e., Indirect Model (Method 1) vs. Direct Models (Methods 2-6), 2) the
calculation method used to estimate Vmax (Methods 2-6), and 3) when and how Vmax, Km,
and nH are modeled in the ATPOX calculation (Methods 2-6; baseline vs. post-fatigue vs.
adjusted for changes observed from baseline to post-fatigue). Collectively, these 3 factors
created 16 ATPOX methods that could be compared to ViPCr.
To To test hypotheses 5 and 6, differences between ViPCr and each of the 5 Direct
ATPOX Methods that were adjusted for changes in Vmax were compared using 2x4 Mixed
Model ANOVAs (Method x Trial; ViPCr vs. Direct Method; 24, 60, 120, and 240 s). We
then calculated intraclass correlations (ICC). To eliminate the repeated measures
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component of our ICC (i.e., multiple ViPCr and ATPOX measurements for each
participant), we averaged ViPCr and ATPOX values for each participant across the 4 main
timepoints (24, 60, 120, and 240 s) and then performed a two-way mixed ICC for
absolute agreement. The slope of the ICC between ViPCr and each ATPOX method was
also calculated via linear regression with the intercept set to 0. We then constructed
Bland-Altman plots and performed one-sample t-tests to analyze whether the average
difference between matched measurements of ViPCr and ATPOX calculations were
statistically different from 0.

Results
Descriptive data for the participants are listed in Table 4.2. This was a young,
relatively active cohort with normal BMIs.

Muscle Fatigue and Metabolites for All Trials
There were no between-Trial differences in muscle fatigue (% peak power) or
absolute power output (Watts) at any timepoint (Figure 4.1), but trial effects were
observed for muscle metabolites at varying timepoints. The only between-Trial difference
observed at rest was a slightly higher PCr concentration at the start of the 120-s trial
compared to the 240-s trial (37.8 ± 0.03 vs 36.6 ± 0.6 mM). At 24 s, between-trial
differences were found for PCr (24-s trial lower than 240-s trial: 17.0 ± 1.1 vs. 19.4 ± 0.9
mM), Pi (24- and 120-s trials greater than 240-s trial: 22.6 ± 0.9 and 21.4 ± 0.6 vs. 20.0 ±
0.6 mM, respectively), ATP (24-s trials greater than 120-s and 240-s trials: 8.2 ± 0.00 vs.
8.06 ± 0.04 and 8.05 ± 0.06 mM, respectively; and 60-s trial greater than 240-s trial: 8.15
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± 0.05 vs. 8.05 ± 0.06), ADP (24- and 120-s trials greater than the 240-s trial: 0.074 ±
0.006 and 0.67 ± 0.003 vs. 0.062 ± 0.003 mM, respectively), and CPP (24- and 120-s
trials greater than the 240-s trial: 0.209 ± 0.022 and 0.179 ± 0.012 vs. 0.155 ± 0.012,
respectively). One difference was also observed at 60 s, with pH being significantly
lower at the end of the 60-s trial compared to 60 s into the 240-s trial (6.81 ± 0.03 vs.
6.86 ± 0.04). No metabolite differences were observed at 120 s between the 120- and
240-s trials.
During the 240-s trial, muscle power (Watts), PCr, and pH all progressively
decreased (p < 0.05, all comparisons; Figures 4.1 and 4.2). [ATP] decreased below
resting levels by 60 s and continued to progressively decline thereafter (60 > 120 > 240 s,
p < 0.05), whereas [ADP] and CPP progressively increased over the first 120 s (24 < 60 <
120 s, p < 0.05) and then plateaued over the final 120 s (p = 0.173).

Comparisons of Vmax Estimations at Baseline
Estimations of Vmax from Methods 2-6 are described in Table 4.3. At baseline,
Vmax estimated by Method 2 was greater than all other Methods (p < 0.05). Vmax
estimated by Methods 4 and 5 were not different from one another (p = 0.679) but were
both lower than Methods 3 and 6 (p < 0.05). Vmax estimated by Method 3 was also lower
than Method 6 (p < 0.05).

Changes in kPCr, ViPCr, ATPCOST, and Vmax
Main effects of trial were found for kPCr, ViPCr, and Vmax (Table 4.3). Compared to
the 24 s trial, kPCr was slower following the 60, 120, and 240-s trials (p > 0.05, all), and

89

following the 240-s trial compared to the 60-s trial (p < 0.05), but did not change from
120 to 240 s (p = 0.25). Consistent with our first and second hypotheses, ViPCr peaked
following the 60- and 120 s trials but then declined following the 240 s trial (Table 4.3,
Figure 4.3). In contrast, and consistent with our fourth hypothesis, we did not observe a
main effect of trial for changes in ATPCOST across the four timepoints (Figure 4.4, p =
0.45).
Consistent with our third hypothesis, trial effects were observed for all 5 methods
of calculating Vmax. For Method 2, Vmax steadily declined throughout the full protocol (p
< 0.05, all comparisons). For Method 3, Vmax following the 240-s trial was lower than all
other trials (p < 0.05), whereas the only difference observed for Method 4 was between
the 240- and 60-s trials. For Method 5, Vmax following the 60-s trial was faster than the
24-s trial, and Vmax following the 240-s trial was slower than both the 60- and 120-s
trials. For Method 6, Vmax steadily declined beyond the 60-s trial (p < 0.05, all
comparisons), but was not different between the 24- and 60-s trials.
No effect of time was found for the Hill coefficient (nH) using either of the
multiparametric analyses (Methods 4 and 6). However, several differences were observed
for Km. For Method 4, Km was lower following the 120- and 240-s trials compared to the
24-s trial (p < 0.05) and following the 120-s trial compared to the 60-s trial (p < 0.05).
For Method 6, Km progressively decreased over the first 120 s (24 > 60 > 120; p < 0.05)
but did not change thereafter.
There was a main effect of time for rates of ADP-specific ATPOX at 0.2 mM
(Figure 4.5), which was the concentration of ADP at the end of the 240 s trial. No
differences were observed between the 24 and 60 s trials. ADP-specific ATPOX was
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lower following the 240 s trial than all other trials (p < 0.01, all), and following the 120 s
trial compared to the 24 s trial (p< 0.01), but no other differences were observed, though
there was a trend for lower values following the 120 s trial compared to the 60 s trial (p =
0.07).

Accuracy of ATPOX Calculation Methods
Consistent with our fifth and sixth hypotheses, adjusting traditional calculation
methods for changes in Vmax improved the accuracy of predicting ViPCr and the method
used to estimate Vmax had a marked impact on the magnitude of inaccuracy. All six
ATPOX Methods exhibited a significant intraclass correlation when compared to ViPCr
(Table 4.4; p < 0.01, all). Methods 1 and 2 exhibited moderate validity, Method 4
exhibited good validity, and Methods 3, 5, and 6 all exhibited excellent validity (108).
However, whereas ATPOX Methods 1, 3, 5, and 6 were not different from ViPCr
across timepoints when analyzed by a Mixed-Model ANOVA (p > 0.05), a main effect of
Method was observed for Methods 2 and 4 (p < 0.05, both), with Method 2 significantly
overestimating ViPCr and Method 4 underestimating ViPCr (Figure 4.7). Accordingly, Vmax
estimated by Method 2 were significantly greater than all other Methods at baseline (3-6,
all p < 0.05), whereas Vmax estimated by Methods 4 and 5 were not different from one
another (p = 0.679) but were both lower than Methods 3 and 6 (p < 0.05; Table 4.3).
Moreover, the average difference between pairs of ViPCr and ATPOX calculations from
Methods 2-5 were all different from zero (1-way t-test; -0.068 ± 0.014, 0.025 ± 0.008,
0.048 ± 0.008, and 0.032 ± 0.007 mM·s-1, respectively; p < 0.02, all). These differences
are further illustrated in the Bland-Altman Plots shown in Figure 4.8. Almost every
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ATPOX calculation from Method 2 was greater than ViPCr, whereas ATPOX calculations
from Methods 3-5 were consistently lower than ViPCr. Although the average difference
between ViPCr and ATPOX measurements from Method 1 were not statistically different
from 0 (p=0.803), the difference between matched measurements was not consistent
across all rates of ATPOX (significant Bland-Altman regression, p < 0.01), with low rates
of ATPOX consistently undercalculating ViPCr and higher rates of ATPOX consistently
overcalculating ViPCr. Method 6 exhibited an excellent ICC with ViPCr (0.948) and the
relationship was stable across the entire range of ATPOX values measured in the present
study (Figure 4.8). Additionally, the average difference between ViPCr and ATPOX
calculations from Method 6 were not different from 0 (-0.001 ± 0.010 mM·s-1, p = 0.96)
and the ICC slope was identical 1.00, whereas Methods 1-5 exhibited slopes of 1.04,
1.12, 0.96, 0.92, and 0.94, respectively.

Discussion
The global objectives of the present study were to: 1) use multiple measurements
of ViPCr to examine changes in ATPOX and oxidative capacity throughout 4 minutes of
high-intensity contractions, and 2) assess the validity and accuracy of traditional methods
for continuously calculating ATPOX during high-intensity contractions. In agreement with
our first two hypotheses, the most important physiological result of the present study is
that rates of oxidative energy production can decline during high-intensity contractions
despite drivers of oxidative phosphorylation, such as ADP, CPP, or PCr breakdown,
progressively increasing (Figure 4.3). This observation is deductively opposed to the
hypothesis that high-intensity contractions cause an increase in the ATP cost of force

92

generation but directly aligned with the prediction that high-intensity contractions induce
mitochondrial uncoupling. Another critical finding of the present study was that the
decline in ViPCr was primarily driven by significant reductions in Vmax (Table 4.3), which
subsequently resulted in substantially reduced rates of ADP-specific ATPOX (Figure 4.5).
These latter results are consistent with recent findings from Layec et al., who reported
lower rates of ADP-stimulated respiration following a 5 km cycling time trial, despite no
change in maximal respiratory capacity (127). That is, the capacity for ATPOX was
diminished despite no change in the capacity for mitochondrial oxygen consumption.
This is critically important, because although mitochondrial uncoupling would be
expected to reduce ADP-stimulated respiration by impairing ADP/ATP transport across
the inner mitochondrial membrane by adenine nucleotide translocase (105, 117, 159), it
would not be expected to have an effect on mitochondrial respiratory capacity. We also
found no change in the ATP cost of force generation throughout the 240 s trial (Figure
4.4), which leaves mitochondrial uncoupling as the only remaining explanation for the
VO2SC and augmentation of muscle metabolism during all-out exercise protocols in
which muscle metabolism remains elevated despite large increases in muscle fatigue.
Our metabolite results are in excellent agreement with previous work in both
humans (29, 31, 201) and animal models (155, 221), which have shown that
intramuscular metabolic processes, including muscle oxygen consumption (30, 80, 200),
remain elevated despite substantial reductions in torque or power generation during allout contraction protocols. These data have been interpreted as an indication that the
VO2SC originates within the fatiguing muscle mass. However, what has remained unclear
is whether the sustained elevation of muscle metabolism, despite progressively
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diminishing power or torque production, is due to increases in ATPCOST or mitochondrial
uncoupling. The results of this study suggest that changes in ATPCOST do not play a role
in the VO2SC during high-intensity, all-out contractions (Figure 4.4). Our results conflict
with those of Broxterman et al. (29), who reported an increase in the ATPCOST of torque
generation during an isometic all-out knee extension protocol that was very similar to the
dynamic protocol implemented here. However, the method used to calculate ATPOX in
that study did not account for changes in Vmax observed from baseline to the end of
fatiguing contractions. In the present study, Vmax progressively declined beyond the first
60 s, regardless of the calculation method used. Consequently, because Broxterman et al.
did not measure Vmax or kPCr at baseline (i.e., before the fatigue protocol), it is possible
that the discrepancy in our results may be due to the two different methods used to
calculate ATPOX. Specifically, the ViPCr method used in the present study allowed us to
observe ATPOX decline over the final 120 s, whereas the ATPOX method employed by
Broxterman et al. is mathematically unable to model this behavior.
In contrast, Cannon et al. also calculated ATPOX from ViPCr measurements and
reported that ATPCOST increased during 8 minutes of submaximal bilateral knee
extensions (35). The reasons for the discrepancy between our results and those of Cannon
et al. are not immediately clear, but may be due to differences in contraction intensity or
protocol duration. For example, as has been discussed previously (18), all-out contraction
protocols produce a mirror-like VO2SC response, where muscle VO2 remains elevated
despite decreasing power output or torque generation. In contrast, submaximal squarewave exercise to power outputs above the lactate threshold produce the ‘classical’ VO2SC
response, where VO2 gradually increases despite constant muscle work due to muscle
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fatigue necessitating increases in motor unit recruitment. Consequently, it is possible that
we did not observe changes in ATPCOST during the present study because motor unit
recruitment was likely maximal from the onset of the protocol. Moreover, Cannon et al.
observed changes in ATPCOST over the final 5 minutes of an 8-minute protocol, whereas
our protocol lasted only 4 minutes. Thus, we may have observed changes in ATPCOST had
we extended the protocol to longer durations.
Nevertheless, that we did not observe a change in ATPCOST throughout the 240 s
trial really should not come as a surprise. High-intensity contractions have repeatedly
been shown to impair all three of the major ATPases within skeletal muscle. For
example, high-intensity contractions drastically reduce ion pumping activity by both Na+K+- and Ca2+-ATPases (56, 137, 138, 160, 164, 190). Notably, Stienen et al.
demonstrated that high concentrations of H+ and inorganic phosphate (Pi), such as those
seen here and during other all-out contractions protocols (29, 31, 201), can depress rates
of ATP turnover by Ca2+-ATPase by as much as 80% (190). Myosin ATPase is also
markedly impaired by high H+ and Pi (52, 157, 190). Based on these observations, if the
rate of ATP turnover progressively decreases with increasing H+ and Pi accumulation,
then skeletal muscle ATP demand, metabolic rate, and oxygen consumption should
decrease as well.
If skeletal muscle metabolism is indeed uncoupled from cellular ATP demand
during high-intensity, all-out contractions, mitochondrial uncoupling may offer a
mechanistic explanation. As Hill and Lupton pointed out nearly a century ago, oxidative
metabolism is a recovery process, even during exercise, whereby the end-products of
non-oxidative metabolism are recycled to yield gaseous waste products that can be
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excreted from the whole organism in copious quantities (79). Mitochondrial uncoupling
directly impairs this recyclative process by dissipating the proton motive force, which
alters the behavior of electrophoretic transport proteins imbedded in the inner
mitochondrial membrane. For example, adenine nucleotide translocase (ANT) catalyzes
the exchange of matrical ATP for ADP in the intermembranous space. The exchange of
ATP and ADP by ANT, as well as the ratio of [ATP]/[ADP] within the matrix vs.
intermembranous space, is dependent upon the magnitude of the electrical potential
energy of the proton motive force. Accordingly, the net consequence of mitochondrial
uncoupling on ANT function is export of ADP from the mitochondrial matrix into the
intermembranous space and cytosol (105, 117, 188). In turn, this should be expected to
cause a right-shift in the cytosolic creatine-kinase equilibrium, thereby augmenting PCr
breakdown and impairing the capacity for PCr resynthesis (192, 193). Thus, whereas
mirror-like augmentations in oxygen uptake and PCr breakdown were initially postulated
as an indication of increased ATPCOST (174), the considerations described above suggest
that mitochondrial uncoupling offers an equally plausible explanation.
Similarly, mitochondrial uncoupling also impairs glutamate-aspartate translocase
(118, 195), the transport protein primarily responsible for driving the malate-aspartate
NADH shuttle. As the magnitude of mitochondrial uncoupling increases, the capacity for
lactate oxidation by the malate-aspartate NADH shuttle is also progressively diminished,
which may explain why the magnitude of the VO2SC is so tightly correlated with
increases in lactate accumulation (175). Moreover, that mitochondrial uncoupling permits
protons to cross the inner mitochondrial membrane passively may also provide a crucial
explanation as to how muscle oxygen consumption can be augmented above the lactate
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threshold despite the fact that the acidosis accompanying lactate accumulation should
actually inhibit mitochondrial respiration by exogenously contributing to the proton
motive force.
Considered in toto, mitochondrial uncoupling clearly offers a potential
explanation for how muscle oxygen consumption, PCr breakdown, and acidosis can
remain suspended in an elevated state despite progressively diminishing muscle power
and ATP turnover by cellular ATPases. Specifically, as long as exercise continues, and
the stimulus for mitochondrial uncoupling remains present, then regardless of muscle
fatigue and intramuscular ATP demand, PCr breakdown and acidosis will remain
elevated because uncoupling impairs PCr resynthesis and malate-aspartate NADH shuttle
function, and mitochondrial oxygen consumption will remain augmented indefinitely
because uncoupled respiration is not controlled by the thermodynamic constraints of H+
conductance through ATP synthase. However, this now begs two important questions:
what causes mitochondrial uncoupling during high-intensity contractions, and why?
Several studies have repeatedly demonstrated that the VO2SC is associated with
muscle Type-II fiber content or recruitment (112, 139, 141–143, 220). Not only do TypeII muscle fibers exhibit characteristics that potentiate ROS generation (3), they also
exhibit lower antioxidative enzyme concentrations (63, 165) and greater uncoupling
protein 3 content (77, 176). Type-II fibers also rely more heavily on the glycerol-3phosphate NADH shuttle than Type-I fibers (63, 184, 185). This latter detail is notable
because unlike the malate-aspartate shuttle, which is driven by the electrical potential
energy of the proton motive force (118), the glycerol-3-phosphate shuttle passes electron
pairs directly to the quinone pool, and therefore operates fastest when the electron
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transport chain is most active (i.e., uncoupled from constraint by ADP-limited control).
Moreover, when the proton motive force is high, glycerol-3-phosphate shuttle activity
promotes ROS generation by increasing reversed electron flux through complex 1 (26).
Given these considerations, it is possible that the VO2SC is caused by a ROS-induced
stimulation of mitochondrial uncoupling within Type-II muscle fibers.
However, although mitochondrial uncoupling appears to offer several logical
explanations to several components of the VO2SC, results from intricate experiments in
vitro suggest ROS-stimulation of mitochondrial uncoupling is unlikely during exercise.
Gnaiger et al. demonstrated that mitochondrial P/O ratio improves as the rate of State-3,
ADP-limited respiration increases (64). Similarly, Goncalves et al. showed that ROS
generation decreases in vitro when the respiratory medium mimics conditions seen during
exercise (66). Other studies have suggested that the muscle’s maximal capacity for ADPlimited respiration exceeds maximal rates of cardiovascular oxygen delivery during
whole body exercises (24, 25, 62). That is, skeletal muscle mitochondria appear to exhibit
a reserve capacity for oxidative phosphorylation. However, these latter observations are
based on assumptions that: 1) maximal rates of state-3 respiration measured in vitro
under supraphysiological ADP concentrations reflect the muscle’s true maximal capacity
to consume oxygen in vivo under ADP-limited conditions, 2) the maximal rate of state-3
oxygen consumption in a single muscle sample represents the maximal capacity for
respiration across the entire muscle mass being studied in vivo, and 3) motor unit
recruitment and metabolic demand are maximal across the entire muscle mass when
measuring maximal oxygen consumption in vivo, as this assumption is necessary to
normalize calculated rates of absolute muscle oxygen consumption to a measure of
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muscle mass (i.e., absolute muscle O2 consumption in mL O2/min → mL O2/kg/min). All
three of these assumptions are questionable. First, the supramaximal boluses of ADP that
are used to stimulate maximal respiration in vitro (2 mM or more), are well above the
maximal concentrations of ADP observed in vivo during all-out contraction protocols (0.2
mM in the present study). There is also marked inter-muscle metabolic heterogeneity
even during single-joint exercises (36, 106), suggesting that normalizing in vivo measures
of absolute muscle oxygen consumption to the whole working muscle mass may lead to
underestimation of maximal oxygen consumption rates in the more metabolically active
muscle masses.
Additional work is clearly necessary to delineate whether skeletal muscle
undergoes mitochondrial uncoupling during high-intensity contractions. Skeletal muscle
P/O ratio has been investigated previously by combining 31P-MRS measures of ATPOX
with measures of pulmonary oxygen uptake (38, 128), but given that pulmonary oxygen
uptake reflects whole body oxygen consumption and not just that of the muscle mass,
more direct measures of muscle oxygen consumption would be preferable. Direct,
continuous measurement of muscle P/O ratio may be achievable by combining 31P-MRS
measures of ATPOX with optical imaging techniques (1, 34, 145), such as near-infrared
and diffuse correlation spectroscopy (13, 68), which, if combined with 31P-MRS, may
also help expand our understanding of how changes in conduit blood flow and oxygen
delivery or extraction effect skeletal muscle oxidative capacity (73, 74, 134).

Changes in ATPOX and Vmax during High-Intensity Contractions
Another notable finding in the present study is that for Vmax calculation Methods
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3-5, the highest estimations of Vmax in the vastus lateralis muscle of this group of healthy
young adults tended to occur following the 60-s trial, rather than following the 24-s trial.
Traditionally, skeletal muscle oxidative capacity has been measured following a short
period of contractions, lasting anywhere from 16-30 seconds (124, 132, 207). However,
as demonstrated by Combs et al., accurate estimation of skeletal muscle Vmax requires
sufficient metabolic strain to maximally activate oxidative phosphorylation (48). In the
present study, ADP doubled from 24 to 60 s, suggesting the 24 s trial may have been
insufficient for eliciting maximal estimations of Vmax. Alternatively, Layec et al. showed
that estimations of Vmax can be improved by augmenting post-exercise conduit blood
flow through reactive hyperemia (134), suggesting that vascular hemodynamics also need
to be considered when measuring skeletal muscle Vmax in vivo from PCr recovery
kinetics. Consequently, the faster Vmax observed following the 60 s trial in the present
study could have been due to improved vascular conductance. Additional work is needed
to identify contraction protocols that are optimized for measuring skeletal muscle Vmax
using 31P-MRS. Given previous work, optimal protocols will vary depending on: 1) the
population or species being studied, 2) the calculation method used to estimate Vmax, 3)
the muscle group being investigated (124, 135), and 4) whether the investigation
implements isometric or dynamic contractions (48, 178).

Calculating ATPOX Continuously during High-Intensity Contractions
The second goal of this study was to examine the validity and accuracy of
traditional methods for calculating ATPOX continuously. The traditional methods for
calculating ATPOX were separated by: 1) inherent assumptions of constant ATPCOST
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(Method 1) or mitochondrial coupling (Methods 2-6); 2) the calculation method used to
estimate Vmax, Km, or nH (Methods 2-6); and 3) how changes in Vmax are accounted for in
the final estimation of ATPOX (Methods 2-6). Methods 2-6 were deemed invalid if they
only measured Vmax at baseline or at the end of the fatigue protocol because they were
inherently, mathematically unable to model the decline in ViPCr (Figure 4.6). However,
consistent with our fifth hypothesis, this mathematical limitation was overcome by
adjusting Methods 2-6 to account for changes in Vmax measured from baseline to the end
of a fatigue protocol (Figure 4.7). Thus, Direct Methods 2-6 that only measured Vmax at
baseline or at the end of the fatigue protocol were excluded from the accuracy analysis,
thereby narrowing down the total pool of traditional ATPOX methods from 16 to 6.
In the present study, we defined accuracy as the difference between pairs of ViPCr
and ATPOX calculations. Although Method 1 was accurate at the group mean level
(Figure 4.7), the significant linear-regression slope in the Bland-Altman plot (Figure 4.8)
showed that this method is inaccurate across a wide range of ATPOX values. Adjusting
ATPOX calculations for changes in Vmax observed from baseline to post-fatigue improved
the validity of all 5 Direct Methods (i.e., Methods 2-6). However, consistent with our
sixth hypothesis, the improvement was dependent on the calculation method used to
estimate Vmax. As has been shown previously (131), the greatest estimations of Vmax came
from Method 2, whereas Vmax calculations from Methods 4 and 5 tended to be lowest.
Accordingly, ATPOX calculations from Method 2 drastically overestimated ViPCr, whereas
ATPOX calculations from Methods 4 and 5 tended to underestimate ViPCr (Figures 4.7 and
4.8).
These observations led us to develop a new method for estimating Vmax, which
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was based on the multiparametric approach described by Jeneson et al. and Wust et al.
(89, 90, 218) but limited the multiparametric fitting procedure to just the first 10 rates of
PCr resynthesis. This modification improved the accuracy of predicting ViPCr across the
entire 240 s trial. Like Methods 3 and 5, Method 6 exhibited an excellent ICC with ViPCr.
However, the average difference between ViPCr and ATPOX calculations from Method 6
was not different from zero, and the slope of the ICC regression for Method 6 was
identical to 1.0. The Bland-Altman plot in Figure 4.8 further demonstrates that Method 6
also provides accurate estimations of ViPCr across a wide range of ATPOX values.
Consequently, a crucial finding of the present study is that valid, accurate
measurements of ATPOX can be obtained continuously during high-intensity contraction
protocols by adjusting ATPOX calculations for the changes in Vmax observed from
baseline to the end of the fatiguing protocol. This holds true despite substantial reductions
in skeletal muscle oxidative capacity (kPCr and Vmax, Table 4.3), muscle pH, and [ATP].
Not only does this eliminate the need to have participants perform several bouts of
contractions to measure changes in ATPOX over time, but the ability to continuously
measure ATPOX accurately during high-intensity fatigue protocols will further permit
continuous calculations of ATPCOST, which will allow future investigations to study the
biochemical mechanisms underlying the VO2SC in greater depth.

Limitations
There are multiple notable limitations to the present study. First, we assumed that
the post-contraction responses (i.e., measurements of kPCr, ViPCr, Vmax, etc.) from each
trial could all be merged into one continuous measurement across time as long as muscle
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metabolic demand was similar between trials and across each timepoint. As shown in
Figures 4.1 and 4.2, the four trials were indeed well matched for changes in muscle
power and metabolites, and in many cases, the responses from each trial were
superimposed on one another. Although there was a cluster of metabolite differences
between the 240-s trial and the 24-s trial at 24 seconds, no other consistent differences in
muscle power or metabolites were observed. Consequently, we were confident that the
metabolic demands were matched well enough between trials to permit treating
measurements of kPCr, ViPCr, and Vmax from each trial as a single set of continuous
measurements changing over time.
The second critical assumption made during this study was that ViPCr measured at
the end of each trial accurately reflects the suprabasal rate of ATPOX at the end of
contractions. This assumption is, in and of itself, predicated on two additional
assumptions about the recovery period: 1) that non-contractile ATP turnover is
negligible, and 2) glycolytic ATP synthesis does not contribute to PCr resynthesis. First,
prior work has shown that ATP consumption by Na+-K+-ATPase only accounts for ~2-5
% of total ATP turnover during maximal exercise (9, 148), and post-activation uptake of
Ca2+ into the sarcoplasmic reticulum by Ca2+-ATPase is completed in under 1 s, even
under fatiguing conditions (160, 210). Moreover, as described above, given that highintensity contractions impair Na+-K+-ATPase and Ca2+-ATPase (56, 137, 138, 160, 164,
190), it seems highly unlikely that these enzymes could have consumed ATP at a fast
enough rate to substantially reduce ViPCr, or at the very least, the effects should have been
similar between the 120- and 240-s trials. Previous work has also demonstrated that PCr
resynthesis does not occur during ischemia (71, 168), suggesting glycolysis does not
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contribute to ViPCr, or that any contribution would be negligible.
Another potential limitation to the present study is that our calculations of ViPCr
and Vmax could have been affected by the large decreases in intramyocellular pH.
Previous studies have repeatedly demonstrated a positive relationship between decreases
in cytosolic pH and decreases in skeletal muscle kPCr (28, 135). Walsh et al. also reported
that low pH reduces submaximal rates of creatine-stimulated respiration in vitro (205).
However, the results of the present study, as well as others (207), suggest that while kPCr
may be affected by acidosis, calculations of ViPCr are not. Walter et al. reported that
acidosis (end-exercise pH = 6.45) had no effect on estimations of ViPCr and Vmax when
using a first-order ADP calculation method (i.e., Method 3 in the present study) (207).
Accordingly, in the present study, changes in ViPCr and acidosis were not temporally
aligned: Whereas muscle pH decreased substantially from 60 to 120 seconds, ViPCr
plateaued. Then, ViPCr decline from 120 to 240 s despite little to no change in muscle pH.
Finally, although kPCr tended to steadily decrease throughout the protocol, methods that
did not use kPCr to estimate Vmax (i.e. Vmax Methods 3-6) exhibited minimal changes over
the first 120 s, where decreases in muscle pH were most apparent. Together, these
observations suggest ViPCr and Vmax Methods 3-6 are not directly affected by acidosis and
can therefore be used to investigate changes in the capacity for ATPOX over time during
high-intensity contractions.
Another limitation of the present study is that we did not collect any measures of
oxygen utilization. Although previous studies have shown that V̇O2 rapidly achieves
V̇O2max and then plateaus during all-out whole-body exercise (30, 80, 200), we cannot
rule out the possibility that the decline in ViPCr observed over the final 2 minutes of the
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240-s trial was not matched by a proportional drop in pulmonary or muscle V̇O2, and
therefore cannot definitively conclude whether or not muscle mitochondrial P/O ratio
declined. Future studies should replicate the protocol described here while also collecting
direct measures of muscle V̇O2, such that changes in P/O ratio can be measured directly.
Alternatively, given that the majority of pulmonary V̇O2SC emanates from the working
muscle mass (111, 167), preliminary studies may consider calculating P/O ratio by
combining 31P-MRS with pulmonary V̇O2. This approach has been used previously to
measure P/O ratio during moderate-intensity contractions (38, 128), but to the best of my
knowledge, has not been performed during an all-out contraction protocol like the one
used in this study.

Conclusions
In summary, during all-out contractions, the VO2SC does not appear to be caused
by augmented rates of ATPOX due to increases in the ATP cost of force generation.
Instead, high-intensity contractions progressively diminish Vmax and ADP-specific rates
of ATPOX while not affecting ATPCOST. These findings suggest that high-intensity
contractions induce mitochondrial uncoupling, though the mechanism for how this
process would be stimulated during exercise in vivo remains unclear. Given the maximal
intensity of the protocol implemented in this study, additional work is needed to
investigate whether similar observations are also observed during submaximal highintensity contractions (i.e., at power outputs between the lactate threshold and V̇O2max).
Future investigations should also seek to better characterize the impact that mitochondrial
uncoupling has on creatine kinase and NADH shuttle activity in vivo.
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We also demonstrated that traditional methods for calculating ATPOX during
high-intensity contractions are invalid unless they account for changes in Vmax observed
from baseline to the end of the fatigue protocol. Moreover, the calculation method for
estimating Vmax also has a significant impact, with Method 2 leading to overestimations
of ATPOX, and Methods 3-5 tending to underestimate ATPOX. In contrast, Method 1,
though accurate at the group-mean level, showed poor accuracy across a wide range of
ATPOX values, and is therefore an unreliable method for calculating ATPOX during
dynamic high-intensity contractions. The new method we developed for calculating
ATPOX overcame all of these limitations and demonstrated both high validity and strong
accuracy across a wide range of ATPOX values throughout the 240-s trial. This method
can be used to accurately calculate changes in ATPCOST over time during high-intensity
fatigue protocols, which may help further unravel the mechanisms underlying the VO2SC
and augmentation of skeletal muscle metabolism at power outputs above the lactate
threshold.
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Vmax Estimation
Model

ATPOX
Method #

Equation

Sources

Linear Model

2

Vmax = kPCr · [PCr]Rest

(45, 124,
162)

ADP-1st Order
Control

3

Vmax = ViPCr · (1 + ( Km / [ADP]End ))

(55, 207)

ADP-MPA*

4

VPCr (t) = (Vmax · [ADP]tnH) / (KmnH + ADPtnH)

ADP-2nd Order
Control

5

Vmax = ViPCr · (1 + ( Km / [ADP]End )2.2)

ADP-MPA

6

VPCr (t) = Vmax / (1 + (Km / [ADP]t )nH )

(89, 90, 218)
(29, 197)

Table 4.1: Calculations for Estimating ATPOX-Vmax In Vivo. Methods 2-6 calculate ATPOX
based upon first- or second-order changes in ADP and vary in the method used to calculate Vmax.
The multiparametric equation listed below for Method 4 (*), is from Wüst et al. (218). A
different equation was presented by Jeneson et al. (89, 90), but was not tested here. The
multiparametric analysis in Method 6 is presented as a development that emerged from this study.

107

Age (years)
Height (cm)
Body Mass (kg)
BMI (kg/m2)
PA (counts·day-1/1000)
MVPA (minutes·day-1)
Torque (Nm)
Power (Watts, 120°·s-1)

27.3 ± 1.0
172.9 ± 4.2
70.4 ± 4.4
23.4 ± 0.6
294.3 ± 29.4
44.9 ± 4.9
274.1 ± 24.2
255.4 ± 22.4

Table 4.2: Study 1 Participant Characteristics. Data are presented as means ± SE.
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Measure
kPCr (·s-1) †

Trial 1 (24 s)
0.025 ± 0.001
#,‡,§
0.491 ± 0.031
#,‡

Trial 2 (60 s)
0.021 ± 0.001
*,§
0.603 ± 0.020
*,§

Trial 3 (120 s)
0.019 ± 0.001*

0.91 ± 0.03
#,‡,§
0.70 ± 0.03
§
0.57 ± 0.03

0.72 ± 0.05
*,#,§
0.67 ± 0.05
§
0.59 ± 0.03

0.57 ± 0.03
#
0.81 ± 0.03
‡,§

0.79 ± 0.03
*,‡,§
0.73 ± 0.02
§
0.62 ± 0.02
§
0.62 ± 0.02
*,§
0.77 ± 0.02
‡,§

0.61 ± 0.03
§
0.70 ± 0.04
*,#,§

0.62 ± 0.05
*,#,‡
0.61 ± 0.05
*,#,‡
0.51 ± 0.04
#
0.53 ± 0.04
#,‡
0.61 ± 0.05
*,#,‡

Km M6 (μM) †

26.5 ± 1.0
‡
46.0 ± 2.0
#,‡,§

24.5 ± 1.0
‡
35.8 ± 1.7
*,‡,§

21.1 ± 1.2
*,#
28.2 ± 1.9
*,#

22.1 ± 1.1
*
29.9 ± 1.7
*,#

nH M4
nH M6

1.72 ± 0.07
1.17 ± 0.03

1.59 ± 0.06
1.03 ± 0.02

1.71 ± 0.08
1.05 ± 0.03

1.68 ± 0.06
1.04 ± 0.04

ViPCr (mM·s-1) †

Vmax M2 (mM·s-1) †
Vmax M3 (mM·s-1) †
Vmax M4 (mM·s-1) †
Vmax M5 (mM·s-1) †
Vmax M6 (mM·s-1) †

Km M4 (μM) †

0.602 ± 0.032
*,§

Trial 4 (240 s)
0.017 ± 0.001
*,#
0.524 ± 0.037
#,‡

Table 4.3: Changes in ATPOX parameters as the duration of high-intensity knee extensions
increase. Significant effect of Trial (†), Significantly different from Trial 1 (*), significantly
different from Trial 2 (#), significantly different from Trial 3 (‡), significantly different from
Trial 4 (§). Data are presented as means ± SE.
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ICC
Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

0.593 *
0.706 *
0.929*
0.838 *
0.905 *
0.948 *

ICC
Classification
Moderate
Moderate
Excellent
Good
Excellent
Excellent

Linear Reg.
Slope
1.04
1.12
0.96
0.92
0.94
1.00

Average Difference
(ViPCr-ATPOX, mM·s-1)
-0.013 ± 0.049
-0.068 ± 0.014, #
0.025 ± 0.008, #
0.048 ± 0.008, #
0.032 ± 0.007, #
-0.001 ± 0.010

Table 4.4: Relationship between measurements of ViPCr and calculations of ATPOX.
Measurements of ViPCr and ATPOX were averaged across time (n = 4 each) to eliminate repeated
measures within each participant (n = 9). Significant ICC (*), Average difference between
matched pairs of ViPCr and ATPOX significantly different from 0 (1-way t-test, #). ICC
classifications are from Koo and Li (108). Data are presented as means ± SE.
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Figure 4.1 – Changes in muscle power output between trials. To avoid congestion, error bars
are only presented for the final datapoint in each trial. Data are presented as means ± SE.
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Figure 4.2 – Changes in muscle metabolites between trials. Changes in PCr (A), pH (B), ADP
(C), and CPP (D) across time for each trial. Filled circles represent the 24-s trial, open circles
represent the 60-s trial, filled triangles represent the 120-s trial, and open triangles represent the
240-s trial. To avoid congestion, error bars are only presented for the final datapoint in each trial.
Data are presented as means ± SE.
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Figure 4.3 – Changes in ViPCr during 240 s of maximal isokinetic knee extensions. ViPCr was
calculated after each trial from the change in [PCr] observed over the first 4 s of mono- or
biexponentially fitted PCr-recovery. ViPCr increased rapidly at the onset of contractions and
plateaued from 60-120 s. However, by the end of the 240-s trial, ViPCr decreased by 15%, despite
cytosolic ADP and phosphorylation potential remaining elevated (see Figure 4.2).
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Figure 4.4 – Changes in ATPCOST throughout 240 s of high-intensity knee extensions.
ATPCOST (W/mM·s-1) was calculated by dividing power output (Watts) by the sum of ATP
synthesis by the creatine kinase, non-oxidative glycolytic, and oxidative phosphorylation
pathways. Because [ATP] significantly declined during the 240 s trial, we also calculated rates of
ATP consumption from the decline in [ATP] between successive timepoints, as well as rates of
ATP synthesis by the adenylate kinase reaction. However, these latter two processes only
contributed ~ 0.17% and 0.0005% to the total rate of ATP consumption throughout the 240 s trial.
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Figure 4.5 – Changes in ADP-specific rates of ATPOX over time. ADP-specific rates of ATPOX
were calculated using the Vmax, Km, and nH values derived from the multiparametric analysis of
ATPOX Method 6, which was selected because it exhibited the most accurate estimations of ViPCr
across the entire 240-s protocol. As depicted above, the sensitivity of ATPOX to changes in [ADP]
was progressively diminished as the duration of high-intensity contractions progressed.
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Figure 4.6 – Impact of not adjusting ATPOX calculations for changes in Vmax. Regardless of
whether Vmax was calculated at baseline or after the 240-s trial, not adjusting for changes in Vmax
observed from baseline to post-fatigue resulted in poor estimations of ViPCr. In the image below,
filled and open circles represent ATPOX calculations from Method 2 when Vmax is measured only
at baseline or post-fatigue, respectively, and the red bars indicate ViPCr measured at 24, 60, 120,
and 240 s. Data are presented as means ± SE.
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Figure 4.7 – Calculations of ATPOX using Method 1 and all 5 Direct Methods (Methods 2-6)
when Vmax is adjusted for changes observed from baseline to the end of the 240-s trial. Bars
indicate ViPCr at 24, 60, 120, and 240 s. Significantly different than ViPCr by Mixed-Model
ANOVA (*). Significantly different than ViPCr by 1-way t-test (#). Data are presented as means ±
SE.
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Figure 4.8 – Bland-Altman Plots of ATPOX Calculations vs. ViPCr: Comparisons of ViPCr
measurements and ATPOX calculations from Methods 1-6. Solid lines indicate 0 on the y-axis.
Dashed lines indicate the mean difference between ViPCr measurements and ATPOX calculations,
and the maroon bold lines indicate the 95% confidence interval for the mean difference between
ViPCr measurements and ATPOX calculations.
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CHAPTER 5
RATES OF OXIDATIVE ATP SYNTHESIS IN HUMAN QUADRICEPS ARE
NOT AUGMENTED ABOVE THE pH THRESHOLD DURING AN ISOTONIC
STEPWISE PROTOCOL
Abstract
Skeletal muscle metabolism and oxygen consumption are augmented during highintensity contractions above the lactate threshold, but it is unclear whether these
augmentations are caused by increases in the ATP cost of force generation (ATPCOST) or
impairments in the efficiency of oxidative ATP synthesis (ATPOX). Although recent
evidence suggests that maximal contraction protocols impair muscle’s capacity for
ATPOX (i.e., Vmax), other studies suggest ATPCOST plays a greater role during submaximal
high-intensity contractions (i.e., at power outputs above the lactate threshold but below
maximal oxygen uptake). Consequently, we used 31P-MRS to measure changes in muscle
phosphates, ATPOX, and ATPCOST during a stepwise knee extension protocol. For
workloads above and below the muscle pH threshold (pHT; used here as a proxy for the
lactate threshold), we calculated slopes relating stepwise changes in muscle work to
changes in muscle phosphates, ATPOX, and Vmax. Changes in muscle phosphates and
ATPOX were linearly related to workload below the pHT. However, above the pHT,
changes in muscle phosphates were augmented (p<0.05), whereas increases in ATPOX
were attenuated (p<0.05) and Vmax declined (p<0.05). ATPCOST did not change
throughout the stepwise test (p=0.10). Consistent with results from maximal contraction
protocols, these results suggest ATPCOST is unchanged during submaximal high-intensity
contractions. Instead, augmentations in muscle metabolism observed during high-
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intensity contractions at workloads above the pH or lactate threshold appear to be caused
by reductions in Vmax and ATPOX efficiency, which we postulate may be caused by
mitochondrial uncoupling due to its impact on ADP-ATP exchange by adenine
nucleotide translocase.
Index Terms: muscle energetics, stepwise, incremental, oxidative phosphorylation,
mitochondrial uncoupling

Introduction
Much is still unknown about the mechanisms that control oxidative
phosphorylation during high-intensity exercise. For workloads below an individual’s
lactate threshold, changes in muscle metabolism and oxygen consumption are linearly
related to stepwise increases in muscle work. However, for workloads above an
individual’s lactate threshold, skeletal muscle metabolism and oxygen consumption are
augmented (2, 10, 85, 102, 104, 174), a phenomenon known as the slow component of
oxygen uptake kinetics (VO2SC). Presently, it is unclear whether the VO2SC is caused by
increases in the ATP cost of force generation (29, 35, 174), or impairments in the
efficiency of oxidative ATP synthesis (ATPOX) due to mitochondrial uncoupling
(Chapter IV). Although recent evidence suggests that mitochondrial uncoupling may
contribute to the VO2SC during maximal exercise protocols (Chapter IV))(127), data from
heavy-intensity protocols (i.e., at power outputs above the lactate threshold but below
maximal oxygen uptake) suggest that ATPCOST may play a greater role. For example,
Cannon et al. reported augmentations in ATPOX and ATPCOST during 8-minutes of heavy
bilateral knee extensions (35). However, the magnitude of the increase in ATPOX was
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insufficient to account for the full magnitude of the VO2SC, suggesting mitochondrial
uncoupling may have played a role during this submaximal high-intensity protocol as
well.
Similarly, several models have been proposed to explain how changes in cytosolic
metabolites control the rate of oxidative ATP synthesis (ATPOX) within skeletal muscle
during steady state contractions: including first- and second-order control mechanisms by
cytosolic [ADP] (40, 41, 90), first-order control by changes in cytosolic phosphocreatine
(PCr) or free creatine (fCr-) (15, 140), and linear nonequilibrium control by changes in
the cytosolic phosphorylation potential (CPP; ADP·Pi/ATP) (149). However, a common
link between each of these models is that they assume a constant relationship between
increases in ATPOX and stepwise changes in cytosolic ADP, fCr-, or CPP. This
assumption is invalid under conditions of mitochondrial uncoupling because dissipation
of the proton motive force alters the electrophoretic behavior of adenine nucleotide
translocase (105, 117), which causes a net efflux of ADP from the mitochondrial matrix
into the intermembranous space and cytosol. Not only would this augment cytosolic ADP
and CPP, but it would also cause a right-shift in the creatine kinase equilibrium, thereby
leading to greater PCr breakdown as well. Consequently, while previous observations of
a PCr-slow component during high-intensity contractions have traditionally been
attributed to a greater ATPCOST of contraction (174, 211), it is also possible that the PCrslow component is a function of uncoupling-induced alterations in the distribution of
adenine nucleotides across the inner mitochondrial membrane. That is, under conditions
of mitochondrial uncoupling, increases in cytosolic [ADP], CPP, and PCr breakdown do
not necessarily reflect concomitant increases in ATPOX.
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Consequently, there is a need to further delineate the contributions that increased
ATPCOST and mitochondrial uncoupling contribute to augmentations in [ADP], CPP, and
PCr breakdown during submaximal high-intensity contractions. To address this issue, we
used 31-phosphorous magnetic resonance spectroscopy (31P-MRS) to measure changes in
muscle phosphates and ATPOX during a stepwise contraction protocol similar to that
described by Binzoni et al. (16). Briefly, the protocol consisted of 6 stages of isotonic
knee extensions. Each stage lasted 3 minutes and was followed by 3-10 minutes of
recovery, which allowed us to measure ATPOX from the initial velocity of PCr
resynthesis, and kinetic parameters controlling ATPOX using multiparametric analyses
(Vmax, Km, and nH; described below). We specifically selected this approach to examine
the relationship between changes in muscle phosphates, ATPOX, and ATPCOST across
multiple workloads above and below the muscle pH threshold (pHT; used here as a proxy
for the lactate threshold), which was calculated in each participant using a bilinear fitting
procedure (102). We predicted that changes in muscle [ADP], CPP, PCr breakdown, and
ATPOX would be linearly proportional to changes in workload for all stages at intensities
preceding the pHT. However, consistent with our previous mitochondrial uncoupling
hypothesis (Chapter IV), we predicted that changes in [ADP], CPP, and PCr breakdown
would be augmented for workloads above the pHT, whereas changes in ATPOX would be
attenuated. We further predicted that the capacity for ATPOX (i.e., Vmax) and substratespecific rates of ATPOX would progressively decline above the pHT, whereas the ATP
cost of force generation (ATPCOST) would remain unchanged, thereby supporting the
concept that mitochondrial uncoupling is responsible for the VO2SC (i.e., the
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augmentation of skeletal muscle oxygen consumption and metabolism during highintensity contractions at workloads above the pH and lactate thresholds).

Methods
Participants
Eight healthy young adults (25.2 ± 1.3 years, 3W) were recruited from the local
community using fliers and word-of-mouth. All prospective participants were free of
cardiovascular, respiratory, and musculoskeletal disease and provided written informed
consent, as approved by the Institutional Review Board at the University of
Massachusetts Amherst and in accordance with the Declaration of Helsinki. Because
exercise training improves skeletal muscle oxidative capacity (123, 124, 129), which may
affect the muscle fatigue and bioenergetic responses during the oxidative capacity and
experimental trials (125), we excluded participants who reported engaging in more than 1
hour of physical activity per day at least 5 days per week. Additionally, we quantified
habitual physical activity using uniaxial accelerometry (ActiGraph GT3X, Pensacola,
Florida). Participants were instructed to wear the accelerometer during all waking hours
for a full week and to record their daily physical activity in a logbook. Daily activity
(counts·day-1000) and minutes spent in moderate-vigorous physical activity (MVPA) were
quantified using established thresholds for uniaxial ActiGraph accelerometers (57).

Experimental Approach
To examine changes in the control of oxidative phosphorylation at workloads
above and below the pHT, participants completed 6 stages of a stepwise knee extension
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protocol. Each stage consisted of 3 minutes of isotonic contractions at 0.5 Hz, followed
by 3 minutes of passive recovery. The rate of ATPOX at the end of each stage was
measured from the initial velocity of PCr resynthesis (ViPCr, mM·s-1) by fitting PCr
recovery to either a mono- or biexponential function. Subsequently, changes in the
control of ATPOX by ADP or CPP were examined after each stage using multiparametric
analysis to derive Vmax, Km, and nH, as described previously (Chapter 4). This allowed us
to calculate ATPOX throughout each stage, which, when combined with measures of ATP
synthesis by creatine kinase and non-oxidative glycolysis, permitted estimation of
ATPCOST throughout each stage as well.

Experimental Setup
Participants were positioned supine inside the bore of a 70 cm 3-Tesla MRscanner (Siemens, Erlangen, Germany) running on VE11c platform. A dual-tuned 31P/1H
surface coil (8x10.5 cm) was positioned over the vastus lateralis (VL) of the participant’s
dominant leg and secured using athletic wrap and Velcro straps. Next, the participant’s
leg was securely strapped to a custom-built knee-extension ergometer at the ankle, thigh,
and hips using inelastic straps and positioned inside the bore of the magnet such that the
surface coil and VL were located within the scanner’s isocenter. The knee-extension
ergometer’s contraction mode, duration, and frequency were all controlled using a
custom-written MATLAB program (Mathworks, Natick, Massachusetts). Torque,
position, and work were recorded for each contraction and exported for post-processing
in Excel (Microsoft, Redmond, Washington). The program also provided participants
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with real-time visual feedback about each contraction through display on a non-magnetic
digital screen (LCD BOLD screen, Cambridge Research Systems Ltd., United Kingdom).

Contraction Protocol
The contraction protocol began with 2-3 maximal voluntary isometric
contractions (MVIC), each lasting 3-5 s and followed by at least 1 minute of rest.
Participants then performed 2-3 sets of maximal voluntary isokinetic contractions
(MVDCs) to measure maximal knee-extension power. All MVDCs were isokinetic
(120°·s-1) and performed at a frequency of 0.5 Hz. Next, participants completed a restcontract-recover protocol that began with 90 s of rest, followed by 24 s of MVDCs, and 7
minutes of passive recovery in order to measure baseline skeletal muscle oxidative
capacity (kPCr, ·s-1), as described previously (see Chapter 4).
Participants then completed the stepwise contraction protocol, which began with 3
minutes of rest, followed by 6 stages of isotonic knee extensions. Each stage lasted 3
minutes and was followed by 3 minutes of passive recovery (Figure 5.1), except for stage
6, which was followed by 10 minutes of recovery. The starting workload was set to 810% of the participant’s MVIC torque (Nm) and increased by 2% MVIC each stage
thereafter. Concentric work (Joules) was recorded for each contraction by the customwritten MATLAB program and subsequently exported for further analysis in Excel.

Spectroscopy
Gradient-echo scout images of the thigh were acquired to ensure proper
placement of the coil relative to the participant’s vastus lateralis and magnetic isocenter
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of the MR scanner. The homogeneity of the magnetic field was optimized by manual
shimming on the proton (1H) signal to minimize the width at half-maximum of the water
peak, followed by frequency optimization on the phosphorous (31P) signal to minimize
the width at half-maximum of PCr (12.5 ± 0.6 Hz). Non-localized 31P-MRS freeinduction decays (FIDs) were collected continuously throughout the oxidative capacity
and stepwise contraction protocols using a nominal 60° hard pulse, 4,000 Hz bandwidth,
2,048 complex points, and 2-s repetition time. For the oxidative capacity protocol, FIDs
were acquired during 90 s of rest, throughout the 24 s contractile period, and during 7
minutes of passive recovery. For the stepwise contraction protocol, FIDs were acquired
during 3 minutes of rest and throughout all contractile and recovery periods of the
stepwise exercise test (43 minutes).
All FIDs were analyzed using jMRUI v6.0beta (156). The first 30 s (15 FIDs) of
acquisition were excluded from analysis to avoid partial saturation effects. For the
oxidative capacity protocol, the remaining FIDs were averaged to yield temporal
resolutions of 60 s at rest, 4 s during the contractile period, 4 s for the first 20 s of
recovery, 8 s for the ensuing 280 s of recovery, and 30 s for the remainder of recovery.
For the stepwise protocol, FIDs were averaged to yield temporal resolutions of 150 s at
rest, 10 s during contractions, 4 s for the first 20 s of recovery, 8 s for the ensuing 280 s
of recovery, and 30 s for the remainder of recovery. FIDs were then zero-filled (2,048
points) and apodized using a 1Hz Lorentzian filter. Following Fourier transform, spectra
were manually phased and the frequency was zeroed on PCr. The AMARES algorithm
was used to linefit peaks corresponding to phosphomonoesters (PME), inorganic
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phosphate (Pi), phosphodiesters (PDE), phosphocreatine (PCr), the γ- and α-ATP
doublets, and the β-ATP triplet (199).
Millimolar concentrations of phosphorous metabolites were calculated by
correcting metabolite signal intensities using experimentally-derived saturation correction
factors that were collected on a separate sample of 12 young adults (5 women), and
assuming [Pi]+[PCr]+[PME] is equal to 42.5 mM (72). Total muscle creatine was also
assumed to equal 42.5 mM and the concentration of free creatine (fCr) was assumed to be
equal to [Pi] (104, 119). [ATP] was assumed to equal 8.2 mM at rest (119, 122, 125) and
changes in [ATP] during the experimental trials were calculated by comparing the γ-ATP
signal intensity at each timepoint to the γ-ATP signal intensity at rest. We then conducted
linear regressions of [ATP] vs. time to determine if [ATP] declined in any given stage.
[ADP] was calculated based on the creatine kinsae equilibrium (K’CK):
[ADP] (mM) = ([ATP][Pi]) / ([fCr] · K’CK)

Eq 1

K’CK was corrected for changes in cytosolic pH according to an exponential
equation derived from experimental data reported by Golding et al. (65). Muscle pH was
calculated from the chemical shift between Pi and PCr (154). Muscle pHT and Pi/PCr
thresholds were determined for each participant using a bilinear fit, as described
previously (102).

Skeletal Muscle Oxidative Capacity
Baseline skeletal muscle oxidative capacity (kPCr, ·s-1) was calculated following 24
s of MVDCs by fitting the observed PCr recovery to a mono-exponential function:
PCrFit (t) = PCrEnd + Amp·(1-Exp(-kPCr · t))

Eq 2
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Where PCrFit is the calculated [PCr] at time point (t), PCrEnd is the measured [PCr]
at the end of the 24 s trial, Amp is the amplitude of the recovery in mM, and kPCr is the
mono-exponential rate constant, which reflects the system’s oxidative capacity (149,
150). This process was then repeated following each stage of the stepwise protocol. For
stages above the pHT, PCr recovery did not always follow a mono-exponential pattern
(71, 193). In these cases, PCr recovery was modelled using a biexponential function:
PCrFit (t) = PCrEnd + ((Amp1·(1-Exp(-kPCr1 ·t ))) + (Amp2·(1-Exp(-kPCr2 · t)))

Eq 3

where PCrFit, (t), Amp, and kPCr, all have their original meanings, and 1 and 2
denote the primary and secondary PCr recovery components, respectively. To avoid
physiologically unrealistic amplitude and kPCr estimations, the sum of (Amp1 + Amp2)
was constrained to be no greater than the difference between the concentration of PCr
observed at the end of the trial and the greatest concentration of PCr observed in
recovery. Subsequently, the overall kPCr of the biexponential function was calculated by
weighting the kPCr1 and kPCr2 rate constants to their respective amplitudes:
Biexponential kPCr = (kPCr1 · (Amp1/Total Amp)) + (kPCr2 · (Amp2/Total Amp))

Eq 4

Rates of oxidative ATP synthesis (ATPOX) at the end of each stage were
calculated from the initial velocity of PCr resynthesis (ViPCr, mM·s-1). ViPCr was
calculated as the change in [PCr] measured over the first 4 s from the fitted PCr recovery
estimation, using a mono-exponential fit for workloads prior to the pHT and a
biexponential fit for workloads beyond the pHT. Consistent with our previous work
(Chapter 4), we then calculated kinetic parameters of ATPOX using multiparametric
analysis. Briefly, the first 10 rates of PCr resynthesis after each stage were fit against
CPP to derive Vmax, KmCPP, and nH CPP according to the equation:
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VPCr (mM·s-1) = Vmax / ( 1 + (Km-CPP / CPP)nHCPP )

Eq 5

where VPCr is one of the first 10 rates of PCr resynthesis, Vmax is the maximal rate
of ATPOX (mM·s-1), Km-CPP is the CPP at which Vmax is half-maximal, nHCPP is the Hill
coefficient. This process was then repeated while fitting the first 10 rates of PCr
resynthesis against [ADP]:
VPCr (mM·s-1) = Vmax / ( 1 + (Km-ADP / [ADP])nHADP )

Eq 6

where VPCr, Km-ADP, and nHADP all have their original meanings, and Vmax is
constrained to the value obtained from the CPP multiparametric analysis to avoid
physiologically unrealistic estimations, as previously (Chapter IV).

pH and Pi/PCr Thresholds
Thresholds for intracellular pH and Pi/PCr were calculated for each participant
using a bilinear model described by Kent-Braun et al. (102):
y = m1 * W + b1

for

0 < W ≤ ip

Eq 7

y = m2 * W + b2

for

ip ≤ W

Eq 8

b2 = (m1 – m2)ip + b1

Eq 9

where ‘ip’ is the inflection point, m1 and m2 represent the slopes of the equations
defining workloads below (Eq# 7) and above (Eq# 8) the inflection point, and b1 and b2
represent the respective intercepts. To examine whether changes in end-stage metabolite
concentrations and ViPCr were similar above and below the pHT, separate linear slopes
were fit for each variable of interest against workload. End stage metabolite
concentrations were averaged over the final 30 s of each stage.
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Statistical Analyses
All statistical analyses were conducted using SPSS v25.0 (IBM Statistics,
Armonk, New York). Unless noted otherwise, data are presented as mean±SE, with pvalues < 0.05 considered statistically significant. Prior to conducting any statistical
comparisons, all data were tested for normal distrubution using the Shapiro-Wilk test.
Changes in end-stage metabolite concentrations, ViPCr, kinetic parameters of ATPOX, and
ATPCOST across stages were compared using repeated measures ANOVAs or the nonparametric Friedman test, with estimated marginal means or Wilcoxon signed-rank tests
to determine individual differences, respectively. Slopes describing stepwise changes in
muscle work and: 1) end-stage metabolite concentrations, 2) ViPCr , and 3) kinetic
parameters of ATPOX above and below the pHT were compared using paired t-tests.
Finally, to ensure that ViPCr calculated at the end of each stage in the stepwise test was not
confounded by the shortened recovery period (i.e., 3 minutes), we conducted Pearson
correlations between ViPCr measurements obtained by fitting all of recovery after the
baseline oxidative capacity protocol (7 minutes) and the final stage of the stepwise test
(10 minutes) to measurements of ViPCr obtained by fitting only the first 3 minutes of
recovery.

Results
Descriptive data for the participants are listed in Table 5.1. This was a young,
moderately active cohort with normal BMIs. Representative data from one participant
showing the work done for each contraction of a single stage are shown in Figure 5.1A.
Figure 5.1B depicts the mean work done for each contraction of the entire stepwise
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protocol for all participants. Changes in cytosolic pH, PCr, and ADP throughout the
protocol are shown in Figure 5.2. None of the participants exhibited decreases in [ATP]
(p > 0.05) but end-stage values for pH, PCr, ADP, and CPP changed across all stages (all,
p < 0.01).
The workloads corresponding to the pHT and Pi/PCr threshold were not different
from one another (23.6 ± 2.4 vs. 23.3 ± 2.2 Joules, respectively; p = 0.44). Group mean
slopes above and below the pHT are described in Table 5.2. As shown in Figure 5.3, the
slopes of cytosolic [ADP] and CPP vs. workload were greater above the pHT than below
it (p < 0.02), but this was not the case for PCr (p = 0.78). ViPCr also increased linearly
with workload for the first 4 stages but plateaued thereafter (Figure 5.4), resulting in the
slope above the pHT being significantly lower than that observed below the pHT (p =
0.03).
Results from the multiparametric analyses for ADP- and CPP-specific ATPOX are
presented in Table 5.3. There was no main effect for changes in Vmax across stages (p =
0.135) but the slope for changes in Vmax above the pHT was lower than the slope observed
below (p = 0.045, Table 5.2 and Figure 5.5). Similarly, no main effect of stage was
observed for Km-ADP, Km-CPP, or nHCPP, although nHADP did exhibit a main effect of stage (p
= 0.001), with post hoc analysis indicating that nHADP progressively declined across
stages, except for stage 2 compared to stage 3 (p = 0.19), and stage 6 compared to stages
4 and 5 (p = 0.081 and p = 0.704, respectively). A main effect of stage was also observed
for both ADP- and CPP-specific ATPOX (p < 0.05, both; Figure 5.6). For ADP-specific
ATPOX, Stage 6 was lower than Stages 2-4, and Stage 5 was lower than Stages 2 and 4.
For CPP-specific ATPOX, Stages 5 and 6 were both lower than Stages 2 and 4.
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Finally, there was no change in ATPCOST across stages throughout the stepwise
test (Figure 5.7; p = 0.10).

Discussion
The main finding of the present study is that augmentations in cytosolic ADP and
CPP during high-intensity contractions at workloads above the pHT are not accompanied
by concomitant increases in ATPOX. In accordance with our main hypothesis, changes in
cytosolic [ADP], CPP, PCr breakdown, and ViPCr were linearly related to workload for
stages below the pHT (Figure 5.3). However, for workloads above the pHT, changes in
cytosolic [ADP] and CPP were augmented, whereas ViPCr tended to plateau after stage 4
(Figure 5.4). Moreover, Vmax began to decline after stage 4 (Figure 5.5), which lead to
declines in both ADP- and CPP-specific ATPOX (Figure 5.6). Furthermore, consistent
with our second hypothesis, we did not observe a change in ATPCOST throughout the
protocol (Figure 5.7). Consequently, the results of this study suggest that the VO2SC is
caused by impairments in the capacity for ATPOX, possibly due to mitochondrial
uncoupling.
Our stepwise test produced most of the stage-stage changes in muscle work and
metabolites that we expected to see. As demonstrated in Figure 1, within-stage muscle
work performances were stable and increased linearly across all 6 stages. The pHT
occurred after stage 2 in one participant, after stage 3 in 5 participants, and after stage 4
in 2 participants, thereby allowing us to compare changes in muscle phosphates, ATPOX,
and ATPCOST above and below the pHT in all participants. Consistent with previous work,
changes in muscle phosphates were linearly related to changes in muscle work for
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workloads below the pHT but augmented thereafter (10, 85, 102, 104). However, we did
not observe a significant augmentation in PCr breakdown above the pHT (Figure 5.3).
This null finding appeared to be due to a floor-effect, as PCr breakdown reached 70% of
the baseline resting level by the end of stage 4 and only decreased an additional 15%
thereafter, which may have been a consequence of the high energy cost of overcoming
inertia associated with isotonic contractions. Nevertheless, the augmentation of cytosolic
[ADP], CPP, and proton (H+) accumulation indicated that muscle metabolism was indeed
augmented above the pHT. Subsequently this allowed us to examine whether the
augmentations in muscle metabolism were caused by increases in ATPCOST or
mitochondrial uncoupling-induced alterations in the capacity for ATPOX.
Consistent with our primary hypothesis, ViPCr was not augmented above the pHT.
This finding is deductively opposed to the hypothesis that augmentations in muscle
oxygen consumption during high-intensity contractions reflect increased rates of ATPOX
caused by increases in the ATPCOST of force generation (29, 35, 174, 211). Moreover, we
saw no change in ATPCOST throughout the stepwise test (Figure 5.7). These results
contrast those of Cannon et al. (35), who observed increases in ViPCr and ATPCOST during
high-intensity bilateral knee extensions. One possible explanation for this discrepancy is
the duration of the two contraction protocols. Whereas Cannon et al. calculated changes
in ATPCOST over the final 5 minutes of an 8-minute bout of contractions, our stages were
only 3 minutes. Consequently, we cannot rule out the possibility that our 3-minute stages
were not long enough to permit changes in ATPCOST to develop. That this is the second
time we have reported no change in ATPCOST using contraction protocols that last 3-4
minutes per bout, strongly suggests that additional work is necessary to identify whether
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the observations reported here, and previously (Chapter IV), are replicable during longer
stepwise stage durations and all-out contraction protocols.
Collectively, the results presented here suggest that contraction intensities above
the pHT are associated with impairments in the capacity for ATPOX, which is consistent
with the notion that high-intensity contractions stimulate mitochondrial uncoupling
(Chapter IV) (35). However, another notable finding of the present study is that although
increases in ViPCr relative to workload were attenuated above the pHT, the relationship
was not immediately impaired. Stage 4 was above the pHT in six of the eight participants,
but the increase in ViPCr continued to follow the linear relationship observed for
workloads below the pHT. Rates of ADP- and CPP-specific ATPOX were also well
maintained. Consequently, it is possible that mitochondrial uncoupling does not
immediately impair ATPOX provided respiration by the electron transport chain can
increase sufficiently to compensate for the passive proton conductance. Put another way,
mild mitochondrial uncoupling may alter P/O ratio and the behavior of electrophoretic
transport proteins (105, 117, 118), but if proton pumping by the electron transport chain
can increase sufficiently to account for H+ conductance by both mitochondrial
uncoupling and ATP synthase activity, then ATPOX may not necessarily be compromised.
Consistent with this notion, mitochondria appear to exhibit a reserve capacity for
respiration, as peak rates of mitochondrial oxygen consumption in vitro tend to occur
when respiration is uncoupled from thermodynamic constraint by ATP synthase and
matrical phosphorylation potential (54, 87, 126, 127, 163). This latter observation adds to
the symmorphosis concept described by Gifford et al. (62). Specifically, multiple studies
have reported that State-3 respiratory capacity in vitro exceeds oxygen delivering
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capacity in vivo (24, 25, 62), the paradox being why skeletal muscle would develop such
a large capacity for ATPOX if the capacity is physiologically unachievable in vivo.
Possibly even more perplexing, however, is how and why uncoupled respiratory capacity
would be greater than State-3 respiratory capacity if oxygen delivery by the
cardiovascular system only barely matches the muscle’s capacity for in vivo State-3
respiration in the first place.
In light of this latter symmorphosis, perhaps we need to start considering the
possibility that, in healthy young adults, oxygen delivery and availability may not be
limiting to oxidative phosphorylation in vivo. Instead, perhaps the true limit to oxidative
phosphorylation in vivo is not oxygen availability or respiratory capacity, but rather the
mitochondria’s intrinsic capacity for ATP synthesis (i.e., phosphorylation capacity). If
this were the case, the magnitude of the proton motive force would always remain high
and intramuscular oxygenation would always, theoretically, be excessive, or hyperoxic,
because respiration would always be under State-3, phosphorylative control. In turn, this
may lead to greater rates of reactive oxygen species generation, which could stimulate
mitochondrial uncoupling to attenuate oxidative stress.
Although this scenario may appear radical at first, it becomes much more tenable
when one considers that the VO2SC is associated with the recruitment of Type-II muscle
fibers (114, 141, 143), which tend to exhibit a lower mitochondrial content and oxidative
capacity than Type-I fiber (63, 67, 86, 115), as well as lower antioxidative capacities (63,
165) and greater uncoupling protein 3 content (77, 176). Moreover, this hypothesis also
provides an explanation for why the VO2SC is attenuated following endurance training, as
improvements in mitochondrial phosphorylation capacity would improve the muscle’s
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capacity to utilize oxygen for ATPOX, thereby attenuating the magnitude of hyperoxia and
reducing the generation of ROS that stimulated mitochondrial uncoupling prior to the
endurance training regimen. Thus, perhaps we need to consider the possibility that for
healthy young adults, high-intensity exercise at workloads above the lactate threshold are
associated with hyper-oxia, rather than hypo-oxia.

Limitations
There are two major limitations to the present study that need to be addressed in
the near future. First, we did not measure muscle or pulmonary oxygen consumption
during the present study, and therefore cannot say for certain that the plateauing of ViPCr
after stage 4 was strictly due to changes in the efficiency of oxidative ATP synthesis.
Indeed, ViPCr would also be expected to plateau if the muscle achieved VO2max by stage 4.
Consequently, we cannot say for sure that mitochondrial uncoupling was occurring in
skeletal muscle during stages above the pHT. Follow-up studies should address this
limitation by combining 31P-MRS measures of ATPOX with pulmonary oxygen uptake
(38, 128) or direct measures of muscle oxygen consumption (13, 49, 68, 145).
Second, from an applied physiology perspective, another factor we have to
consider is that oxygen delivery by the cardiovascular system is less limiting to oxidative
metabolism during single-leg knee extensions than during whole body exercises (24, 25,
62). Consequently, it is possible that if mitochondrial uncoupling does occur in vivo, it
may only present during high-intensity single-joint contraction protocols, and not wholebody exercises, such as cycling or treadmill running where cardiovascular oxygen
delivery may not be able to match intramuscular demand. To overcome this limitation,
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future investigations should continue to implement large muscle mass protocols inside
magnetic-resonance scanners, such as bilateral knee extensions (35, 174) or cycling (91),
to investigate whether whole-body exercises induce similar impairments in ViPCr and
Vmax that we have observed here and in our previous investigation (see Chapter IV).
Indeed, Jeneson et al. developed an MR-compatible cycle ergometer that elicited heart
rates of ~150 beats per minute, 80% PCr breakdown, and pH values of 6.7 at the end of
an incremental exercise test (91); values that are consistent with the results reported in
this study.

Conclusions
In conclusion, we have demonstrated that oxidative ATP synthesis, measured
from the initial rate of PCr resynthesis, is not augmented during high-intensity
submaximal contractions at workloads above the pHT, despite significant augmentations
in two key driving factors for mitochondrial energy production: cytosolic [ADP] and
CPP. Instead, the capacity for ATPOX, as well as ADP- and CPP-specific rates of ATPOX,
are diminished above the pHT, though these impairments do not present immediately.
Notably, we also observed no change in the ATPCOST of contraction across a range of
workloads, including those above the pHT, suggesting that mechanical efficiency is not
impaired during high-intensity contraction in healthy young adults. Collectively, these
results add to the growing body of evidence suggesting that mitochondrial uncoupling is
the mechanism responsible for the VO2SC and augmentations in muscle metabolism
during high-intensity exercise at workloads above the pHT. Future studies should look to
collect measures of muscle oxygen consumption simultaneously with 31P-MRS measures
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of ATPOX to determine more directly whether mitochondrial P/O ratio is decreasing
during high-intensity contractions. Additionally, in contrast to the single-leg knee
extension model used here, it would be advantageous to develop and employ MRcompatible ergometers that can mimic whole-body exercise models inside MR-scanners
(35, 91), where oxidative metabolism and exercise performance are more likely to be
centrally limited by the cardiovascular system’s oxygen delivering capacity.
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Age (years)
Height (cm)
Body Mass (kg)
BMI (kg/m2)
PA (counts·day-1/1000)
MVPA (minutes·day-1)
Peak isometric torque (Nm)
Peak power (Watts, 120°·s-1)

25.2 ± 1.3
175.7 ± 3.5
74.4 ± 5.0
23.9 ± 0.8
284.4 ± 25.5
46.7 ± 4.6
251.5 ± 20.0
277.4 ± 34.4

Table 5.1: Study 2 Participant Characteristics. Data were collected on 8 healthy young adults
(3F). Data are presented as means ± SE.
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PCr Breakdown (∆mM/∆J)
ADP (∆mM/∆J)
CPP (∆CPP/∆J)
ViPCr (∆mM·s-1/∆J)
Vmax (∆mM·s-1/∆J)

Stages < pH Threshold
-1.07 ± 0.13
0.005 ± 0.001
0.021 ± 0.005
0.019 ± 0.005
0.002 ± 0.008

Stages > pH Threshold
-1.28 ± 0.28
0.016 ± 0.003 *
0.081 ± 0.014 *
0.000 ± 0.005 *
-0.020 ± 0.003 *

Table 5.2: Slopes for changes in muscle metabolites, ViPCr, and Vmax vs. muscle work (J) at
intensities above or below the pHT. After determining each participant’s pHT, slopes were
calculated by using a linear estimation to fit ∆variable/∆muscle work for stages above and below
an individual’s pHT respectively. * Denotes a significantly different slope above the pHT
compared to below. Data are presented as mean ± SE.
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Stage 1
0.025 ±
0.002 e,f

Stage 2
0.024 ±
0.002 c-f

Stage 3
0.022 ±
0.002 b,e,f

Stage 4
0.021 ±
0.002 b,e,f

Stage 5
0.018 ±
0.002 a-d

Stage 6
0.018 ±
0.002 a-d

Vmax (mM·s-1)

0.73 ±
0.04

0.79 ±
0.06

0.75 ±
0.06

0.76 ±
0.07

0.69 ±
0.08

0.65 ±
0.08

Km-ADP
(mM)

0.037 ±
0.004
1.30 ±
0.08 b-f

0.040 ±
0.003
1.17 ±
0.05 a,d-f

0.039 ±
0.002
1.10 ±
0.04 a,d-f

0.039 ±
0.002
1.02 ±
0.03 a,c,e

0.035 ±
0.002
0.96 ±
0.02 a-d

0.030 ±
0.002
0.97 ±
0.02 a-c

0.085 ±
0.014
0.79 ±
0.04

0.098 ±
0.010
0.74 ±
0.02

0.094 ±
0.007
0.72 ±
0.01

0.101 ±
0.008
0.71 ±
0.01

0.091 ±
0.007
0.70 ±
0.00

0.080 ±
0.005
0.73 ±
0.02

kPCr (·s-1) *

nH ADP *
Km CPP

nH CPP

Table 5.3: Oxidative kinetics at the end of each stage of the stepwise test. kPCr declined
throughout the contraction protocol. Vmax was not different across stages when analyzed by
repeated measures ANOVA, but the slope of Vmax above the pH threshold was different from the
slope below the acidic threshold (p=0.045, see text for details). The only other parameter that
changed across stages was nH-ADP (*, p < 0.001). a – significantly different from stage 1; b –
significantly different from stage 2, c – significantly different from stage 3, d – significantly
different from stage 4, e – significantly different from stage 5, f – significantly different from
stage 6.
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Figure 5.1: Muscle performances during the stepwise knee extension protocol. The
representative data in panel A illustrate the work (Joules) performed for each contraction of a
single stage in one participant. Panel B illustrates group mean data for all contractions performed
throughout the stepwise protocol. Data are presented as mean ± SE, with error bars shown at the
end of each minute.
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Figure 5.2: Changes in muscle metabolites throughout the stepwise contraction protocol.
Muscle pH, PCr, and ADP for six 3-minute stages of isotonic contractions and 3 minutes of
recovery are shown. Data are presented as mean ± SD, with error bars shown intermittently.
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Figure 5.3: End-stage changes in muscle metabolites. Metabolites during the final 30 s of each
stage. Open and filled circles represent variables at the end of workloads above and below the
pHT, respectively. The dashed and solid lines illustrate the mean linear relationships observed for
changes in metabolites relative to workload above and below the pHT, respectively. Data are
presented as mean ± SE.
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Figure 5.4: Changes in ViPCr across stages. As expected, ViPCr increased linearly with workload
below the acidic threshold, but beyond stage 4, the increase in ViPCr was attenuated relative to the
increase in workload. Data are presented as mean ± SE.
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Figure 5.5: Estimations of Vmax across stages. There was little to no change in Vmax across the
first 4 stages (slope < pHT = 0.002 mM·s-1/J), but after stage 4, Vmax steadily declined (slope >
pHT = -0.020 mM·s-1/J). Data are presented as mean ± SE.
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Figure 5.6: End-stage rates of substrate-specific ATPOX. Rates of substrate-specific ATPOX
were calculated after every stage for each participant. Substrate-specific ATPOX remained similar
across the first 4 stages but tended to be lower following stages 5 and 6 for both ADP (A) and
CPP (B) (see Results for more details). Data are presented as mean ± SE. Error bars are shown for
the final 4 substrate levels for clarity.
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Figure 5.7. Changes in ATPCOST during the stepwise knee extension protocol. Mean ATPCOST
(J·mM ATP·s-1) was calculated for each stage by averaging all timepoints (10-s resolution) in
each stage and did not change throughout the stepwise contraction protocol (p = 0.10). Mean
ATPCOST for each timepoint throughout the full protocol are shown. Data are presented as mean ±
SE.
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CHAPTER 6
DISSERTATION SUMMARY
Current models of oxidative phosphorylation sufficiently describe skeletal muscle
energetics during moderate-intensity contractions because ATP demand is met mainly by
oxidative ATP synthesis (ATPOX) and steady-state muscle metabolism is linearly related
to the rate of muscle work. These metabolic conditions allow researchers to use 31phosphorous magnetic resonance spectroscopy (31P-MRS) and basic principles of
chemical thermodynamics to calculate rates of ATPOX from known relationships with
cytosolic free creatine, [ADP], or the phosphorylation potential (CPP) (19, 95, 98, 119,
120, 129, 149, 158).
However, the mechanisms that limit and control oxidative phosphorylation in vivo
during square-wave high-intensity contraction protocols (i.e., above the lactate threshold)
are not fully understood. Not only is steady-state metabolism delayed until 5-6 minutes
into exercise (58, 212, 213, 219), or unachievable, but the linearity between skeletal
muscle metabolism and power output is distorted (58, 109). Specifically, the oxygen cost
of high-intensity contractions is greater than would be predicted by the linear relationship
observed during moderate-intensity contractions, and is accompanied by greater changes
in phosphocreatine (PCr) breakdown, acidosis, [ADP], and the free energy of ATP
hydrolysis (10, 44, 83, 85, 104, 170, 174, 191).
Previously, researchers postulated that the augmentation of skeletal muscle
oxygen consumption during high-intensity contractions was driven either by: 1) increases
in the ATP cost of force generation (174), or 2) decreases in the efficiency of ATPOX due
to mitochondrial uncoupling. However, methodological limitations had hindered a
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definitive evaluation of either hypothesis in vivo. Specifically, although several methods
exist for using 31P-MRS to calculate rates of ATPOX, all of these methods assume that the
ATP cost of force generation does not change (99) or that mitochondrial uncoupling does
not occur (29, 119). Given that these two assumptions formulate the basis of the two
hypotheses that have been put forth to explain why skeletal muscle oxygen consumption
is augmented above the lactate threshold (35, 169, 174), they cannot be used to study
changes in the control of oxidative phosphorylation. Consequently, the objective of this
dissertation was to unravel the mechanisms that alter the control of oxidative ATP
synthesis during contractions at workloads above the lactate threshold by measuring
changes in ATPOX from the initial velocity of PCr resynthesis (ViPCr). Because ViPCr
yields only one measure of ATPOX per bout of contractions, a secondary objective was to
develop and validate new methods for calculating ATPOX continuously during highintensity contractions.
Study 1 allowed us to achieve both of these objectives. Participants performed
repeated bouts of maximal voluntary dynamic contractions lasting 24, 60, 120, and 240 s
that were matched for changes in power and metabolites. ViPCr increased over the first 60
to 120 s but then declined over the final 120 s. The decrease in ViPCr from 120 to 240 s
occurred despite elevated cytosolic ADP, CPP, and PCr breakdown. That cytosolic ADP,
CPP, and PCr breakdown remained elevated over the final two minutes indicates that the
decline in ViPCr was not a function of muscle fatigue and motor unit dropout, as this
would have caused each of these metabolic measures to partially recover before the end
of the 240-s trial. Instead, the decline in ViPCr over the final 2 minutes appeared to be
caused by a diminished capacity for ATPOX. Multiparametric analyses performed after
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each trial to calculate Vmax, Km, and nH confirmed this suspicion, with Vmax being
significantly lower after the 120- and 240-s trials than the 24-s trial. Together, these data
strongly suggest that augmentations in oxidative metabolism during high-intensity
contractions are caused by mitochondrial uncoupling. Regretably, however, we did not
collect any measures of oxygen consumption, and therefore cannot conclude without a
doubt that mitochondrial uncoupling affected ATPOX in this study.
On the other hand, we did calculate ATPCOST throughout the 240-s trial and found
that ATPCOST did not change across any timepoints. These findings conflict with those of
Broxterman et al. (29), who reported an increase in the ATPCOST of torque generation
during a maximal isometric contraction protocol in the knee extension muscles of healthy
young adults. However, the method for calculating ATPOX in that study did not account
for changes in Vmax from baseline to the end of fatiguing contractions, which the second
half of Study 1 in this dissertation (described below) showed is necessary for accurate
calculation of ATPOX. Consequently, it is possible that the increase in ATPCOST observed
in that study was a function of inaccurate ATPOX calculation.
The ATPCOST results of Study 1 also conflict with those of Cannon et al. (37),
who reported increased ATPCOST during 8 minutes of submaximal bilateral knee
extensions. Notably, although Cannon et al. calculated ATPOX from ViPCr, it is unclear if
they fit PCr recovery to a monoexponential following both the 3- and 8-minute trials, or
if biexponential fitting was used when PCr recovery did not follow a mono-exponential
pattern. As shown in Figure 3.1, this methodological consideration is one that requires
greater investigation to ensure that calculations of kPCr, ViPCr, Vmax, and ATPOX are
accurate and consistent across labs using 31P-MRS to investigate skeletal muscle
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energetics. Alternatively, the discrepancy between our results could have been due to
differences in contraction intensity and protocol duration. Although we saw no change in
ATPCOST throughout the stepwise contraction protocol in Study 2, where changes in
muscle metabolites were augmented for several workloads above the pH threshold, we
cannot rule out the possibility that changes in ATPCOST may have been observed if we
had extended the duration of our stages to 6 minutes or longer.
The second major finding of Study 1 was that ATPOX can be calculated
continuously during high-intensity, non-steady state contractions by adjusting for changes
in Vmax. That is, ATPOX can be calculated continuously, regardless of the contraction
intensity, by measuring Vmax, Km, and nH at baseline following an oxidative capacity
protocol, and then again during the recovery period immediately after the bout of
contractions. The ATPOX method I developed and presented in this dissertation, which
was a modification of traditional Direct ATPOX methods, should help pave the way for
future investigations of skeletal muscle bioenergetics during high-intensity contractions
in both healthy young adults, as well as in clinical populations that are easily fatiguable
and would not be able to perform repeated bouts of contractions.
Subsequently, the purpose of Study 2 to follow up on Study 1 by measuring
changes in ADP, CPP, PCr breakdown, and parameters of ATPOX (ViPCr, Vmax, Km, and
nH) after each stage of a stepwise, or incremental, isotonic contraction protocol. Similar
to previous studies (40, 101), muscle metabolites and ATPOX increased linearly with
workload for all workloads below the pH threshold (pHT). Calculations of Vmax, Km, and
nH were also consistent across stages, indicating the capacity for ATPOX, and control by
ADP or CPP, were not affected by the contractions. For workloads above the pHT,
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however, changes in muscle metabolites were augmented relative to workload, yet this
was not accompanied by an augmentation in ATPOX. Instead, ATPOX plateaued, and Vmax
declined (slope above pHT < slope below pHT), over the final 2 stages, leading to
decreases in substrate-specific phosphorylation rates of ATPOX by ADP and CPP (stages
5 and 6 lower than stages 2-4 for ADP specific ATPOX, and stages 2 and 4 for CPPspecific ATPOX). Moreover, there was no change in ATPCOST throughout the protocol,
suggesting once again that augmentations in muscle metabolism during high-intensity
contractions are not caused by greater rates of ATP demand due to increased ATP cost of
force generation.
Collectively, these results suggest that the declines in ViPCr and Vmax observed in
Study 1 were not simply a function of the all-out, maximal intensity and high energy
demand of the contaction protocol. Instead, the impairment of Vmax during high-intensity
contractions appears to be a function of both intensity (i.e., the magnitude of the
workload above the pHT) and duration (i.e., length of the contraction protocol). However,
we did not collect any measures of oxygen consumption, such as pulmonary oxygen
uptake, during Study 2, and therefore cannot conclude beyond a reasonable doubt that
these obervations were definitively caused by mitochondrial uncouping. However, that
ATPOX was not augmented above the pHT strongly refutes the suggestion that
augmentations in skeletal muscle oxygen consumption during high-intensity contractions
are caused by increased rates of ATPOX, leaving mitochondrial uncoupling as the only
viable hypothesis remaining.
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Prospective Considerations
My undergraduate mentor, Dr. Robert Lehnhard, once told me; “the only
limitation to science is the inability to ask the right questions…”. In Chapter II, I
explained how mitochondrial uncoupling offers as valid an explanation to the slow
component of oxygen uptake kinetics (VO2SC) as does increases in the ATP cost of force
generation. Yet, mitochondrial uncoupling rarely garners significant attention as a
potential explanation for the VO2SC because there is no clear mechanistic hypothesis that
explains both how and why it would occur during high-intensity exercise, which
precludes the development of testable predictions that permit deductive separation of
mitochondrial uncoupling from increases in ATPCOST in vivo. As I have mentioned
several times throughout this dissertation, there are numerous metabolic and
bioenergetics aspects of high-intensity exercise that the increased ATPCOST hypothesis
cannot reconcile, and, in my opinion, the only reason this hypothesis has persisted for so
long is because there has never been a viable alternative hypothesis to clearly oppose it.
In my opinion, the presentation of an alternative mechanistic hypothesis is the
single most important next step to unraveling the mechanisms that limit oxidative
phosphorylation in vivo and alter its control during high-intensity contractions. Although
I have developed a theoretically comprehensive hypothesis to address this gap, which
posits that phosphorylation capacity is the true limit to oxidative phosphorylation in vivo
and that hyperoxic mitochondrial uncoupling is responsible for the VO2SC, as well as
many other unresolved metabolic and bioenergetic phenomena, such as the lactate
paradox and excess post-exercise oxygen consumption, I will wait to unveil its complete
description until each component of the hypothesis can be organized and explained in a
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single unadulterated manuscript without being diminished by the novel observations and
methodologies presented in this dissertation.
Moving forward, researchers should look to collect measures of skeletal muscle
oxygen consumption alongside 31P-MRS measures of ATPOX, which should permit
calculation of the P/O ratio and direct demonstration of mitochondrial uncoupling.
Changes in mitochondrial coupling within skeletal muscle could also be examined by
measuring changes in muscle metabolites that are distributed in the matrical and cytosolic
compartments according to the proton motive force (117, 118, 159). That is, conditions of
oxygen-limited metabolism could be separated from conditions of mitochondrial
uncoupling by identifying specific ‘biochemical signatures’ for each condition. However,
to the best of my knowledge, this has not been investigated comprehensively. Future
studies should also look to combine other techniques with 31P-MRS, such as near-infrared
spectroscopy (46, 172, 177), diffuse correlation spectroscopy (5, 171, 198), and surface
fluorimetry (42, 92), which will provide additional insight into the role oxygen
availability plays in limiting or altering the regulation of oxidative phosphorylation
within skeletal muscle during moderate- and high-intensity contractions.
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APPENDIX A
INFORMED CONSENT DOCUMENT (STUDY I)
INFORMED CONSENT DOCUMENT
University of Massachusetts
Amherst, MA 01002
Project Title: Calculating Oxidative Energy Production during Non-Steady State
Contractions
Principal Investigator: Jane A. Kent, PhD
Co-Investigators: Rajakumar Nagarajan, PhD, Miles F. Bartlett, Liam F. Fitzgerald,
Joseph A. Gordon, Julia D. Miehm
Your written informed consent is required before you can participate in this project.
Please read this document carefully and then sign your name on the last page if you agree
to participate. This document is in accordance with regulations for the Protection of
Human Research Subjects (45 CFR 46). You are encouraged to ask questions at any time
before, during or after participating.
Purpose: Aerobic energy production in skeletal muscles can be measured during
moderate-intensity contractions, but this becomes difficult during high-intensity
contractions. We recently developed a new method for calculating aerobic energy
production in contracting skeletal muscles that appears to overcome the limitations of
previous methods, and so the purpose of this study is to test the validity of our new
method.
Eligibility: To participate in this study you must be healthy and between 25-40 years of
age. You may not have any: neurological or neuromuscular disease; a history of stroke,
peripheral vascular disease, cardiac or pulmonary disease; be a smoker; or have a history
of any metabolic diseases/disorders. You may not be pregnant. You may not have any
metal implants or anything that would prevent you from undergoing a magnetic
resonance imaging (MRI) exam.
Procedures: Prior to your first visit, you will be screened by telephone interview for
general health, medical history, current medications, usual physical activity habits, and
eligibility for the study. If you are qualified and agree to participate, you will be invited
to the Human Magnetic Resonance Center (HMRC) at the University of Massachusetts
Amherst for one visit.
Paperwork and Muscle Contraction Protocol (~2 hours)
Upon arriving to the HMRC, you will read the informed consent document and
have any questions answered by the investigator. After agreeing to participate and
signing the consent form you will fill out the following documents (attached):
- Physical Activity Readiness Questionnaire
- Medical History Form
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- Magnetic Resonance (MR) Safety Form
Next, measures of blood pressure, height, and body weight will be obtained.
Before entering the magnet room, you will empty your pockets and walk through a metal
detector. We will then escort you to the MR scanner and position you on your back with
your dominant leg on top of our custom-built leg exercise apparatus. The lower leg (shin)
will be strapped to the apparatus just above the ankle, and at the knee using Velcro straps.
Inelastic straps will also be secured over your hips to prevent unwanted movement during
the muscle contractions. A specially designed copper coil encased in a plastic box will be
secured over the thigh muscles using Velcro straps. This coil will be used to measure
changes in muscle biochemistry during the contractions. Headphones will be provided to
limit the amount of noise from the MR scanner, and to enable clear and constant
communication between you and the investigators. We will talk with you and explain
each set of measures as we go along. These measures are described next.
First, we will position you in the center of the MR scanner and “tune” the magnet
to the thigh muscles. We will then take resting measures of your muscle biochemistry.
During this time, you will lay quietly for about 10-15 minutes. Next, you will complete 23 maximal isometric (i.e., ‘static’) contractions, each lasting 3-4 seconds, to determine
your maximal strength. You will be given 1-2 minutes of rest between each of these
contractions. Then, you will repeat this effort, but this time you will maintain the
maximal isometric contraction for 24 seconds, after which you will rest quietly without
moving for up to 10 minutes. This procedure will be used to determine your muscle’s
“aerobic” capacity.
You will then perform 2-3 sets of 3 rapid, maximal dynamic contractions (i.e.,
“with movement”). The dynamic contractions will all be isokinetic; that is, the speed of
the contraction will be limited by our custom-built exercise apparatus. These contractions
will be used to determine your maximal dynamic strength. You will be given 1-2
minutes of rest between each of these sets.
Next, you will perform our experimental protocol, which will include 4 sets of
dynamic knee extensions. You will perform one contraction every 2 seconds by kicking
as hard and as fast as you can. The duration of each set will vary, beginning with 24
seconds for set 1 and increasing to 60, 120, and 240 for sets 2, 3, and 4, respectively. Up
to 10 minutes of rest will be given between each set.
Lastly, before leaving, we will give the you a uniaxial accelerometer, which is a
small activity monitor that will record the amount and intensity of physical activity you
perform over the next 7 days. You will be instructed on how and when to use it and how
to keep a simple physical activity log book. At the end of the week-long wear period, a
member of the Muscle Physiology Laboratory will collect the accelerometer and log book
at a time that is most convenient for you.
Subject Enrollment/Length of Study: We expect to enroll 10-20 participants in this
study. Your participation will include 1 visit lasting approximately 2 hours.
Possible Risks and Discomforts: There are minimal risks associated with the
procedures used in this research study. You may experience soreness in your muscles in
the days following the testing, but this would be a normal response and should be
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temporary. Injury is possible if you have any metal in or on you during the magnetic
resonance testing, but we will check you beforehand to detect any such metal.
Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) – The United States Food
and Drug Administration (FDA) has established guidelines for magnet strength and
exposure to radio waves, and we carefully observe those guidelines. No ill effects have
been reported for the radio wave exposure associated with this protocol. Some people
may feel uncomfortable or anxious while in the MR scanner, which is a large magnet. If
this happens to you, you may ask to stop the study at any time and we will take you out
of the MR scanner. On rare occasions, some people might feel dizzy, get an upset
stomach, have a metallic taste, feel tingling sensations, or experience muscle twitches.
These sensations usually go away quickly but please tell the research staff if you have
them.
MRI and MRS pose some risks for certain people. If you have a pacemaker or certain
types of metal objects inside your body, you may not be in this study because the strong
magnet used for these MR studies might harm you. Another risk is a metallic object
flying through the air toward the magnet and hitting you. To reduce this risk we require
that all people involved with the study remove all metal from their person and all metal
objects from their pockets. Nothing metal can be brought into the magnet room at any
time. Also, once you are in the magnet, the door to the room will be closed so that no
one accidentally bring a metal object near the magnet while you are in it.
Please read the Magnetic Resonance Safety Form and complete it very carefully.
Those questions are for your safety. Take a moment now to be sure that you have read
this Form and be sure to ask any questions and tell us any information you think might be
important. Even if you think that it is probably okay, we would rather have you ask
us to make sure.
If you experience significant claustrophobia during the MR testing, you will be removed
immediately. You will be positioned feet-first in the magnet and your head will remain
near the opening in order to minimize claustrophobia.
What if there is an unexpected finding on my MRI scan? The investigators for this
research project are not licensed or trained diagnosticians or clinicians. The testing
performed in this project is not intended to find abnormalities, and the images or data
collected do not comprise a diagnostic or clinical study. However, occasionally in the
process of research, investigators may perceive an abnormality, the health implications of
which may not be clear. When this occurs, UMASS Amherst researchers will consult
with a radiologist. If the radiologist determines that an additional inquiry is warranted,
the researcher will then contact you regarding the radiologist’s opinion of the unexpected
finding(s).
In such a case, you are advised to consult with a licensed physician to determine whether
further examination or treatment would be prudent. Although the images collected for
this research project do not comprise a diagnostic or clinical study, the images can be
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made available to you for clinical follow-up. The costs for any care that will be needed to
diagnose or treat an unexpected finding(s) would not be paid for by University of
Massachusetts, Amherst. These costs would be your responsibility. If you have further
tests done by your licensed physician, those results will then become part of your medical
record, which may affect your current and future health or life insurance.
Regardless of the health implications, the discovery of an unexpected finding(s) may
cause you to feel anxious or worried. You may wish to talk to your physician or a
qualified mental health clinician. You can contact the Center for Counseling and
Psychological Health (CCPH) at (413) 545-2337 (Mon-Fri from 8-5pm) - on weekends or
after 5pm, call (413) 577-5000 and ask for the CCPH clinician on call. You can also
contact the Psychological Services Center at 413-545-0041 (Monday-Friday 8am-5pm)
or psc@psych.umass.edu. In a serious emergency, remember that you can also call 911
for immediate assistance.
Confidentiality: Steps are taken to protect the identities of you and the data collected in
this study. The Informed Consent, Physical Activity Readiness Questionnaire, and MR
Safety Form (all of which will have your name on them) will be stored and locked in a
filing cabinet within a locked office. All other data collection sheets will be coded with
your participant number and the study name instead of your name, so that no potential
identifiers can be linked back to you. Data collection sheets and lists of participant codes
and names are kept separate from all other study materials. Paper documents with names
or codes will be stored in separate locked filing cabinets located in a locked office. All
electronic data will be kept on a password-protected computer in a locked office. Any
data that are published or used in a presentation will not include any names or identifiers
that could link back to you.
In Case of Injury: In the unlikely event of an injury resulting directly from participation
in this study, we will do everything we can to assist you in seeking medical treatment.
The University of Massachusetts does not have a program for compensating subjects for
injury or complications related to human subject research.
Benefits: You will receive no direct benefit from participating in this study.
Costs and Reimbursement: There is no cost to participate in this study. To compensate
you for your participation, we will give you $10 cash for completing all of the contraction
protocols, and another $10 for completing all of the physical activity measures.
Withdrawal from Participation: Participation in this research is voluntary. You have
the right to refuse to continue or withdraw from the study at any point, without prejudice.
Alternative Procedures: The procedures described above are non-invasive techniques
that are commonly used in muscle research. There are no other non-invasive techniques
that can be used to obtain the information necessary in this study.
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Request for Additional Information: You are encouraged to ask questions about the
study. The investigators will attempt to answer all of your questions to the best of their
knowledge. The investigators fully intend to conduct the study with your best interest,
safety, and comfort in mind. Please address any questions regarding the study to the
Muscle Physiology Laboratory. Our phone number is (413) 545-5305. We can also be
reached by email at umassmplab@umass.edu. You may also address questions to Prof.
Kent by calling her at (413) 545-9477 or by emailing her at jkent@kin.umass.edu. If you
would like to speak with someone not directly involved in the research study, you may
contact the Human Research Protection Office at the University of Massachusetts via
email at humansubjects@ora.umass.edu; telephone (413) 545-3428; or mail at the Human
Research Protection Office, Research Administration Building, University of
Massachusetts Amherst, 70 Butterfield Terrace, Amherst, MA 01003-9242.
Subject Statement of Voluntary Consent: By signing this form, I am agreeing to
voluntarily enter this study. I understand that, by signing this document, I do not waive
any of my legal rights. I have had a chance to read this consent form, and it was
explained to me in a language that I use and understand. I have had the opportunity to
ask questions and have received satisfactory answers. A copy of this signed Informed
Consent Form will be given to me.

________________________________________________________________________
Participant’s name
Address

________________________________________________________________________
Signature
Phone Number
Date
STUDY REPRESENTATIVE STATEMENT:
The investigator has read and understands the federal regulations for the Protection of
Human Research Subjects (45 CFR 46) and agrees to comply with all of its clauses to the
best of her ability. The investigator also pledges to consider the best interests of the
subject beyond the explicit statement contained in the aforementioned federal regulations
and to exercise professional expertise to protect the rights and welfare of the subject.

________________________________________________________________________
Signature of Person Obtaining Consent
Date
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APPENDIX B
TELEPHONE ELIGIBILITY SCREENING SCRIPT (STUDY 1)
Calculating Oxidative Energy Production during Non-Steady State Contractions
Telephone Screening Script

“Hello, my name is ______________ and I’m calling from the Muscle Physiology
Lab at the University of Massachusetts Amherst. I am contacting you today because you
have expressed interest in participating in our study about muscle metabolism. If now is
a good time, I can explain the study to you, answer any questions you may have, then ask
you a few questions about yourself to see if you would qualify.
Before we begin, what is your age?”
•

*If the participant is not 25-40 years of age we will inform them that they do not
qualify for the study, and ask if they would like to be contacted for future studies. If
their age falls within these ranges, we will move onto the script below.
“As I describe the study to you, feel free to ask any questions that you may have.”

“In this study, we are investigating how high intensity exercise affects aerobic, or
oxidative, metabolism within contracting skeletal muscles. Oxidative energy production
can be measured during moderate intensity exercise because skeletal muscle metabolism
reaches a plateau. However, the precision and accuracy of these methods are reduced
during high intensity exercise because this metabolic plateau is altered or not reached.
We recently developed a new method for calculating oxidative energy production that
appears to overcome this limitation. Thus, the purpose of this study is to investigate the
validity of our new method.”
“The study involves one visit and will take about 2 hours in total. We will provide
free parking, if needed. All testing will take place at the Human Magnetic Resonance
Center in the new Life Sciences Lab Building. Upon arriving, you will read an Informed
Consent document and have any questions you might have answered by the investigators.
Following completion of this consenting procedure, you will be asked to fill out a
Medical History Form, Physical Activity Readiness Questionnaire, and Magnetic
Resonance Safety Form. We will then measure your blood pressure while you are seated,
and obtain your height and weight. Next, we will review your Magnetic Resonance
Safety Form, have you remove all jewelry, and change into paper pants for the study. We
will also ask you to walk through a metal detector for your safety. You will be escorted to
the Magnet Room, where you will be positioned in the scanner on your back with your
dominant leg on our non-magnetic leg exercise apparatus, which is similar to a knee
extension machine you would use at a gym. Your leg will be strapped to the apparatus
just above your ankle and at your knee using Velcro straps. Straps will also be secured
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over your hips. A specially designed copper coil encased in plastic will be secured over
your thigh muscles using Velcro straps. This coil will non-invasively measure changes in
your muscle biochemistry while you exercise (if they ask: non-invasively means we
will not be poking into you). Headphones will be provided to you to limit the amount of
noise from the scanner, and to enable clear and constant communication between you and
the investigators.”
“We will then determine your strength during 2-3 maximal static contractions, each
lasting 3-4 seconds. For these, you will attempt to straighten your leg as quickly and
forcefully as possible, but the exercise apparatus will not let your leg move. You will be
given 1-2 minutes of rest between each of these contractions. Next, we will have you
repeat this effort, but this time you will maintain your strongest contraction for 24
seconds, after which you will rest quietly without moving for up to 10 minutes. This
procedure will be used to determine your muscle’s “aerobic” capacity.”
“You will then perform 2-3 sets of 3 rapid, maximal dynamic contractions to
determine your maximal dynamic strength. The dynamic contractions will all be
isokinetic; that is, the speed of the contraction will be limited by our custom-built
exercise apparatus. You will be given 1-2 minutes of rest between each of these 2 sets.
You will then perform the experimental protocol, which will include 4 sets of maximal
dynamic (‘with movement’) knee extensions. During each of these sets, you will be asked
to kick your leg out as hard and fast as you can once every 2 seconds. The duration of
each set will vary, beginning with 24 seconds for set 1 and increasing to 60, 120, and 240
seconds for sets 2, 3, and 4, respectively. Up to 10 minutes of rest will be given between
each set.”
“Lastly, before you leave, you will be given a small accelerometer, which is an
activity monitor that will record the amount and intensity of physical activity you
perform over the next 7 days. You will be instructed on how and when to use it and how
to keep a simple physical activity log book. At the end of the week-long wear period, a
member of the Muscle Physiology Laboratory will collect the accelerometer and log book
at a time that is most convenient for you. To compensate you for your participation, we
will give you $10 cash for completing all of the contraction protocols, and another $10
for completing all of the physical activity measures.”
“None of these tests will cause permanent damage and any discomfort that you may
feel will go away shortly. You may have some muscle soreness in the 2-3 days following
the study, but that will also go away. Do you have any questions?”
“If you don’t mind, I am now going to ask you a few questions about your medical
history to determine if you are eligible for the study. Any information I receive today
and all information collected during the study will be kept private and locked in a filing
cabinet within a locked room. If you do not qualify for the study and are not interested in
participating in further studies, your information will be destroyed. We follow careful
procedures to make sure your privacy is protected at all times. Do you have any
questions?”
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•

Complete ‘Telephone Eligibility Screening Form’ and ‘MR Safety Form.’
“Do you have any other questions? Thank you very much for your time. We
will get back to you once we determine if you are eligible. If you are eligible,
we schedule your first visit.”
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APPENDIX C
TELEPHONE ELIGIBILITY SCREENING FORM (STUDY 1)

Screened by:
Date:
Status:___________________________________
TELEPHONE SCREENING FORM: MR STUDIES

1) Name________________________________
2) Phone # (Circle preferred contact):

Best time/day to contact:

a. Home ___________________________

Message?

Yes

No

b. Work

Message?

Yes

No

c. Cell

Message?

Yes

No

3) Email:
4) Age________

Sex________ Height

Weight

BMI

(calculate)
5) How did you find out about this
study?________________________________________
6) Have you ever participated in a research study
before?____________________________
a. Are you currently participating in any other research studies right now?
i. If yes, describe:
ii. End date: __________________________
7) Current health status (general)________________________
8) Do you have any physical limitations?______________________________________
9) Are you pregnant?
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10) Do you, or have you ever had, any of the following:
a. Stroke?
b. Peripheral vascular disease?
c. Cardiac disease?
d. Pulmonary disease?
e. Neurological disease?
f. Arthritis in the lower leg?
Have you used ambulatory devices during the last month (i.e., ankle-foot
orthotic, cane, wheelchair,
etc.)?_________________________________________________________
11) Do you smoke or have you ever smoked before?___ For how long?____Quit?______
12) Do you have any allergic reactions?_______________________________________
13) Do you have any significant past medical history? (e.g. hypertension, CAD, etc.)
______________________________________________________________________
14) Current medications:
Drug Name

Classification Dosage Frequency

a. Do you take any Statins?

Duration Prescribed
for?

If yes, please describe:
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b. Do you take any beta-blockers, sedatives, tranquilizers, or other medication
that may impair physical function?

If yes, please

describe:
15) Current physical activity level (regular exercise, none, athlete, etc.)

16) Has your Doctor ever told you not to exercise?__________________If yes, please
describe:
17) What was the date of your last doctor’s visit?________________________________
18) Is fatigue a problem for you?___________________ Leg fatigue?_______________
19) What type of transportation will you be using?_Will you need a parking pass? ______
20) Would you like to be contacted again for future studies?

Yes

No

21) Comments:___________________________________________________________
______________________________________________________________________
______________________________________________________________________
22) Go through Magnetic Resonance Safety Questionnaire:
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APPENDIX D
MEDICAL HISTORY FORM
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APPENDIX E
PHYSICAL ACTIVITY READINESS QUESTIONNAIRE
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APPENDIX F
MAGNETIC RESONANCE SAFETY FORM
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APPENDIX G
PHYSICAL ACTIVITY LOG
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APPENDIX H
INFORMED CONSENT (STUDY 2)
INFORMED CONSENT DOCUMENT
University of Massachusetts
Amherst, MA 01002
Project Title: Does Mitochondrial Uncoupling Alter the Efficiency of Aerobic
Metabolism in Contracting Skeletal Muscles?
Principal Investigator: Miles F. Bartlett
Co-Investigators: Jane A. Kent, PhD, Rajakumar Nagarajan, PhD, Liam F. Fitzgerald,
Joseph A. Gordon, Julia D. Miehm
Your written informed consent is required before you can participate in this project.
Please read this document carefully and then sign your name on the last page if you agree
to participate. This document is in accordance with regulations for the Protection of
Human Research Subjects (45 CFR 46). You are encouraged to ask questions at any time
before, during or after participating.
Purpose: During low- and moderate-intensity exercise, skeletal muscle metabolism rises
in a predictable manner. However, during high-intensity exercise, muscle metabolism
increases much more than would be predicted by the pattern seen at lower exercise
intensities. The cause of this difference is not known, but we think that it has to do with
changes in the efficiency of aerobic metabolism. We recently developed an experimental
technique that allows us to measure the efficiency of aerobic metabolism in exercising
skeletal muscle. Thus, the purpose of this study is to test the hypothesis that the
efficiency of aerobic metabolism declines during high-intensity exercise.
Eligibility: To participate in this study you must be healthy and between 21-40 years of
age. You may not have any: neurological or neuromuscular disease; a history of stroke,
peripheral vascular disease, cardiovascular disease, blood vessel disorders such as deep
vein thrombosis, pulmonary embolisms, or varicose veins cardiac or pulmonary disease;
be a smoker; or have a history of any metabolic diseases/disorders. You may not be
pregnant. You may not have any metal implants or anything that would prevent you from
undergoing a magnetic resonance imaging (MRI) exam.
Procedures: Prior to your first visit, you will be screened by telephone interview for
general health, medical history, current medications, usual physical activity habits, and
eligibility for the study. If you are qualified and agree to participate, you will be invited
to the Muscle Physiology Laboratory for your first visit.
Visit 1 – Paperwork and Familiarization (Muscle Physiology Laboratory, ~1 hour):
Upon arriving to the MPL, you will read this informed consent document and
have any questions answered by the investigator. After agreeing to participate and
signing this consent form, you will fill out the following documents (attached):
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- Physical Activity Readiness Questionnaire
- Medical History Form
- Magnetic Resonance (MR) Safety Form
Next, measures of your blood pressure, height, and weight will be obtained. You
will then be familiarized with the contraction protocols and procedures that will be
performed during your second visit (described in detail below). First, you will be
strapped into a knee extension dynamometer, which is very similar to a leg extension
machine that you might find at a gym. We will start by measuring your maximal knee
extension strength and power and then have you perform an incremental contraction test.
The starting workload will be light but will get progressively heavier as the test
continues. You will also experience the blood pressure cuff on your leg, as described in
detail for visit 2.
Before leaving, we will schedule your second visit and give you a small activity
monitor that you will wear at your waist. This monitor will record the amount and
intensity of physical activity you perform over the next 7 days. You will be instructed on
how and when to use it and how to keep a simple physical activity log. The activity
monitor and log book will be returned at visit 2, or at the end of the week-long wear
period. If the materials are not returned at visit 2, a member of the Muscle Physiology
Laboratory will collect the monitor and log book at a time and location that is most
convenient for you.
Visit 2 – Study Procedures (Human Magnetic Resonance Center, ~2 hours)
Upon arriving to the Human Magnetic Resonance Center at the Institute for
Applied Life Sciences, you will meet with the MR Operator to review the MR Safety
Form. Before entering the magnet room, you will remove any jewelry, empty your
pockets, and walk through a metal detector. You will then be escorted to the MR scanner
and positioned on your back with your dominant leg on top of our custom-built leg
exercise apparatus, which is similar to a knee extension machine you would use at a gym.
The lower leg (shin) will be strapped to the apparatus just above your ankle and at your
knee using Velcro straps. Inelastic straps will also be secured over your hips to prevent
unwanted movement during the muscle contractions, and a specially designed copper coil
encased in a plastic box will be secured over your thigh muscles using Velcro straps. This
coil will be used to measure changes in muscle metabolism during your contractions.
Two large inflatable blood pressure cuffs will then be wrapped around your leg,
one each around the upper thigh and calf. To ensure that the inflatable cuffs are
comfortable and positioned correctly, we will inflate the cuffs to a relatively low pressure
(~150 mmHg) and then slowly increase the pressure to 240mmHg, which will be the
target pressure during the study protocol. Once you are comfortable with the cuff
placements, we will perform 1-2 rapid inflations (~ 1 second each), which will be used
during the study procedures to temporarily block blood flow. If necessary, the cuffs will
be repositioned to make you more comfortable.
Lastly, you will be given headphones to use, to limit the amount of noise from
the MR scanner and allow you clear and constant communication with the investigators.
We will talk with you and explain each set of measures as we go along. These measures
are described next.
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After you have been strapped to the exercise apparatus, we will position you in
the center of the scanner and collect measures of your muscle metabolism at rest. During
this time, you will lay quietly for about 10-15 minutes. Next, we will remeasure your
knee extension strength to establish the workloads that you will perform during the
incremental contraction test. About 1 minute of rest will be given between each of these
contractions. You will then be refamiliarized with the dynamic contractions (1
contraction every 2 seconds) by performing a few sets of 2-3 maximal contractions at a
fixed speed. Once you are comfortable with the dynamic contraction procedures, you will
perform 24 seconds of maximal dynamic contractions, after which you will rest quietly
without moving for up to 10 minutes. This procedure will be used to measure your
muscle’s maximal “aerobic” capacity.
Next, you will perform an incremental exercise test consisting of 6 stages of
dynamic knee extension contractions, again 1 contraction every 2 seconds. These
contractions will start with a very light load, and every 3 minutes, the load will be
increased a little (by 8% of your maximum). Your muscle metabolism will be measured
continuously throughout this protocol. At the end of each stage, we will measure the
efficiency of your aerobic energy production, as follows:
5- Up to 12 seconds of rest will be given
6- The blood pressure cuffs will be inflated rapidly, to 240mmHg
7- The cuffs will remain inflated for up to 40 seconds while we measure your
muscle biochemistry
8- The cuff will be rapidly deflated to allow your muscles to rest and recover
Following step 4, the next 3-minute stage of contractions will begin. This process
of inflating and deflating the blood pressure cuffs may be uncomfortable, but will not
cause any damage to your muscle, and any discomfort will subside quickly once the cuff
is deflated. Additionally, after the cuff procedures have been completed for stage 6 (the
final stage), you will complete one more minute of contractions followed by up to 10
minutes of rest, so that we can measure your muscle’s maximal ‘aerobic’ capacity once
again. Finally, after the 10-minute recovery period, you will undergo a final 10-minute
cuff-inflation period while resting quietly. The cuffs will then be deflated and we will
remove you from the scanner.
Subject Enrollment/Length of Study: We expect to enroll 10-20 participants in this
study. Your participation will include 2 visits; the first lasting about 1 hour and the
second lasting approximately 2 hours.
Possible Risks and Discomforts: There are minimal risks associated with the
contraction procedures used in this research study. However, cardiovascular events and
rises in blood pressure are possible due to the contractions, as well as muscle soreness in
the days following the testing, but these are normal physiological responses and should
be temporary. Injury is possible if you have any metal in or on you during the magnetic
resonance testing, but we will check you beforehand to detect any such metal.
Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) – The United States Food
and Drug Administration (FDA) has established guidelines for magnet strength and
exposure to radio waves, and we carefully observe those guidelines. No ill effects have
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been reported for the radio wave exposure associated with this protocol. Some people
may feel uncomfortable or anxious while in the MR scanner, which is a large magnet. If
this happens to you, you may ask to stop the study at any time and we will take you out
of the MR scanner. On rare occasions, some people might feel dizzy, get an upset
stomach, have a metallic taste, feel tingling sensations, or experience muscle twitches.
These sensations usually go away quickly but please tell the research staff if you have
them.
MRI and MRS pose some risks for certain people. If you have a pacemaker or certain
types of metal objects inside your body, you may not be in this study because the strong
magnet used for these MR studies might harm you. Another risk is a metallic object
flying through the air toward the magnet and hitting you. To reduce this risk we require
that all people involved with the study remove all metal from their person and all metal
objects from their pockets. Nothing metal can be brought into the magnet room at any
time. Also, once you are in the magnet, the door to the room will be closed so that no
one accidentally bring a metal object near the magnet while you are in it.
Please read the Magnetic Resonance Safety Form and complete it very carefully.
Those questions are for your safety. Take a moment now to be sure that you have read
this Form and be sure to ask any questions and tell us any information you think might be
important. Even if you think that it is probably okay, we would rather have you ask
us to make sure.
If you experience significant claustrophobia during the MR testing, you will be removed
immediately. You will be positioned feet-first in the magnet and your head will remain
near the opening in order to minimize claustrophobia.
Blood Pressure Cuffs and Ischemia – All of our blood pressure cuff-inflation procedures
are intended to temporarily block off blood flow and carry a risk of blood vessel injury.
However, the inflation times we are using are short compared to those used in lower-limb
surgeries, which can last over an hour, and the inflation pressure is also well below the
recommended threshold of 300mmHg. You may experience discomfort and numbness in
the leg during inflation, as well as warmth and a prickly, needle-like, feeling once the
cuffs are deflated, but these feelings will go away shortly and will not cause long-term
damage. You may experience some bruising from the cuffs, but this too will not cause
any long-term damage and should clear up over the course of a few days. Overall, the risk
to healthy young adults is low. If at any point in time you wish to stop the inflation
procedures, just tell one of the data collectors and we will release the pressure cuff
immediately. However, if you have a history of cardiovascular or blood vessel
disease, such as deep vein thrombosis or varicose veins, it is imperative that you
inform us because the cuff-inflation procedures utilized in this study may pose a
serious risk to your health.
What if there is an unexpected finding on my MR scan? The investigators for this
research project are not licensed or trained diagnosticians or clinicians. The testing
performed in this project is not intended to find abnormalities, and the images or data
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collected do not comprise a diagnostic or clinical study. However, occasionally in the
process of research, investigators may perceive an abnormality, the health implications of
which may not be clear. When this occurs, UMass Amherst researchers will consult with
a radiologist. If the radiologist determines that an additional inquiry is warranted, the
researcher will then contact you regarding the radiologist’s opinion of the unexpected
finding(s).
In such a case, you would be advised to consult with a licensed physician to determine
whether further examination or treatment would be prudent. Although the images
collected for this research project do not comprise a diagnostic or clinical study, the
images can be made available to you for clinical follow-up. The costs for any care that
will be needed to diagnose or treat an unexpected finding(s) would not be paid for by
University of Massachusetts, Amherst. These costs would be your responsibility. If you
have further tests done by your licensed physician, those results will then become part of
your medical record, which may affect your current and future health or life insurance.
Regardless of the health implications, the discovery of an unexpected finding(s) may
cause you to feel anxious or worried. You may wish to talk to your physician or a
qualified mental health clinician. You can contact the Center for Counseling and
Psychological Health (CCPH) at (413) 545-2337 (Mon-Fri from 8-5pm) - on weekends or
after 5pm, call (413) 577-5000 and ask for the CCPH clinician on call. You can also
contact the Psychological Services Center at 413-545-0041 (Monday-Friday 8am-5pm)
or psc@psych.umass.edu. In a serious emergency, remember that you can also call 911
for immediate assistance.
Confidentiality: Steps are taken to protect the identities of you and the data collected in
this study. The Informed Consent, Physical Activity Readiness Questionnaire, and MR
Safety Form (all of which will have your name on them) will be stored and locked in a
filing cabinet within a locked office. All other data collection sheets will be coded with
your participant number and the study name instead of your name, so that no potential
identifiers can be linked back to you. Data collection sheets and lists of participant codes
and names are kept separate from all other study materials. Paper documents with names
or codes will be stored in separate locked filing cabinets located in a locked office. All
electronic data will be kept on a password-protected computer in a locked office. Any
data that are published or used in a presentation will not include any names or identifiers
that could link back to you.
In Case of Injury: In the unlikely event of an injury resulting directly from participation
in this study, we will do everything we can to assist you in seeking medical treatment.
The University of Massachusetts does not have a program for compensating subjects for
injury or complications related to human subject research.
Benefits: You will receive no direct benefit from participating in this study.
Costs and Reimbursement: There is no cost to participate in this study. To compensate
you for your participation, we will give you $20 cash for completing all of the contraction
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and cuff inflation protocols for each visit ($40 total for completing both visits 1 and 2),
and another $10 for completing all of the physical activity measures.
Withdrawal from Participation: Participation in this research is voluntary. You have
the right to refuse to continue or withdraw from the study at any point, without prejudice.
Alternative Procedures: The procedures described above are non-invasive techniques
that are commonly used in muscle research. There are no other non-invasive techniques
that can be used to obtain the information necessary in this study.
Request for Additional Information: You are encouraged to ask questions about the
study. The investigators will attempt to answer all of your questions to the best of their
knowledge. The investigators fully intend to conduct the study with your best interest,
safety, and comfort in mind. Please address any questions regarding the study to Miles
Bartlett in the Muscle Physiology Laboratory. His phone number is (413) 545-5305. We
can also be reached by email at umassmplab@umass.edu. You may also address
questions to Prof. Kent by calling her at (413) 545-9477 or by emailing her at
jkent@kin.umass.edu. If you would like to speak with someone not directly involved in
the research study, you may contact the Human Research Protection Office at the
University of Massachusetts via email at humansubjects@ora.umass.edu; telephone (413)
545-3428; or mail at the Human Research Protection Office (HRPO), Mass Venture
Center, 100 Venture Way, Suite 116, Hadley 01035.
Subject Statement of Voluntary Consent: By signing this form, I am agreeing to
voluntarily enter this study. I understand that, by signing this document, I do not waive
any of my legal rights. I have had a chance to read this consent form, and it was
explained to me in a language that I use and understand. I have had the opportunity to
ask questions and have received satisfactory answers. A copy of this signed Informed
Consent Form will be given to me.

________________________________________________________________________
Participant’s name
Address

________________________________________________________________________
Signature
Phone Number
Date
STUDY REPRESENTATIVE STATEMENT:
The investigator has read and understands the federal regulations for the Protection of
Human Research Subjects (45 CFR 46) and agrees to comply with all of its clauses to the
best of her ability. The investigator also pledges to consider the best interests of the
subject beyond the explicit statement contained in the aforementioned federal regulations
and to exercise professional expertise to protect the rights and welfare of the subject.
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________________________________________________________________________
Signature of Person Obtaining Consent
Date

184

APPENDIX I
TELEPHONE ELIGIBILITY SCREENING SCRIPT (STUDY 2)
Muscle Physiology Lab
Does Mitochondrial Uncoupling Alter the Efficiency of Aerobic Metabolism in
Contracting Skeletal Muscles?
Telephone Screening Script

“Hello, my name is ______________ and I’m calling from the Muscle Physiology
Lab at the University of Massachusetts Amherst. I am contacting you today because you
have expressed interest in participating in our study about muscle metabolism. If now is
a good time, I can explain the study to you, answer any questions you may have, then ask
you a few questions about yourself to see if you would qualify. Passing this initial
screening process means that you are likely qualified to participate but it not a guarantee.
We will collect a more comprehensive medical history when you come in for your visit,
and if those data reveal a contraindication, we will have to exclude you for your own
safety.
Before we begin, what is your age?”
•

*If the participant is not 21-40 years of age we will inform them that they do not
qualify for the study and ask if they would like to be contacted for future studies. If
their age falls within these ranges, we will move onto the script below.
“As I describe the study to you, feel free to ask any questions that you may have.”

“In this study, we are investigating how high-intensity exercise affects aerobic
metabolism in skeletal muscle. In short, during high-intensity exercise, muscle
metabolism increases much more than would be predicted by the pattern seen at lower
exercise intensities. The cause of this difference is not known, but we think that it has to
do with changes in the efficiency of aerobic metabolism, which is similar to a car’s gas
mileage being reduced. Thus, the purpose of this study is to test the hypothesis that the
efficiency of aerobic metabolism declines during high-intensity exercise.”
“The study involves two visits and will take about 3 hours in total. Visit 1 will
take place at the Muscle Physiology Lab in Totman Gymnasium on the UMass Amherst
Campus and require about 1 hour of time. Upon arriving, you will read an Informed
Consent document and have any questions you might have answered by the investigators.
Following completion of this consenting procedure, you will be asked to fill out a
Medical History Form, Physical Activity Readiness Questionnaire, and Magnetic
Resonance Safety Form. We will then measure your blood pressure while you are seated
and obtain your height and weight. You will then be familiarized with the contraction
protocols and pressurized cuff inflation procedures that will be performed during visit 2,
which I will describe in detail next.”
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“Before leaving at the end of visit 1, we will schedule your second visit and give
you a small activity monitor that will record the amount and intensity of physical activity
you perform over the next 7 days. You will be instructed on how and when to use it and
how to keep a simple physical activity log. The activity monitor and log book will be
returned at visit 2, or at the end of the week-long wear period.”
“Visit 2 will take place at the Human Magnetic Resonance Center in the new Life
Sciences Lab building and require about 2 hours of time. Upon arriving you will remove
any jewelry, empty your pockets, and walk through a metal detector. You will then be
escorted to the MR scanner and positioned on your back with your dominant leg on top of
our custom-built leg exercise apparatus, which is similar to a knee extension machine you
would use at a gym. The lower leg (shin) will be strapped to the apparatus just above the
ankle, knee, and hips. A specially designed copper coil encased in plastic will also be
secured over the thigh muscles using Velcro straps. This coil will be used to measure
changes in muscle metabolism and biochemistry during the contractions.
Two large inflatable cuffs will then be wrapped around your leg, one each around
the upper thigh and calf. To ensure these inflatable cuffs are comfortable and positioned
correctly, we will perform a familiarization procedure. First, we will inflate the cuffs to a
relatively low pressure (~150 mmHg) and then slowly increase the pressure to
240mmHg, which will be the target pressure during the study protocol. Once you are
comfortable with the cuff placements, we will perform 1-2 rapid inflations (~ 1 second),
which will be used during the study procedures to temporarily block blood flow. If
necessary, the cuffs will be repositioned to make you more comfortable.
Lastly, headphones will be provided to limit the amount of noise from the MR
scanner, and to enable clear and constant communication between you and the
investigators. We will talk with you and explain each set of measures as we go along.
These measures are described next.”
“To begin, you will lay quietly for about 15-20 minutes while we will measure
your muscle biochemistry at rest. Next, we will measure your knee extension strength
and power using 2-3 sets of maximal static and dynamic contractions. You will then
perform a 24 second contraction protocol, after which you will rest quietly without
moving for up to 10 minutes. This procedure will be used to measure your maximal
“aerobic” capacity. Do you have any questions thus far?”
“Next, you will perform the study protocol, which is an incremental exercise test.
The test will have 6 stages. Each stage will last 3 minutes, with 1 knee extension
contraction being performed every 2 seconds. The workload for stage 1 will be light but
will get progressively heavier with each stage as the test continues. Muscle metabolism
will be measured continuously throughout the contraction period.
At the end of each stage, we will measure the efficiency of aerobic energy
production using our intermittent-ischemia protocol, which will be performed in the
following sequence:
9- Up to 12 seconds of rest will be given to allow muscle recovery
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10- The blood pressure cuffs will be rapidly inflated
11- The cuffs will remain inflated for up to 40 seconds while we measure rates of
muscle energy production and oxygen consumption
12- The cuff will be rapidly deflated to allow muscles to fully recover
Do you have any questions about the blood pressure cuffs or intermittent ischemia
protocol? I can go more into detail on those procedures if you’d like.”
*If the participant indicates they’d like more detail, the screener will go into more
depth with examples of what will be done and what can be expected*
“Following step 4 of the intermittent-ischemia protocol, the next 3-minute stage
of contractions will begin. Additionally, after the cuff inflation procedures have been
completed for the final stage, you will complete one more minute of knee extensions,
which will allow us to remeasure your maximal ‘aerobic’ capacity. Lastly, after the
recovery measures have been collected at the end of the incremental protocol, you will
undergo 10 minutes of cuff inflation, which will allow us to calibrate the signal we use to
calculate muscle oxygen consumption. Do you have any questions?”
“To compensate you for your participation, we will give you $20 cash for completing
all of the contraction and cuff inflation protocols for each visit ($40 total for completing
both visits 1 and 2), and another $10 for completing all of the physical activity measures.
None of these tests will cause permanent damage and any discomfort that you may feel
will go away shortly. You may have some muscle soreness in the 2-3 days following the
study, but that will also go away. Do you have any questions?”
“If you don’t mind, I am now going to ask you a few questions about your medical
history to determine if you are eligible for the study. Any information I receive today
and all information collected during the study will be kept private and locked in a filing
cabinet within a locked room. If you do not qualify for the study and are not interested in
participating in further studies, your information will be destroyed. We follow careful
procedures to make sure your privacy is protected at all times. Do you have any
questions?”
•

Complete ‘Telephone Eligibility Screening Form’ and ‘MR Safety Form.’

“Do you have any other questions? Thank you very much for your time. We will get
back to you once we determine if you are eligible. If you are eligible, we schedule your
first visit.”
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APPENDIX J
TELEPHONE ELIGIBILITY SCREENING FORM (STUDY 2)

Screened by:

Date:

Status:___________________________

TELEPHONE SCREENING FORM: MR STUDIES

23) Name________________________________
24) Phone # (Circle preferred contact):

Best time/day to contact:

a. Home ___________________________

Message?

Yes

No

b. Work

Message?

Yes

No

c. Cell

Message?

Yes

No

25) Email:
26) Age______

Sex________ Height

Weight

BMI

(calculate)
27) How did you find out about this study?____________________________________
28) Have you ever participated in a research study before?________________________
a. Are you currently participating in any other research studies right now?
i. If yes, describe:
ii. End date: __________________________
29) Current health status (general)________________________
30) Do you have any physical limitations?______________________________________
31) Are you pregnant?
32) Do you, or have you ever had, any of the following:
a. Stroke?
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b. Peripheral vascular disease?
c. Cardiac disease?
d. Pulmonary disease?
e. Neurological disease?
f. Arthritis in the lower leg?
g. Blood vessel disorders such as blood clotting, deep vein thrombosis, or
varicose veins?
Have you used ambulatory devices during the last month (i.e., ankle-foot
orthotic, cane, wheelchair, etc.)?_________________________________
33) Do you smoke or have you ever smoked before?_________ For how long?____
Quit?______
34) Do you have any allergic reactions?________________________________________
35) Do you have any significant past medical history? (e.g. hypertension, CAD, etc.)
______________________________________________________________________
36) Current medications:
Drug Name

Classification Dosage Frequency

a. Do you take any Statins?

Duration Prescribed for?

If yes, please describe:
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b. Do you take any beta-blockers, sedatives, tranquilizers, or other medication
that may impair physical function?

If yes, please

describe:
37) Current physical activity level (regular exercise, none, athlete, etc.)
_________________________________________________________
38) Has your Doctor ever told you not to exercise?__________________If yes, please
describe:
39) What was the date of your last doctor’s
visit?_____________________________________________
40) Is fatigue a problem for you?_______________ Leg fatigue?___________________
41) What type of transportation will you be using?____Will you need a parking pass? ___
42) Would you like to be contacted again for future studies?

Yes

No

43) Comments:___________________________________________________________
______________________________________________________________________
44) Go through Magnetic Resonance Safety Questionnaire:
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